The pharmacokinetics of local vascular drug delivery : demonstration with a model vasotherapeutic compound, heparin by Lovich, Mark A
The Pharmacokinetics of Local Vascular
Demonstration with a Model Vasotherapeutic
Drug Delivery:
Compound, Heparin
by
Mark A. Lovich
B.S. Mechanical Engineering
Columbia University, 1988
M.S. Mechanical Engineering
University of California at Berkeley, 1990
SUBMITTED TO THE HARVARD-M.I.T. DIVISION OF HEALTH SCIENCES AND
TECHNOLOGY
IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF
DOCTOR OF PHILOSOPHY IN
MEDICAL ENGINEERING AND MEDICAL PHYSICS
AT THE
MASSACHUSETTS INSTITUTE OF TECHNOLOGY
JUNE, 1997
c 1997 Mark A. Lovich. All rights reserved.
The author hereby grants MIT permission to reproduce and to distribute publicly paper and
electronic copies of this thesis document in whole or in part
Signature of Author:
Division of Health Science and Technology
A /1 January 7, 1997
Certified by
Certified by
J: " -v -
Elazer R. Edelman
Hermann Von Helmholtz Associate Professor of
Health Sciences and Technology
Thesis Supervisor
: I I
(J~... .' 'I
Martha L. Gray
J.W. Kieckhefer Associate Professor of
Electrical Engineering and Computer Science
Co-Director, Health Sciences and Technology
MAY 2 71997
1'
t·rh,
L~P"~r 42TS'E% rLh:·i Ut;~rra r
·4~u~t I·Y
·'i·5;1"J
The Pharmacokinetics of Local Vascular Drug Delivery:
Demonstration with a Model Vasotherapeutic Compound, Heparin
by
Mark A. Lovich
Submitted to the Harvard-M.I.T. Division of Health Sciences and Technology on
January 7, 1997 in Partial Fulfillment of the Requirements for the Degree of Doctor
Of Philosophy In Medical Engineering And Medical Physics
ABSTRACT
Aim: To predict vascular deposition and distribution of exogenous regulatory compounds.
Motivation: The hyperproliferative response to vascular injury is the greatest limitation to the
potential of mechanical revascularization. Tissue and animal models have defined classes of
compounds that might combat these diseases, yet none work clinically. One limitation of
extrapolating from tissue culture to humans is the uncertainty of whether such failure is from a
resistant human arteriopathic lesion or simply a limitation of drug residence within the vessel.
Only detailed pharmacokinetic models describing drug-tissue interactions can differentiate between
these failures. Detailed analyses are especially important for the development of local vascular
drug delivery strategies which impart large dynamic drug concentration gradients across tissues.
Transport and Binding Properties: A series of experiments elucidated the mechanisms of
deposition and distribution. Diffusive and convective transport, and binding in each arterial layer
were characterized for a model inhibitor of smooth muscle cell growth, heparin. The molecular
diffusivity of heparin in media and adventitia, and the transendothelial resistance were measured
with in vitro perfusion experiments. Both the adventitia and endothelium were shown to exert
minimal resistance to heparin transport. Theoretical predictions and perfusion studies showed that
diffusion outweighs convection in controlling transmural transport in thin arteries, but these forces
are more balanced in thicker vessels or following endothelial injury. The density of all binding
sites, their average dissociation constant, and the fractional available space were measured with an
equilibrium distribution technique. More heparin binding sites were identified in arterial media
than adventitia, the latter with higher affinity. The transport of drug to the vessel wall from the
perivascular space was characterized through inulin clearance and arterial heparin deposition
studies. Most of the perivascularly released inulin was shown to be cleared by extramural
capillaries, and yet most of the heparin deposited in arteries diffuses directly from the exterior.
Pharmacokinetics: Computational models of intramural drug deposition and distribution were
constructed based on the accumulated data. Augmentation of animal data with simulations has
helped overcome limitations of standard labeled-drug deposition assays by providing high spatial
and temporal resolution and by predicting transmural concentration profiles of soluble, bound and
internalized drug. The simulations suggest that heparin is not retained in the arterial wall for
appreciable periods, implying that sustained modes of delivery are needed to treat vascular disease.
Conclusions: Definition of the physical interaction between soluble compounds and vascular
tissues has shed light on the mechanisms of proliferative vascular disease and its therapy. The
same principles can be applied to any therapeutic, physiologic, and pathophysiologic process
where cells communicate through soluble signals.
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1. BACKGROUND AND INTRODUCTION
1.1. Anatomy of the Blood Vessel Wall
A brief review of arterial architecture and content will put into context many of the terms and
concepts used throughout this work. Arteries are living tubes composed of three concentric tunics
or layers, each with distinct structure, cell types, and functions: 1) The innermost layer is the tunica
intima and consists of a monolayer of endothelial cells supported by the internal elastic lamina, a
layer of connective tissue comprised mostly of elastin. The endothelial cells are interconnected
through intercellular tight junctions, forming an intact monolayer wherein each cell is aligned along
the axis of flow in the artery. In many blood vessels in humans and higher animal species, the
subendothelial space, just luminal of the internal elastic lamina, may contain vascular smooth
muscle cells. 2) The middle layer is the tunica media and consists of alternating sublayers or
lamellae of circumferentially oriented vascular smooth muscle cells and thin sheets of collagen and
elastin. These cells provide the contractile force required to modulate vessel diameter and alter
perfusion to downstream tissues. 3) The outermost layer is the tunica adventitia, which consists
primarily of type I collagen with scattered fibroblasts and adipocytes. Coursing through this layer
in arteries approximately 0.5 mm thick or greater are vasa vasorum, also referred to as the blood
vessels of the blood vessel wall. 1 In many arteries, the extent of the adventitia is less well-defined
than the intima or media, and further away from the lumen it gradually blends into layers of fascia
and fat.
The cells within the arterial wall communicate and regulate each other through biochemical
paracrine signals. Endothelial cells, for example, are sensitive to shear stress and respond by
releasing factors such as Endothelial Derived Relaxing Factor (EDRF) which causes medial smooth
muscle cells to relax leading to vasodilation and enhanced regional blood flow. 2-4 Endothelial cells
and smooth muscle cells also secrete compounds that promote and inhibit each others' growth,
both in quiescent states and in states of dysregulation and repair. For example, injured vascular
smooth muscle cells release compounds such as basic fibroblast growth factor (bFGF) which are
mitogenic to both endothelial and smooth muscle cells, possibly in attempt to repair the vessel
wall. 5-9 On the other hand, confluent endothelial cells secrete soluble inhibitors of vascular
smooth muscle cell growth, such as heparan sulfate proteoglycans, that may provide negative
feedback on the reparative process and limit the hyperplasia initiated by wound healing.1
0-13
Thus, the cells of the blood vessel wall are constantly communicating through soluble signals in
order to optimally regulate vascular function and homeostasis.
1.2. Proliferative Vascular Diseases
It has been postulated that injury to the endothelial monolayer and underlying smooth muscle
disrupts the normal arterial homeostasis and initiates a cascade of cellular and molecular events that
culminate in vascular hyperproliferation.14-16 Endothelial injury leads to platelet aggregation,
thrombus formation, inflammation, activation of macrophages and the local release of
cytokines.8' 17 Direct injury to the arterial media kills a substantial fraction of smooth muscle cells,
releasing growth factors and other mediators that stimulate their proliferation, in an attempt to heal
the blood vessel.7-9,18 Many of these mediators promote their own synthesis and release from
neighboring cells in a self-amplifying manner, which stimulates DNA synthesis and cell division
throughout the injured artery in a synchronized fashion. Several days after injury, under the
influence of other chemotactic agents, smooth muscle cells begin migrating towards the lumen of
the artery, some dividing once within the expanded intima.18 These smooth muscle cells in the
lumen change to a synthetic rather than contractile phenotype, produce extracellular matrix and
proliferate further.
Cardiovascular diseases, which derive from chronic forms of injury and endogenous repair,
account for over 1 million deaths each year in the United States and almost 1.5 million
interventions. Currently, the only available therapies are mechanical revascularizations such as
percutaneous transluminal coronary angioplasty, venous interposition and prosthetic grafting,
endovascular stent placement, and atherectomy. Unfortunately, all of these mechanical attempts at
alleviating the symptoms of low coronary flow rates are beset by accelerated vascular disease of
their own. For example, 30 - 40% of coronary angioplasty patients will require another
angioplasty or bypass surgery within 3-6 months. 16 The mean lifetime of a saphenous vein
interposition graft is seven years and 10% are occluded within two weeks after surgery, 20% at
one year and 35% at five years. 16 Endovascular stenting can increase luminal diameter, prevent
elastic recoil, and yet is associated with a similar rate of clinical failure. All of these mechanical
interventions expand the functional lumen of the artery, but as a byproduct they also injure the
blood vessel wall, and initiate the cellular and molecular events described above and culminate in a
space occupying lesion within the arterial lumen that consists primarily of vascular smooth muscle
cells. 16 This injury and proliferative response is referred to as intimal hyperplasia or restenosis.
Randomized clinical trials on patients following revascularization and subsequent arterial injury
have included readily available cardiovascular drugs that in theory should modulate the molecular
mechanisms involved in forming the restenotic lesion. Antiplatelet agents, anticoagulants, calcium
channel blockers, angiotensin converting enzyme inhibitors, lipid lowering agents, steroids,
growth inhibitors, and antiproliferative compounds have all been unsuccessful in limiting human
accelerated arteriopathies. 19,20 Efficacy of these agents at regulating the proliferative response to
injury is therefore limited to the animal, and is not demonstrable in the human, or is only evident at
doses and for exposure times much greater than previously utilized. The lack of an "off-the-shelf"
pharmacologic solution to the restenosis problem has sparked numerous cell culture investigations
to find inhibitors of vascular smooth muscle cell proliferation and migration. 11, 12,2 1-2 5 Animal
models of arterial injury have been used to evaluate the antiproliferative effects of
heparin, 10,'13 2 6,27 Hirulog, 2 8 anti-inflammatory drugs such as dexamethasone, 29 ,30 angiotensin
converting enzyme inhibitors, 3 1 antimitotic inhibitors of tubulin polymerization such as
colchicine, 32,33 anti-platelet drugs such as forskolin, 34 antineoplastic antibiotic agents such as
mitomycin c35 or gamma interferon, 36 antisense oligonucleotides directed against cell cycle
proteins, 37-39 and cytotoxic compounds directed against growth factor receptors. 40 Although
these investigations showed promising results, many of these compounds are non-specific
inhibitors of cell growth and therefore cause inadvertent injury to other tissues, such as the rapidly
proliferating gut epithelium and lymphoid cells. Systemic levels of other compounds have
profound toxic effects independent of their antiproliferative properties. For example steroid
hormones are associated with hypertension, diabetes, immunosupression, and profound systemic
morphologic effects. 41 Heparin in large concentrations can cause hemorrhage, osteoporosis,
alopecia, electrolyte shifts and thrombocytopenia. 42' 43 Furthermore, for many of these compounds
the concentration in injured arterial tissues need to be elevated for days to weeks to achieve
inhibition of intimal hyperplasia, however, their rapid plasma clearance and denaturation require
continuous administration, which can be clinically burdensome. Lastly, some of the above
compounds are extraordinarily expensive. For example, at current commercial rates, a single
intravenous bolus of antisense oligonucleotides large enough to elevate plasma levels high enough
to treat a 70 kg man would cost approximately $1.4 million. Therefore, for any of these
compounds to be effective and practical, a route of delivery is required that minimizes systemic
concentrations and side effects, that allows drug to reach target tissues and act before it is cleared
or denatured, and minimizes waste by not loading unnecessary tissues. Recent pharmacologic
strategies have evolved to deliver these compounds to the immediate vicinity of the diseased blood
vessel segment, in an attempt to elevate concentrations in target tissues while minimizing systemic
levels.26-30,32-35,37-40
1.3. Local Delivery
Several technologies have evolved that can deliver compounds locally to the environment of the
blood vessel wall in an attempt to achieve the goals stated above, and are shown schematically
(Fig. 1.1). These can be organized into two groups: systemic administration and local release.
Systemic administration through intravenous injection or infusion, intramuscular injection,
transdermal patch or subcutaneous polymeric controlled-release implants delivers drug to all tissues
in the organism, requiring drug to circulate to the target tissue. Local modes of release
preferentially load adjacent tissues over systemic sites can be classified either as bolus delivery,
such as through permeable and double balloon catheters, or as sustained or controlled-release
modes of delivery. Several generations of permeable balloons have been designed with various
sizes, numbers, and configurations of holes that transmit soluble drug to the endovascular aspect
of blood vessel wall.33 '4 4-47 Local sustained delivery methods typically utilize erodable or
nonerodable polymeric release devices which are implanted on or near either the endovascular or
perivascular aspect. Perivascular delivery devices have been formed into a number of shapes, to
release drug from a slab, a point source or a complete circumferential wrap. Endovascular
sustained release has been accomplished by crosslinking hydrogels to the intimal surface,
4 8
,
49
deploying more rigid polymeric sheets,50 or from mechanotherapeutic expandable endovascular
stents.34 ,5
1
,
52
1.4. Pharmacokinetic Framework
Despite the theoretical advantages of local delivery systems to treat proliferative vascular
diseases, only a small group of antiproliferative compounds have shown benefit in animal models
and none in clinical trials. The central hypothesis of this work is that the application of local
vascular release systems to inhibit restenosis requires sophisticated coupling of both
pharmacokinetic and pharmacodynamic processes. The former describes the fate of a drug within
an organism and the latter describes the biologic effect of that drug in tissues where it is
distributed.
It is the goal of this work to determine drug deposition and distribution following any mode of
Intravascular
Luminal Paving
Endovascular Stent
Double Balloon
Figure 1.1 Modes of local vascular drug delivery.
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vascular drug delivery. With this ability, one could predict a priori whether a drug delivery
strategy maintains arterial concentrations adequately for a sufficient duration to achieve the desired
biologic effect. Alternatively, the ability to predict tissue concentrations of drug could be used to
correlate biological effect with vascular delivery experiments, to determine the duration and local
concentration required to modulate injured blood vessel repair. A traditional pharmacokinetic
approach will be used to provide a quantitative framework by which to establish vascular drug
deposition and distribution and to compare these modalities. Classic pharmacokinetics
quantitatively describe the administration, distribution, and elimination. It should be noted that the
analysis of local delivery described in this thesis differs from classical pharmacokinetic studies as
the compartment of interest is not the systemic circulation, extracellular fluid, or the entire
organism but rather the blood vessel wall. Therefore, in the context of local delivery,
administration refers to release from implanted polymer matrices or catheters and transport to the
perivascular and endovascular boundaries of the blood vessel wall (Fig. 1.2). Similarly,
distribution refers to the transport of soluble drug, and potential binding into an immobile phase.
Elimination includes dissociation from binding sites, transport through the vessel wall and out the
boundaries, cellular internalization, and local degradation.
1.5. Foundations of Local Vascular Pharmacokinetics
The vascular administration, distribution and elimination of drugs is highly dependent on
mechanisms of soluble drug transport and deposition (Fig. 1.3). Forces of solute transport include
diffusion which results from random molecular collisions and Brownian motion, and convection
which arises from the physiologic transmural hydrostatic pressure gradient and the hydraulic
A
(21D
A
Fig. 1.2. Local vascular pharmacokinetics describes the administration (A) to, the
distribution (D) through, and the elimination (E) from the blood vessel wall.
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conductivity of the arterial wall. Anatomical barriers such as the endothelium or adventitia inhibit
the distribution of solutes. The deposition of drug is influenced by reversible binding to both
biologically active as well as nonspecific sites, and endocytotic and transmembrane cellular
internalization. Classical ligand binding studies include steps to eliminate nonspecific binding and
therefore, little quantitative information exists on the magnitude of these effects for any compound,
let alone vasoactive substances in arterial tissues. 53 The transvascular transport of soluble
compounds, however, has been studied extensively with respect to the infiltration of atherogenic
substances. The entry of plasma born macromolecules, such as low-density lipoprotein (LDL),
into the arterial wall has been implicated as a causative process in the long-term development of
atherosclerosis. 5 4' 55 The precise mechanisms of transmural molecular transport has been the
subject of intensive experimental and theoretical study over the last 50 years and continues to be so
today. Much attention has focused on quantifying transendothelial permeability56 -62 and
subsequent arterial distribution by diffusive and convective mechanisms, 63-74 of LDL and more
convenient representative macromolecules such as serum albumin75-90 and horseradish peroxidase
(HRP).9 1-96 Many theoretical treatises have described the transmural transport in terms of several
physicochemical properties of the compound in the tissue. 9 7 -10 2 Although many of the
compounds used in atherogenic studies, such as LDL, albumin, and HRP bear little resemblance to
vasoactive compounds, the same principles potentially govern the transport of exogenous drug in
vascular structures. Application of atherogenic-transport models to soluble vasotherapeutic agents
might simply require applying the correct physicochemical properties of the drug in arterial tissues.
I I
Figure 1.3 Potential mechanisms of vascular deposition and distribution of drug.
IC_
I
1.6. Review of Atherogenic Transvascular Transport Models
A review of the evolution of atherogenic transport models is presented and forms the basis of
the local vascular pharmacokinetic framework. Rather than recapitulate every transvascular
transport model in detail, a few analyses are presented which represent significant developments or
specific classes of models.
1.6.1. Lumped Parameter Models
One of the first models was developed by Duncan et al. to help explain radiolabeled albumin
uptake by various segments of the canine aorta and other peripheral tissues. 8 1 The artery and
plasma were each considered well mixed compartments, where the solute in the plasma crossed
into the tissue according to first order kinetics (kl), and was degraded or cleared also by first order
kinetics (k2). A mass balance of the tissue compartment yields:
dt(cT) = k1cp - k2cT I CP F ]-
Following the injection of the solute, the serum concentration (cp) was empirically measured and fit
to a double exponential decay. The rate constants k1 and k2 were fit to experimental tissue
concentration (CT) data at various locations along the aorta. Interestingly, the rate of vascular
uptake, k1, decreased along the length of the aorta where the arterial segments are progressively
thinner. Another two compartment model presented by Ghosh et al., 67 in contrast to the previous
one by Duncan et al., allowed for solute to exchange freely between the plasma and tissue pool,
but did not allow for degradation. Rate constants were determined for LDL, albumin, and gamma-
globulin, however, no correlation was found between the constants and the molecular weight of
the compounds. This led them to hypothesize that the arterial uptake mechanisms were
significantly different for each compound. Krishnan et al. extended this analysis to a three
compartment model including plasma, extracellular, and intracellular tissues.103 The rate constants
were not determined due to an inability to distinguish intracellular from extracellular solute.
1.6.2. Continuum Models
All of the lumped parameter models, such as the one proposed by Duncan et al.,8 1 are
empirical and offer little insight into the mechanisms of vascular solute uptake, and are thus not
extendible to other arterial systems or compounds. Alternatively, a continuum approach, which
views the arterial wall as an infinite number of concentric and infinitesimally thin homogeneous
compartments, was first proposed by Weinbaum and Caro. 10 1 In this approach, the
concentration across the vessel wall is described continuously, and thus local changes in transport
properties are evident as altered concentration gradients. They modeled the diffusive transport and
internalization of labeled macromolecules in a hypothetical in vitro perfusion preparation, by first
defining the following dimensionless groups:
X = x/1, 2 = tD/12 , f = P12/D
where 1 is the thickness of the artery, x is a spatial coordinate oriented from the intima to the
adventitia, t is time, and P is a dimensionless cell permeation parameter based on a cell membrane
permeability, P. Note that the diffusion coefficient, D, is the effective molecular diffusivity of the
solute and is lower than in aqueous solutions due to tortuosity in the solute pathway, the porosity
of the tissue, and steric and charged interactions. The following governing equation then
represents solute accumulation, diffusion in the extracellular phase, and permeation into the
intracellular phase:
Oec d d2 c" = 2 (cic - cec)
where Cec and cic are concentrations in the extracellular and intracellular phases, respectively,
normalized by the perfusate concentration, and a is the volume fraction of each phase. The rate of
accumulation inside cells was equated with the permeation into this compartment:
dciic "- = f(cec - cic)
The boundary conditions assumed that the concentration at the adventitia was zero, and that
transport across the endothelial monolayer was exclusively through vesicles:
Cec(1, T) = 0 at X = 1
cec = [1 -ec] at = 0
The dimensionless parameter a = RVvLI/D, is a ratio of the transendothelial vesicular transport
rate to the diffusive transport rate in arterial media, where OR is the transendothelial vesicle number
flux and V, is the internal vesicular volume. Initially there was no solute in the tissue. These
solutions were solved to predict transmural concentration profiles of solute in this hypothetical
preparation.
1.6.3. More Complete Models and Parameter Estimation
Although the early continuum model of Weinbaum and Caro neglected solute convection,
binding, and degradation, it was an important first application of continuum engineering principles
to the transvascular transport of solutes. Bratzler et al. proposed a model that also included
convection, reversible binding, dissociation, and intracellular degradation.97 Furthermore, the
boundary conditions allowed for solute to cross the endothelium in intercellular junctions as well as
in vesicles. This model is more representative of transport in vivo than the model of Weinbaum
and Caro because the adventitial boundary condition was non-zero, accounting for diffusion and
vesicular transport into lymphatics and additional vesicular transport from vasa vasorum. The
governing equation for free unbound solute in the soluble phase (subscript s) was described:
ds D d2c - Uc - P(cs - cic) - klcs + k2cb
ýt dx2  e dx
Accumulation Diffusion Convection Internalization Binding Dissociation
Where U is the superficial filtration flow velocity, e is the tissue porosity, k1 the first order binding
rate constant, and k2 the first order dissociation rate constant from those binding sites. Additional
governing equations describe bound (subscript b) and internalized (subscript ic) solutes,
respectively.
=- k1cs - k2cbdt
Accumulation Binding Dissociation
dCi 
- k3cic + P(cs 
- cic)dt
Accumulation Degradation Internalization
where k3 is a first order rate constant describing the degradation of internalized solute. The intimal
boundary condition (x=-0O) was described as follows:
E UCf dx
Intercellular Vesicular Convection Diffusion
Endothelium Endothelium Media Media
where the terms represent from left to right: transport in interendothelial junctions, vesicular
transport, convection in media, and diffusion in media. At the adventitial boundary condition
(x=l):
Ucf(1-rL) + KL +Kc cE = Ucf - D
Intercellular Vesicular Vesicular Convection Diffusion
Lymphatics Lymphatic Vasa Vasorum Media Media
and the terms represent from left to right: transport to lymphatics, vesicular transport from vasa
vasorum, vesicular transport to lymphatics, convection in media, and diffusion in media. re and rL
are phenomenological reflection coefficients for the endothelium and lymphatics. Ke, Kc and KL
are vesicular mass transfer coefficients for endothelium, vasa vasorum, and lymphatics,
respectively. The authors tried to fit this model to empirical data and demonstrated a fundamental
limitation of parameter estimation by this technique. Even though they correctly assumed that
binding and degradation were negligible for short-time tracer studies and set kl, k2, and k3 equal to
zero, they still had nine parameters (D, e,V, P, Ke, Kc, KL, re, rL) to determine from one set of
curves. Fitting this many parameters from data that expressed concentration as a function of space
and time represents a mathematically unconstrained problem in which there is not one unique
solution, i.e. many combinations of parameters fit the data with the same accuracy. The fewer the
parameters the more constrained the curve-fit becomes, and they therefore tried to include
independently-measured coefficients to increase the uniqueness of the solution and the confidence
in the estimated parameters. Although they used premeasured values for the tissue porosity (e)
and they held the ratio of velocity to diffusivity constant, they still had seven independent
parameters to estimate. In some cases, the parameters estimated varied by an order of magnitude,
leading to ambiguous conclusions of the mechanisms of transvascular macromolecular transport.
Truskey et al. increased the sophistication of the above analysis even further by adding separate
terms for diffusion and convection into and out of venous and arterial capillaries in the
adventitia. 10 0 Although these models are more complete from the point of view of potential
mechanisms, they have even more parameters to fit than the model of Bratzler et al. 97 Fry was
able to obtain unique parameter estimates from fitting transmural concentration profile data when
the number of independent variables was limited to five or fewer. 98 Some have eliminated
parameters to fit by restricting their models to very short times after solute injection. 99 In this time,
the solute can not completely penetrate the arterial media and therefore this tissue can be considered
mathematically semi-infinite. Thus, the parameters in the adventitial boundary conditions do not
appear in the analysis. Much of the arterial uptake data in the atherogenesis literature is taken
within thirty minutes of solute injection. 63 ,7 6,10 0 Furthermore, Saidel et al. and others have
simplified the intimal boundary conditions with a single parameter describing permeability across
this layer.94 ,99 ,102,104,105 These analyses quantify intimal transport as the sum of several
concentration driven processes, but make no attempt at discriminating between them.
Fry and Vaishnav presented a series of simple models and analytic solutions that build to
incorporate the major mechanisms encountered in arterial uptake. 102 They first discussed steady-
state diffusion across a homogenous slab, then successively added a second zone to form a
composite slab, then a surface barrier, and then allowed for chemical reactions. The homogenous
slab is analogous to arterial media, the surface barrier is analogous to the endothelial monolayer,
and the chemical reaction represents contributions from first-order binding, degradation, and
internalization. They repeated each of these process for non-steady state transvascular transport.
This sequential approach shows, with a minimum of complexity, how each of these effects
individually impacts the transmural distribution of solutes.
1.6.4. Endothelium and Intima
Fry and Vaishnav included solutions for transport into slabs with surface barriers because it is
widely held that the endothelium is the organ that prevents plasma macromolecules from entering
the arterial wall and contributing to the atherogenic process. 63 ,76 ,79 ,87 ,9 3,94 ,10 1,10 6,107 Many
vascular transport models have attempted to elucidate the mechanisms of endothelial permeability to
plasma proteins. 108-114 These works seek to explain the focal nature of endothelial permeability to
tracer molecules, which has been attributed to the normal physiologic turnover of endothelial cells,
and has been called the "leaky junction hypothesis. "57-60,73,84,115,116 Sophisticated models have
shown that the small gap in the otherwise tight intercellular junctions created by normal endothelial
turnover can lead to substantial increases in the overall permeability of the monolayer to large
proteins. 108-114 These analyses model two-dimensional transport both across the subendothelial
space and radially outwards from the leaky cleft in the plane of the intima, in addition to transmural
diffusion and convection. Experimental analyses focusing on the intima and endothelium have
shown that this intact layer is the dominant barrier to transvascular transport of
macromolecules. 63' 76 ,7 9,87 ,9 3,94,'10 1,106' 10 7 This anatomic barrier function observed in vivo
includes the ever present physiologic leaks in the endothelium that are caused by normal mitoses.
Other analyses treat the intima as several discrete layers consisting of endothelial cells, subintimal
matrix and internal elastic laminae, and have resolved the diffusive resistances of each of these
structures.95,117 For example, the internal elastic laminae has been shown to account for 25% of
the diffusive resistance of the intima to HRP.95
1.6.5. Deformable Arterial Wall
All of the aforementioned models are based on rigid nondeformable blood vessels, yet the
arterial wall is a clearly an elastic structure having internal stresses which depend on the transmural
pressure. 118 For example, increased pressure will distend the lumen radius and decrease the wall
thickness. These deformations cause the tissue to compact and may alter transport properties such
as available tissue space for solute distribution or hydraulic conductivity. 65,89,119-122 Applied
transmural pressure can potentially enhance convective transport or decrease available space, and
these effects are difficult to distinguish in many experimental preparations. Building on the fiber
matrix theories of Curry, 123 -125 Kim and Tarbell derived a model for the impact of applied
pressure on the effective molecular diffusivity and the available space for distribution of several
solutes, and the hydraulic conductivity through the arterial wall. 126 They matched the results of
their model to the data of Tedgui and Lever 88,119 ,120 to show that the available space increases
towards the adventitia for macromolecules, but is independent of position for small molecules such
as sucrose. They noted that the fiber dimensions required to make the data fit the model suggested
that molecules diffuse in the interstitium of arteries and circumvent smooth muscle cells. This
elegant analysis illustrates the potential impact of in vitro manipulation of tissues on transport
properties and highlights some of the more subtle physical phenomenon that influence distribution
in the complex blood vessel wall.
1.7. Work In This Thesis
Much quantitative insight into transvascular transport and pharmacokinetics has been gained
from studies motivated by lipid and protein uptake by the arterial wall during atherogenesis.56-96
However, these studies are concerned almost exclusively with endovascular infiltration of
atherogenic compounds such as LDL, marker compounds such as HRP, and inert compounds
such as albumin. None of them bear great resemblance to vasotherapeutic molecules in size,
charge, and steric conformation and therefore careful pharmacokinetic study of any potential
compound is warranted. The experimental studies in this work examine vascular drug deposition
and distribution of an actual vasotherapeutic compound, heparin, which is the gold standard for
smooth muscle cell growth inhibitors. 11-13,127 Endothelial cells produce heparan sulfate
proteoglycan and the ability of their cultured media to inhibit smooth muscle cell growth arises
from a heparin-like product. 11' 128 Exogenous heparin (10-100 gLg/ml) rapidly inhibits DNA and
RNA synthesis in growth arrested cells released from Go block. 12 Continuous intravenous
infusion of heparin virtually abolishes intimal smooth muscle cell proliferation in the injured
artery. 13 Knowledge of the local transport and distribution of these compounds may help to better
understand the role they play in endogenous vascular repair and their potential as therapeutic
agents.
The pharmacokinetic analyses in this work differ from the previous models of transvascular
transport of atherogenic compounds in several additional ways. Rather than applying compounds
to arteries, observing the distribution phenomenologically and attempting to infer the contribution
of each potential mechanism of transport and binding simultaneously from a single set of
experimental data, the experiments performed are the simplest possible that examine each
mechanism in isolation. All of the individual results are then assimilated in a unified model.
Secondly, the effects of binding are not assumed to follow first order rate kinetics, which implies
that the binding sites never approach saturation. The current models allow the examination of
regimes where the binding sites fill, and furthermore explicitly incorporate the effects of
nonspecific binding. Because transvascular transport of vasotherapeutic compounds potentially
includes passage through the adventitia, this layer is studied in greater detail than many of the
previous works which assume it is a loose layer with little impact. Finally, transmural
concentration profiles are generated through computational simulations, which have the benefit of
having entirely flexible boundary conditions which allow easy description of many of the modes of
local vascular drug delivery.
1.8. Summary of Analyses
The following chapters in this work describe the measurement of intramural transport
mechanisms, binding within the arterial wall, and the movement of drug in the vicinity of but
external to the blood vessel wall. The results are combined into a computational model that
predicts vascular deposition and distribution.
Chapter 2. The Mechanisms Of Soluble Heparin Transport
The diffusivity of heparin in arterial media and adventitia and the diffusive resistance of the
endothelium have been quantified through transmural transport measurements in an in vitro rat
abdominal aorta model. The relative contributions of convection and diffusion to transmural
heparin deposition and distribution, as well as the barrier function of endothelium and adventitia
have been evaluated in this and several other animal models including the calf carotid artery in vitro
and the rabbit iliac artery in vivo.
Chapter 3 Tissue Average Binding And Equilibrium Distribution
The equilibrium distribution of heparin in arterial media and adventitia of porcine carotid
arteries has been determined. The fractional volume of distribution, the total binding site density
including specific and nonspecific association, and the average dissociation constant of these
binding sites have been measured from these data.
Chapter 4 Drug Transport Around Local Arterial Environment
The pathways of drug clearance from the perivascular space to the systemic circulation and the
pathways of drug incorporation into the blood vessel wall have been determined. The potential for
drug to be lost to the lumen and extra-arterial capillaries has been compared.
Chapter 5 Computational Simulations Of Vascular Heparin Deposition And Distribution
A finite difference algorithm has been used to construct computational simulations of soluble,
reversible, and internalized transmural concentration profiles of heparin. The model is verified
with experimental data from a novel endovascular hydrogel delivery system, and as an example the
ability of the arterial wall to retain heparin is assessed.
2. THE MECHANISMS OF SOLUBLE HEPARIN TRANSPORT
2.1. Introduction
Vascular pharmacokinetics depend on the movement of soluble drug through tissues, reversible
binding, and cellular internalization. Forces of solute transport include diffusion, which results
from random molecular collisions and Brownian motion, and convection, which arises from the
physiologic transmural hydrostatic pressure gradient and the hydraulic conductivity of the arterial
wall (Fig. 1.3). Structures at the borders of the arterial media, such as the endothelium or
adventitia, potentially limit the transit of solutes into and out of the artery. This chapter describes
the measurement of the diffusivity of heparin in arterial media and adventitia, and the
transendothelial resistance to heparin transport. These measurements were made with a steady
transvascular solute flux assay under conditions where transmural hydrostatic pressure gradients
were eliminated. Thus, the heparin flux was exclusively driven by molecular diffusion. The rat
abdominal aorta was used in these studies as this thin vessel allows steady-state transport to be
established rapidly. Additional transmural transport experiments were performed with the addition
of a physiologic transmural hydrostatic pressure gradient, to illustrate the impact of convective
forces on the transvascular heparin flux in the rat abdominal aorta. These results compared
favorably to theoretical predictions of the ratio of convective to diffusive forces generated by
combining the diffusivity measurements with published correlations of arterial hydraulic
conductivity.
The above experiments quantify the magnitude of transvascular transport mechanisms through
transmural flux assays. The sum of all of these mechanisms define the deposition of applied drug.
Arterial heparin deposition was measured in vitro in the calf carotid artery under varying conditions
which highlighted individually the impact of convective forces, the presence of the endothelial
monolayer, and the application of drugs directly to either the perivascular or endovascular surfaces.
Theoretical predictions suggest that the ratio of convective to diffusive forces of transvascular
heparin transport depends on the medial thickness. The calf carotid artery used in these latter
perfusion experiments is over ten times thicker than the rat abdominal aorta and was used to verify
this prediction. Heparin was also delivered perivascularly to native and deendothelialized rabbit
iliac arteries to examine the potential transendothelial resistance to transport in vivo.
2.2. Materials and Methods
2.2.1. Transvascular Flux Assay in the Rat Abdominal Aorta
2.2.1.1. Preparation of the Rat Abdominal Aorta
Sprague Dawley rats (320-360 g) were anesthetized with an intraperitoneal injection of
ketamine (50 mg/kg) and xylazine (10 mg/kg). The abdominal aorta was exposed, cleaned of fat
and excess fascia, and cannulated proximally just below the splenic vein and distally just above the
iliac bifurcation. Ligatures were placed around each cannula so that the intermediate segment of
artery was isolated from the rest of the circulation. All branch vessels were ligated and severed.
The cannulas were clamped to a rigid frame so that the length of the isolated artery was preserved
at its in vivo dimensions. The artery was excised and the length of the artery between the tips of
cannula was measured under a dissecting microscope (0.99 ± 0.03 cm). Leaks from the artery
were assessed by connecting one cannula to an elevated (100 cm) reservoir and closing the other
cannula. The artery was inspected under the microscope and discarded if any leak was noted.
To assess the integrity of the vessel wall after dissection and to exclude arteries from the
analysis where trauma might lead to potential artifact, each artery was pressurized to 125 cm H20
by connecting an elevated bag of Ringer's solution with the other cannula closed. The artery was
examined for leaks under a dissecting microscope, and the bag for flow for several minutes. In a
separate experiment, the integrity of the endothelial monolayer of excised rat abdominal aortas was
confirmed by perfusing an artery with 4% Albumin and Evan's Blue Dye in buffer. 88
2.2.1.2. In Vitro Perfusion Apparatus
The artery was placed in an in vitro perfusion apparatus (Fig. 2.1), simulating plasma flow
through the artery. The perfusate flowed from an upper reservoir through the artery, emptied into
a lower reservoir, and was pumped back to the upper reservoir, forming a well mixed
endovascular compartment (100 ml). The artery was immersed in a perivascular bath (4 ml), to
which known concentrations of radiolabeled heparin were added, establishing a fixed transmural
concentration gradient. Krebs-Henseleit buffer (Sigma) was used as the perfusate in the
endovascular compartment and in the perivascular bath. The transmural pressure gradient and the
luminal volume flow rate were set by the height, or hydrostatic pressure head, of the upper
reservoir, AH, and the downstream resistance to flow, which was adjusted through a throttle
valve. An overflow line connected the upper and lower reservoirs directly, holding AH constant,
regardless of pump speed. The entire perfusion system was placed within a closed cabinet
maintained at 370 C and 100% relative humidity. Not shown are a stir bar in the perivascular bath,
a thermally controlled water jacket surrounding the lower reservoir, and in the lower reservoir a
thermometer, and a 95% 02 and 5% CO 2 bubbler. The volume flow rate of perfusate was
measured by counting the rate at which drops fell from an outflow needle. Drop volumes were
determined before each experiment from the number of drops collected in a measured volume.
2.2.1.3 Rat Aorta Perfusion Protocol
Heparin was administered to the exterior of the artery by immersion in the perivascular bath
containing 3H-heparin (Du Pont-NEN) and unlabeled heparin (Hepar Industries) in buffer (2.5
mg/ml, 6 gCi/ ml). The artery was perfused for six hours at 37 'C. At one hour intervals, three
50-gl samples were taken from the lower reservoir and one 50-tl sample was removed from the
perivascular bath. The perfusate volume flow rate, temperature, and pH were monitored hourly.
Nine rat aortas were perfused without a hydrostatic pressure head (AH = 0 cm), thus setting
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Figure 2.1. Schematic of the perfusion apparatus.
the transmural pressure gradient (AP) to zero and establishing a scenario wherein all the measured
mass transfer should have been governed solely by diffusion. The endothelium of four of these
arteries were denuded with 3 passes of an inflated 2 French embolectomy catheter (Baxter
Diagnostics). 129 Another 11 rat aortas were perfused with AH equal to 100 cm, mimicking a
physiologic pressure gradient. Before each experiment the pressure just downstream of the artery
was measured with a diaphragm manometer (Omega Engineering). The flow rate was adjusted
with the throttle valve over a range that resulted in a physiologic pressure gradient of 99-103 cm
H20 (1±.25 ml/min). During the subsequent perfusions the flow rate remained within this range.
Five of these arteries were also denuded of endothelium prior to cannulation.
At the end of the experiment, the perivascular bath was switched to a modified Bouin's fixative
(53% EtOH, 4% formaldehyde, 2.5% glutaraldehyde, 7% acetic acid, 0.7% KC1) and the artery
was perfused with fresh buffer for three hours. The artery was then immersion fixed for an
additional 40 hours without perfusing, after which it was dehydrated and processed for paraffin
embedding. Serial 10 pLm cross sections were taken from one cannula tip to the other and stained
with Verhoeff's elastin stain.
Computer assisted morphometric analysis was performed on cross sections taken at 1 mm
intervals along the arterial length. The internal elastic lamina (IEL), the external elastic lamina
(EEL), and outer edge of the adventitia were traced with image analysis software (IPLab Spectrum,
Signal Analytics). The length of the IEL and EEL, and the area of the lumen, media, and adventitia
were measured. The medial thickness of each cross section was calculated by dividing the medial
area by the length of the IEL. The adventitial thickness of each cross section was calculated by
dividing the adventitial area by the length of the EEL. Mean values for medial thickness,
adventitial thickness, luminal area, and internal perimeter were calculated for each artery and used
in subsequent calculations. The perivascular concentration was the average of the measurements at
each time point. The transmural heparin mass transfer rate was defined as the time rate of change
of heparin in the endovascular compartment and was calculated by a linear regression fit over the
steady-state portion of the data.
2.2.2. Diffusivity of Heparin in Aqueous Solutions
The diffusivity of 3H-heparin in water was measured using a standard diffusion cell (Crown
Glass) with a porous hydrophilic membrane (GVWP, mean pore size 0.22 gim, Millipore) that
separated two 3-ml chambers. 3H-heparin was added to the source chamber and an equal
concentration of unlabeled heparin was added to the sink chamber, to create iso-osmotic
conditions. Each chamber was well mixed with magnetic stir bars and maintained at room
temperature. 10-gl aliquots were taken from each chamber at 10 minute intervals for 90 minutes.
The concentration gradient of 3H-heparin was large enough so that it could be considered constant
over the short time of the experiment, and approximated by the average concentration of heparin in
the source chamber (Ch*). The time rate of change of heparin concentration in the sink chamber
(dch/dt) was calculated by performing a linear regression over the steady-state portion of the sink
chamber measurements. From a mass balance for the sink chamber, the diffusivity of heparin in
aqueous solutions (Daq):
(2.1) Daq - ImemVh dch
Aoch* dt
where vh is the volume of the sink chamber, Ao is the total open area of all of the pores and 1mem
is the thickness of the membrane.
2.2.3. Arterial Heparin Deposition
2.2.3.1. Deposition in Calf Carotid Arteries In Vitro
Calf carotid arteries were excised at a slaughterhouse and immediately placed in phosphate
buffered saline with 0.01 mM calcium and 0.1 mM magnesium (Sigma) at 4 oC, and stored for no
more than 3 hours. The arteries were cleaned of excess fat and fascia, and approximately 1.5 cm
long segments were cannulated at each end with polyethylene tubing (1.57 mm ID, 2.08 mm OD,
Clay Adams). Just prior to cannulation, some arteries were denuded with 3 passes of an inflated 3
Fr embolectomy catheter (Baxter). 129 After cannulation, the integrity of the artery was assessed
by connecting one cannula to an elevated bag of Ringer's solution, sealing the other cannula, and
inspecting the artery for leaks under a dissecting microscope.105 Both cannulas were clamped to a
rigid frame while the vessel was expanded under physiologic pressure so that the inflated length
was maintained. The artery was then placed in the perfusion apparatus described above (Sec.
2.2.1.2).
3H-heparin (0.12 gCi/ml, 0.7 mCi/mg, NEN-Dupont) was applied to either the perivascular or
endovascular compartments and the artery was perfused for 1 hour. This time was insufficient for
heparin to fully penetrate the arterial wall and therefore the drug deposition reflects the rate of entry
into the artery. 63,76,99 The endovascular volume was 100 ml for all perfusions, while the
perivascular volume was 12 ml for perivascular and 100 ml for endovascular administration. Three
50-•l samples were taken from both compartments at the start and end of each perfusion
experiment. Following the perfusion, adsorbed drug was removed by either flushing 3 ml of fresh
buffer through the lumen following endovascular delivery, or dipping the artery once in clean
buffer following perivascular delivery. The artery was cut into five segments and the middle three
were freeze-dried, weighed, solubilized with Soluene 350 (Packard), and prepared for
measurement of deposited 3H-heparin through liquid scintillation spectrometry with Hionic Fluor
(Packard). Histologic frozen sections were cut from the two end arterial segments, and stained
with Verhoeff's elastin stain.
Perfusion experiments were performed with all combinations of the following conditions:
perivascular or endovascular administration of heparin, native or denuded arteries, and a
transmural hydrostatic pressure gradient of 0 or 100 cm H20. Four arteries were perfused under
each of these eight conditions, and deposition was measured three times for each vessel. The
deposition is reported as the amount of drug normalized by both the dry mass of tissue and the
average concentration of the applied drug. In a separate experiment, an artery was perfused with
4% Albumin and Evan's Blue Dye in buffer and no dense blue staining was observed on enface
view, indicating the presence of endothelial cells.88
2.2.3.2. Deposition in Rabbit Iliac Arteries In Vivo
Heparin deposition was compared 2 hours after perivascular administration to native and
denuded rabbit iliac arteries in vivo. Heparin releasing hydrogels were formed into hollow
cylindrical tubes by crosslinking a prepolymer solution using a photoreactive technique. 49 The
prepolymer consisted of a backbone of polyethylene glycol (3.3 kD) with lactates on both ends (an
average of 5 lactates per molecule) and capped with acrylate (Focal, Inc.). This prepolymer was
dissolved in 90 mM triethanolamine (30% wt/wt, Aldrich) to which N-vinylpyrrolidone (VP, 2
gl/ml, Aldrich), and 3H-heparin (20 gCi/ml, NEN-Dupont) were added. Just prior to crosslinking
a photoinitiator, eosin Y (20 pg/ml, Sigma), was added to the prepolymer solution. This mixture
was injected into a hollow cylindrical transparent molds (ID 2.08 mm, OD 3.35 mm, thickness 635
gm) and photopolymerized with an argon laser (488-514 nm, 70 mW/cm2 , American Laser).. The
resulting cylinders were cut into 7 mm long segments and slit longitudinally. The elasticity of the
bulk-gelled hydrogel tubes allowed them to be placed around the iliac artery and retain their
cylindrical shape.
Male New Zealand White rabbits (2.75 to 3.25 kg) were anesthetized with an intramuscular
injection of ketamine (50 mg/kg) and xylazine (15 mg/kg) and were maintained with intravenous
and intramuscular boluses as needed. The iliac arteries were exposed through a midline abdominal
incision and displacement of the intestinal viscera, and arterial segments were isolated from the iliac
bifurcation to the inguinal ligament. Heparin releasing hydrogel collars were made fresh before
implantation. Two were applied to adjacent arterial segments such that each animal received four
devices. The abdomen was sutured closed to prevent dehydration. The abdomen was reopened
just prior to removal of each device and the corresponding iliac artery was clamped with a hemostat
distal to the iliac bifurcation. This allowed for vessels to be removed without disrupting the flow
to the contralateral artery, enabling drug delivery to persist for the duration of the experiment, and
insuring that the adventitial surfaces would not become contaminated with blood. Just prior to
implantation in a separate experimental group, both left and right iliac arteries were balloon
denuded with three passes of an inflated 3 French embolectomy catheter passed retrograde from a
femoral arteriotomy. 129
Immediately following excision, the arteries were cut into proximal and distal segments and
stored at -70 0 C. At the time of processing, they were freeze dried, weighed and solubilized with
Soluene-350, and prepared for measurement of deposited 3H-heparin through liquid scintillation
spectrometry with Hionic Fluor. Each experimental group consisted of 3 rabbits, and four
segments of iliac artery were harvested from each, two on each side. The deposition is reported as
the amount of drug normalized by both the dry mass of tissue and the initial concentration of the
drug in the hydrogel release device.
2.3. Calculations
2.3.1. Diffusivities and Resistances of Heparin Within the Arterial Wall
The transvascular transport measurements on the rat abdominal aorta performed with no
hydrostatic head ( AH = 0 cm) had no transmural pressure gradient, and therefore no transmural
hydraulic flux (Sec. 2.2.1.3). Thus, once steady state was established, the mass transfer data
reflected diffusion alone. The arterial wall was modeled as a series of concentric cylindrical tubes
(Fig. 2.2) and the medial and adventitial thicknesses were approximated as the average of those
measured from all the histologic sections of an artery. Furthermore, the perivascular and
endovascular compartments were well mixed so that the only concentration gradient existed in the
transmural direction. The transport was modeled as four resistors in series, one each for the
adventitia (Radv), media (Rmed), endothelium (Rend), and for the mass transfer boundary layer
within the lumen flow (Rbl), which separate the potential or concentration gradient (cpv - Cev).
Thus, by analogy to Ohm's law, the potential difference for diffusive mass transfer is the product
of the flux and the series sum of these resistances:
(2.2) Ce, - c v = (Radv + Rmed + bendRend + Rbl)
j is the transmural heparin transfer rate, L is the length and P is the average perimeter of the
lumen. The coefficient of Rend (bend) is unitless and was 0 following a denuding injury, and I
with intact native arteries.
Since the mass transfer was purely diffusive in these perfusions performed at AH = 0 cm:
Cev
Figure 2.2. The transmural transport of heparin, when perfused with no transmural pressure
gradient (AH=O cm), is modeled as one dimensional. The thicknesses of the media and adventitia
are assumed to be uniform along the length and circumference of the artery.
(2.3) R = ldDd,
and
(2.4) Rmed = lmed /Dmed
ladv and Imed are the adventitial and medial thicknesses, and Dad, and Dmed are the diffusivity of
heparin within the adventitia and media, respectively. Note that the term "diffusivity" is a
proportionality constant that equates the resulting mass flux to an applied concentration gradient. It
is specific to a solute and the medium in which it moves. In a tissue such as an artery, the
measured effective diffusivity will reflect molecular diffusion in the interstitium, tortuosity, steric
and charged interactions, and potential active transcellular transport. Rearrangement of Equation
2.2 allows the unknowns, Dmed, Dadv , and Rend to be determined by multiple linear regression:
(2.5) LP(cp - Cev)/j - Rbl = ladv/Dadv +med/Dmed + bendRend
The boundary layer resistance (Rbl) results from solute that enters the lumen from points upstream
and hinders the entry of solute from the wall at downstream locations (Fig. 2.2). The value of the
boundary layer resistance can be determined from correlations that are specific for fluid momentum
and mass transfer regimes encountered in the perfusion experiments. In all of the perfusion
experiments, while fluid flow in the lumen was fully developed and laminar, the artery was not
long enough to consider the mass transfer fully developed. The Sherwood number, Shd, is a
nondimensional form of the resistance to mass transfer of the boundary layer. 130,13 1
(2.6) Shd =
RblDaq
An appropriate correlation for the Sherwood number for fully developed fluid flow and non-fully
developed mass transfer follows: 130 ,13 1
0.065(d/L) Red V/Daq(2.7) Shd =3.66+
1+ 0.04[(d/L)Red VI/Daq ]2/3
Where the Reynolds number is:
(2.8) Red = ld/v)
and where V1 is the average fluid velocity in the lumen and equals the average volume flow rate of
perfusate divided by the open area of the lumen (A,), and v is the kinematic viscosity. The
hydraulic diameter, d, helps describe the flow regime through non-circular ducts:
(2.9) d = 4AI/P
2.3.2. Balance Between Diffusion and Convection in Transmural Transport
The physiologic hydrostatic pressure gradient gives rise to transmural convective currents
which potentially "drag" drug through the artery. The ratio of the convective to diffusive forces of
transmural transport of a given drug molecule is embodied in the Peclet number (Pe).88,100 ,126
Pe much less than 1 implies that the transmural transport is purely diffusive, and conversely Pe
much greater than 1 implies that the transport is purely convective. Pe about unity implies that
both diffusive and convective effects play a role in drug transport. For heparin in arterial media:
(2.10) Pe = Umedlmed / Dmed
Umed is the heparin drift velocity in arterial media and may be less than the hydraulic velocity (u)
due to steric and charge interactions in the arterial tissue. 100 ,124 The degree of hindrance may
differ for diffusive and convective mechanisms. The hindrance coefficient for diffusive flux of
heparin in arterial media (fred) is defined as the degree by which the diffusivity in arterial media is
reduced from the diffusivity in aqueous solutions:100,102
(2.11) fied = Dmed/Daq
Similarly, a hindrance coefficient for convective flux in arterial media (fCed) can be defined as the
degree by which the solute drift velocity is reduced from the transmural hydraulic velocity (u)102
(2.12) fmied = Umed/U
The transmural hydraulic velocity (u) can be determined by modeling the media and endothelium
as two conductors in series,
AP(2.13) u =(2.13) lmed bend
Kmed K end
where y is the dynamic viscosity. Kmed is the specific hydraulic conductivity of the media and has
been measured to be 2x10 - 14 cm2. 121 The intrinsic hydraulic conductivity of the intact endothelium,
K"nd, is 8.2x10 -11 cm2s/g. 132 Recall that bend, is 0 following a denuding injury, and 1 with intact
native arteries. By combining Equations 2.10 - 2.12:
(2.14) Pe = f med u Imed
fi ed Daq
The hindrance coefficient for convection has not been explicitly measured for any solute in any
model of arterial interstitium. 12 4 The physical constraints that generate the diffusive and
convective restriction coefficients can be similar,100 however, the media does not necessarily have
to hinder convection. Thus, Pe can be framed within limits by assuming at one extreme that the
hindrance for convection and are equivalent: fed = fed , and the other ffed =1, such that:
(2.15) u lmed/Daq < Pe < u Imed/Dmed
The Pe numbers were calculated for arteries over a range of medial thicknesses, for normal and
deendothelialized arteries.
2.3.3. Pore Theory
As a further approximation of the Peclet numbers, the convective hindrance coefficient ( fed)
was estimated from pore theory.133,134 The drug movement across the arterial media was modeled
as an unrotating, uncharged sphere that both diffuses and convects along the centerline of a
transmural pore. The hydrodynamic interactions between a sphere and the wall of the pore have
been described analytically and expressed as the convective (f ed) and the diffusive (f,~d)
hindrance coefficients which vary with the ratio of solute-to-pore radii (Fig. 2.3).133,134 The
diffusive hindrance coefficient for heparin defined by Equation 2.11 was used to estimate an
effective solute-to-pore radii ratio, which was used to estimate the convective hindrance coefficient.
The Peclet numbers for native and deendothelialized arteries were calculated over a range of medial
thicknesses using Equation 2.13 and this convective hindrance coefficient.
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Figure 2.3 The hydrodynamic hindrance factors for diffusion (fD) and convection ( fc) of a
nonrotating uncharged sphere in a cylindrical pore, as derived by Bungay and Brenner 13 3 and
adapted for biological membranes by Deen. 13 4
2.4. Results
2.4.1. Transmural Flux in Rat Abdominal Aorta
The diffusivity of heparin in aqueous solutions at room temperature was measured to be 1.39
x10 -6 cm 2/s (R2 = 0.996). After correction from room temperature to 37 'C using the Stokes-
Einstein relation: 135 Daq = 1.45x10-6 cm 2/s. The multiple linear regression (R = 0.920) of the
data taken without a hydrostatic pressure gradient (Appendices 8.1 and 8.2) showed that Dmed =
7.73 x 10-8 cm 2 /s (P=0.03), Dadv = 1.21 x 10-7 cm 2 /s (P = 0.07 ), and Rend =25,100 s/cm
(P=0.004). The diffusive resistance of these three arterial layers were calculated over a range of
thicknesses (Fig. 2.4).
The estimations of the Peclet numbers are shown for a range of medial thicknesses, for both
native and deendothelialized arteries (Fig. 2.5). Pe was estimated to lie within upper and lower
bounds, reflecting either no convective hindrance or alternatively, convective and diffusive
hindrances that are equal. The range of Pe numbers is less than unity in the rat abdominal aorta,
except following deendothelializing injury. An approximation for the Peclet numbers within these
bounds was predicted by pore theory (Section 2.3.3) to be 0.65 for denuded arteries. Native
arteries were predicted to asymptote toward this value with increasing medial thickness.
Rat abdominal aortas were perfused with and without transmural pressure gradients and direct
comparison of the transmural heparin transfer from each of these sets of data would experimentally
confirm the relative importance of convection and diffusion. However, under physiologic pressure
the arteries are significantly thinner (Appendix 8.1) and greater in perimeter, decreasing the length
over which heparin must migrate and increasing the area perpendicular to transport. Thus, any
impediment to mass transfer attributable to opposing connective flows is overwhelmed by these
effects.
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Figure 2.4. The diffusive resistance of the media and adventitia as a function of
the arterial layer thickness. Note that the endothelial resistance is constant. Diffusive
resistance is defined as the thickness of the arterial layer divided by the diffusivity
of heparin in that layer.
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Figure 2.5. The range of Peclet numbers for both native and denuded arteries,
as a function of medial thickness, computed from the measurements of the diffusivity
of heparin in arterial media and published correlations of hydraulic flux. A range
is shown because the convective hindrance imposed by the media has not been
measured for heparin and is hypothesized to lie between one and the diffusive
hindrance imposed by the media. Centerline pore theory is used to estimate the
convective hindrance more precisely (Fig. 2.3).
Theory)
1000
-
To circumvent the artifact generated by these morphological changes, a non-dimensional
parameter was defined ( V) which evaluated how much of the observed mass transfer was due to
diffusion alone. q equals the right-hand side of Equation 2.2 normalized by the left hand side:
(2.16) (Rad v + Rmed + bendRend + Rbl )
cv - cev)LP
This value represents the mass transfer nondimensionalized by the diffusive driving potential and
diffusive resistances. Note that this characterization only incorporates diffusive terms, and
therefore if diffusion is the only driving force, V = 1. Conversely, if convection is the only
driving force then p= 0 because in these perfusions the concentration gradient of heparin was
directed against the hydraulic flux. Certainly, V should equal 1 for the experiments performed
with AH=0. The coefficient of Rend (bend) is 0 following a denuding injury and 1 with intact
native arteries. The Vy parameter was computed for native and deendothelialized arteries, with and
without a physiologic transmural pressure gradient (Fig. 2.6). Vf was approximately unity except
when there was a pressure gradient and deendothelialization, where the value dropped by 20%.
2.4.2. Heparin Deposition in Calf Carotid and Rabbit Iliac Arteries
3H-heparin deposition in calf carotid arteries following one hour perfusion in vitro is shown
for both native and denuded arteries, with transmural hydrostatic pressure gradients of 0 or 100 cm
H 2 0, and for endovascular (Fig. 2.7a) or perivascular (Fig. 2.7b) heparin administration
(Appendix 8.3). In the absence of a transmural hydrostatic pressure gradient the deposition was
indistinguishable whether the arteries were native or denuded or heparin was applied from the
endovascular or perivascular aspect. The deposition with endovascular delivery was significantly
increased 2.0 fold by the addition of 100 cm H20 pressure gradient, and following denudation this
increase was 2.5 fold. In contrast, the addition of this pressure gradient decreased the deposition
significantly following perivascular delivery by 30% and 36% in native and denuded arteries,
respectively. The heparin deposition in native and balloon deendothelialized rabbit iliac arteries
was indistinguishable following perivascular delivery from hydrogel collars in vivo (Fig. 2.8,
Appendix 8.4).
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Figure 2.6. The ' parameter is a measure of how much of the transmural heparin
transfer can be attributed to diffusion (Eq. 2.16). For these rat aorta perfusion
experiments where the heparin is applied perivascularly and the convective current
is directed against the concentration gradient, Y= 0 implies that heparin moves only
by convection. Y= 1 implies that heparin moves only by diffusion. (average +
SEM.)
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Figure 2.7. The in vitro heparin deposition per applied drug concentration in calf carotid
arteries one hour after a) endovascular and b) perivascular application. Arteries were either
left intact (native) or balloon deendothelialized (denuded), and either subjected to a
physiologic or no transmural pressure gradient (AP). Deposition is normalized by both the
dry mass of the artery and the applied heparin concentration gradient (n=12, average +
SEM).
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Figure 2.8. The in vivo heparin deposition per initial hydrogel concentration in native
and denuded rabbit iliac arteries 2 hours after perivascular release from 635-rtm-thick
hydrogel collars (n= 12, average ± SEM).
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2.5. Discussion
Evaluation of the extent and processes that govern the transvascular transport of
macromolecules is central to our understanding of both the accumulation of atherogenic proteins
and lipids in the vessel wall, and the potential treatment of proliferative vascular diseases with
exogenous vasotherapeutic compounds. These phenomena have been studied extensively in the
context of the former, but have generally not been applied to the latter. Despite decades of
research, controversy remains as to the importance of the role of various mechanisms of
transvascular solute transport. For instance, different investigators using a variety of compounds
and animal models have reported or assumed that diffusion exclusively controls transmural
transport,76,78,102,104,136 that diffusive mechanisms dominate only in healthy arteries but that
convective forces become significant after endothelial injury and denudation,79,87,93,100 or that
convection is always important and may even overwhelm diffusion. 83,88,89,126,137 Although this
debate may focus on a subtle pathophysiologic aspect of chronic atherosclerotic disease, these
issues are essential to pharmacologic treatment of injured blood vessels. Indeed, local vascular
drug delivery systems have been designed to release drug from either the endovascular or the
perivascular aspect of the artery. 26,34,51,138 If convective forces are inconsequential compared to
diffusive forces, then the deposition from either aspect of the artery should be similar. If
convective forces are significant, however, they will be aligned with diffusive forces for
endovascular but opposed for perivascular delivery, leading to potentially overwhelmingly
enhanced deposition in the former over the latter (Fig. 2.9). The above example shows that it is
essential to fully describe all the mechanisms of transmural solute transport in order to rationally
design pharmacologic treatments.
In this chapter, an in vitro perfusion apparatus was used to control the environment inside the
lumen and around the artery, to measure the diffusive resistance of each arterial layer, and to assess
the balance between diffusive and convective mechanisms of transmural transport. In the rat
abdominal aorta diffusion exclusively controls the transmural distribution of heparin under normal
conditions, convective forces rise to one-quarter the magnitude of diffusive forces with extreme
endothelial disruption, the diffusive barrier to heparin posed by the endothelium is minor, and the
barrier to heparin transport posed by the adventitia depends on its thickness.
All of these mechanisms together determine vascular distribution and the extent to which they
individually impact deposited drug was tested in two additional animal models: the calf carotid
artery in vitro and rabbit iliac artery in vivo. The effects of molecular diffusion and the intimal
barrier to transport were examined in vitro in the absence of a transmural pressure gradient, and
therefore without convective forces. The contribution of convection was then assessed when these
experiments were repeated with a physiologic transmural hydrostatic pressure gradient. The
potential of the endothelium to behave as a resistance to the transport of heparin was also examined
in vivo.
2.5.1. The Role of Diffusion and Convection in Transmural Transport
2.5.1.1. Theoretical Peclet Numbers
Diffusion is an omni-directional process resulting from random molecular movements, and
thus the magnitude of diffusive forces should be independent of the aspect of delivery. In contrast,
convective forces are always aligned with the physiologic hydrostatic pressure gradient across the
water-permeable arterial wall, and are directed from the intima towards the adventitia (Fig. 2.9).
Thus, it would appear that endovascular delivery should always be superior to perivascular
delivery because convective and diffusive forces appear to augment the former, while in the later
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Figure 2.9. Schematic showing the directions in which diffusion and convection act in
transmural transport following endovascular and perivascular drug delivery. Diffusion always
moves drug away from the point of administration (shaded region) and convection, which arises
from the transmural hydrostatic pressure gradient, is always directed across the arterial wall from
inside to out.
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drug must diffuse in the face of an oncoming convective current. Yet, it is the balance between the
diffusive and convective mechanisms that will determine the appropriateness of this interpretation.
If diffusive forces are much larger than convective forces, then endovascular delivery is no more
advantageous than perivascular delivery.
The balance between diffusive and convective forces in transmural transport is characterized by
the Peclet number (Pe). For native uninjured rat aortas, the range of Pe was usually less than
one, implying that convective effects are limited by the hydraulic resistance of the arterial media
and endothelium. However, convection can play a more significant role in thicker arteries or when
the endothelial barrier to convective flux is removed. In the former, Pe will increase because the
diffusive resistance increases more so than the hydraulic resistance, due to the nonlinear effects of
the endothelium on the overall arterial hydraulic conductivity. In the latter, Pe will increase to its
theoretical maximum irrespective of medial thickness, as the endothelial monolayer can account for
a large fraction of the hydraulic resistance. 132 Despite limitations in applying pore theory to
transvascular heparin transport (Sec. 2.3.3), this analysis shows that diffusive hindrance always
exceeds convective hindrance (Fig. 2.3), and therefore the actual Peclet number lies between the
two extremes presented (Fig. 2.5). Hence, under conditions of severe endothelial injury or
dysfunction, or for large healthy arteries, the transmural convective currents will reach significance
where they enhance heparin distribution following endovascular delivery, and need to be
considered in vascular pharmacokinetic analyses.
2.5.1.2. Empirical Verification by Transmural Heparin Flux
It is possible to verify these theoretical considerations empirically in the rat abdominal aorta by
comparing transmural transport with and without adverse convective forces. The V/ parameter
represents the measured mass transfer nondimensionalized by the diffusive driving potential and
diffusive resistances, and it evaluates how much of the observed mass transfer arises from
diffusion alone. If diffusion is the only driving force, Vy = 1 and if convection is the only driving
force then p= 0. The data show that i = 1 with native intact arteries (Fig. 2.6), regardless of
whether there is a transmural pressure gradient or not ( AH= 0 or 100 cm). Following a balloon
denuding injury, the introduction of a physiologic transmural pressure gradient reduced V from 1
to 0.8. Under these circumstances, convective forces can reduce the transmural transport of
heparin following perivascular delivery, and thus endovascular delivery may lead to slightly
enhanced distribution of drug.
It is possible that the applied pressure caused the tissue to compact and the transmural transport
to fall, due to increased steric interactions that slow heparin diffusion. Such effects would be
evident in both native and denuded arteries. V was decreased in denuded but not native arteries,
suggesting that changes in the effective molecular diffusivity from compaction were not significant.
2.5.1.3. Empirical Verification by Heparin Deposition
Convection was shown to be an insignificant mechanism of heparin distribution in the native
rat abdominal aorta (Section 2.4.2.2). In contrast, the in vitro perfusions of calf carotid arteries
demonstrated that hydraulic convective mechanisms are significant determinants of transvascular
solute transport, as heparin deposition increased two fold following endovascular administration to
native arteries when subjected to a hydrostatic pressure gradient of 100 cm H20 (Fig. 2.7a).
Conversely, the addition of this pressure gradient lowered the deposition with perivascular delivery
(Fig. 2.7b). In the former, hydraulic convective forces are aligned with the concentration gradient
and assist drug distribution, whereas in the latter they are opposed and thus limit transmural
deposition (Fig. 2.9). These data support the Peclet number predictions that convective forces are
more significant in thicker vessels, as the calf carotid is 450 pm thick and the rat abdominal aorta is
40 pm thick (Fig. 2.5). Experimental evidence that the balance between diffusive and convective
forces may depend on arterial thickness dates back to 1962, when Duncan, et al. reported that
supraphysiologic blood pressure increased arterial uptake of intravascularly administered albumin
in the thick canine ascending aorta, but that this enhancement diminished as one examined thinner
arteries more distally. 83 The introduction of vascular dimension as a governing parameter might
help explain some of the long running controversy over the role of convective arterial transport.
2.5.2. Endothelium Modulate Distribution
The endothelial monolayer can potentially impact the distribution of applied drug in two
independent ways. First, the endothelium may impose a direct barrier to solute flux. There are
several potential pathways for solute to cross the endothelium, such as intercellular diffusion and
convection, and active and passive transcellular transport. All of these processes are readily
characterized as a single resistance.9 4 99 ,102,'1 0 4 ,1 05 The primary resistance to transarterial
transport of macromolecules such as albumin, HRP or LDL, however, is the
endothelium.6 3,76,94 ,139 The ratio of endothelial to medial diffusive resistance varies for different
compounds and arteries. This value was about 10 for albumin or LDL,63 ,76 but only -0.5 for
heparin in the rat abdominal aorta (lmed = 40 glm) used here, and -0.1 in arteries as thick as the
rabbit thoracic aortas used in the albumin studies. In addition to the four fold difference in size of
heparin (12-15 kDa) and albumin (60 kDa), enhanced transendothelial heparin transport may arise
from the flexibility of the linear, highly charged compound. 140,14 1 Phenomenon such as reptation
may allow heparin to pass through far smaller pores than other compounds of similar molecular
weights. Alternatively, transcytotic pathways may exist for heparin but not for albumin. This
distinction in transport properties illustrates the need for in depth analysis for each compound, and
the danger of extrapolating from the results of studies with one molecule to another.
The lack of transendothelial resistance to heparin was corroborated in the calf carotid artery. In
the absence of a pressure gradient the deposition of endovascularly applied drug did not increase
following endothelial denudation (Fig. 2.7a). The possibility exists that the endothelium is not
completely intact in vitro and that intercellular gaps may allow solutes to pass that might be
restricted in vivo. However, the monolayer does modulate pressure driven hydraulic currents
(Figs. 2.6 and 2.7), and therefore should be largely intact, exerting much of its normal resistance
to solute transport.
In vivo delivery experiments to rabbit iliac arteries support the limited role of the endothelium
as a barrier to heparin transport. With perivascular delivery any potential endothelial resistance to
transport would prevent the loss of drug to the lumen flow and would result in elevated deposition
in native over denuded arteries. Yet the data show that the deposition was not significantly
different with and without the endothelium (Fig. 2.8). One might best appreciate these results by
considering hypothetical transmural concentration profiles generated by a simple resistor model to
solute transport (Fig. 2.10).
At steady-state the release device will impose a constant perivascular concentration. If the
endothelium offers no resistance (solid line) the concentration at the lumenal edge of the media
would reflect that of the plasma. Denudation could not reduce the endothelial barrier any further,
the concentration at the lumen would still be that of plasma, and the concentration profile would not
change. Alternatively, if the endothelial resistance to solute flux is high (dashed line) the
concentration at the luminal side of the media would be closer to the perivascular concentration.
Endothelial denudation would remove this barrier and the concentration at the lumen would fall to
plasma levels, resulting in lower arterial deposition. For perivascular delivery to the rabbit iliac
artery the deposition was the same in either the native or denuded case (Fig. 2.8), suggesting that
the endothelial resistance to heparin transport in vivo is immeasurably low.
The second manner in which the endothelium impact vascular drug deposition is by imposing a
barrier to transmural hydraulic flux. Convective currents within the artery are determined by the
hydraulic conductivity of the arterial media and endothelial monolayer, and in a vessels the size of
the rat abdominal aorta and calf carotid artery removal of the endothelium might let transmural
hydraulic velocities increase by 350% and 50%, respectively (Eq. 2.13).132 Indeed, convective
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Figure 2.10. Linear resistor model of drug transport across the media and endothelium from a
perivascular source, and resulting hypothetical transmural concentration profiles. Note that the
thicknesses of each layer are not drawn to scale as the endothelium has virtually no thickness.
forces of heparin transport were only shown to be significant in the rat abdominal aorta after
endothelial removal. Deposition of endovascularly applied heparin in the calf carotid artery with a
transmural pressure gradient of 100 cm H20 was enhanced following endothelial removal precisely
through this mechanism (Fig. 2.7a). Heparin deposition with thin rabbit iliac arteries in vivo was
unaffected by the presence of an intact endothelium after perivascular release (Fig 2.8). In the 80
glm thick rabbit iliac artery, convective forces should be less important in the native than denuded
case, and thus the deposition should be lower for the latter (Fig. 2.5). However, the 635-gm-thick
hydrogel release collar encircled the artery and had an unknown hydraulic conductivity, which may
have impeded transmural convective flows. Convective transport may have been diminished in
this arterial preparation to the point where endothelial removal could not raise it to significance.
The endothelium, therefore, appears to modulate deposition by controlling hydraulic flows, rather
than as a direct anatomic barrier to diffusion. One potential reconciliation for this seemingly
incongruous statement may be that active transcytotic transport may negate the tight endothelial
barrier to solutes, but not to solvent.
2.5.3. Resistance to Transport of the Adventitia.
The adventitial resistance to solute transport can also potentially impact the distribution of
applied drug. Heparin diffuses through this layer almost twice as readily as in arterial media,
perhaps owing to the loose architecture and relative acellularity of the former. The adventitial
resistance increases linearly with thickness and will vary with extent of surgical manipulation (Fig.
2.4). Without a transmural pressure gradient the deposition following perivascular application to
the calf carotid artery in vitro was not significantly different from endovascular delivery, for both
native and denuded arteries (Fig. 2.7). Thus, the resistances to heparin flux at both boundaries are
roughly equivalent. Since the endothelial resistance to heparin transport has been shown to be
negligible in vitro and immeasurably small in vivo, the resistance of the adventitia is also small.
2.6. Chapter Summary
The quantitative methods that have been employed to examine transmural drug transport may
add to the understanding of fundamental structure-function relationships within the blood vessel
wall and drug-vascular tissue interactions, and provide a rational framework for the design of local
vascular drug delivery systems. The diffusivity of a vasoactive compound, heparin, has been
determined in arterial media and adventitia, and the transendothelial resistance to heparin transfer
has been measured. The ratio of convective to diffusive forces of transmural solute transport is
low in thin arteries, but becomes closer to one with thicker vessels. The endothelium and
adventitia are not direct barriers to heparin diffusion, but the former does influence the magnitude
of convective forces within the media. This has implications for local vascular drug delivery, as
convective forces augment deposition from the endovascular aspect and inhibit deposition from the
perivascular aspect.
3. TISSUE AVERAGE BINDING AND EQUILIBRIUM DISTRIBUTION
3.1. Introduction
In the preceding chapter, the mechanisms of soluble heparin transport within the blood vessel
wall were examined and the diffusivity of heparin in different arterial layers was measured.
Detailed descriptions of drug deposition and distribution rely to an equal extent on drug binding.
For example, when exogenous drug is applied to a tissue, binding will remove drug from solution
and impede net transport. In addition, soluble and bound drug function differently in tissues and
therefore need to be distinguished. Soluble drug is available for redistribution and treatment of
distant sites, while bound drug potentially mediates signaling events and is sequestered from or
maintains increased local concentration in the vicinity of active receptors. 142 ,143 Soluble heparin
provides some biologic function by complexing with heparin-binding growth factors, while
intracellular effects of heparin on second messenger systems may require adherence or binding
prior to internalization. 144,145 Finally, the elimination of drug from a tissue will depend upon the
dissociation of bound drug, with multiple subsequent transport and rebinding events. Thus, the
pharmacokinetic evaluation of a therapeutic strategy will be enhanced significantly by
differentiation of soluble and bound drug.
While ligand binding studies almost universally are performed in cell culture and quantify
binding sites and affinity of these sites, drug binding within tissues with their intact architecture is
potentially far more complex. For example, heparin binding to vascular cells has been well
characterized in culture. 145 -14 8 The affinity of heparin binding to individual components of the
extracellular matrix, such as fibronectin, laminin, thrombospondin and type I collagen, have been
quantified as well. 149 In addition, some extracellular vascular components are not expected to be
present at all in homogeneous cell cultures. The majority of drug-tissue binding interactions are
potentially nonspecific without any biologic effect. The overall binding characteristics of drug
within tissues includes the combined effects of all the binding sites and their respective affinities
and have not been measured for any compound in any tissue, let alone heparin within arterial media
or adventitia. In this chapter, a novel approach to characterizing the binding of any solute within
any tissue is derived and quantifies the drug-tissue interaction in terms of binding site density,
tissue-average dissociation constant, and fractional volume of tissue in which drug can distribute.
This technique quantifies both biologically active and nonspecific binding, and provides a rationale
for discriminating bound from soluble fractions of drug in tissues. Though validated here with
heparin, the method is applicable to many drugs and tissues.
3.2. Equilibrium Distribution Model
The equilibrium distribution technique measures the binding and distribution constants by
incubating many samples of tissue in a wide range of radiolabeled drug concentrations and curve-
fitting the resulting data to the following model. The model is derived in general terms and should
be applicable to many compounds and tissues. The total concentration of drug observed within a
volume of tissue (CT) is considered to be the superposition of soluble (c s ) and bound (cb)
components:
(3.1) CT = s + cb
At very low drug concentrations, an increase in total concentration results in a linear increase in
both soluble and bound concentrations (Fig. 3.1).
As binding sites saturate, increases in the total concentration will be solely noted as increases in the
soluble concentration. In a unit volume of tissue there are regions where soluble drug is excluded
by steric interactions. The fractional volume in which drug can distribute (e) is given by:
(3.2) = Va
VT
where Va is the accessible space for drug distribution and VT is the total tissue volume. Note that
the convention used in this work is that the drug concentrations CT, cs and cb are defined as the
moles of drug per unit total volume of tissue. Thus, the moles of soluble drug per unit total volume
of tissue (c s ) is related to the moles of soluble drug per unit accessible volume (ca) by the
fractional volume:
BT
K' Bulk Phase Concentration
Figure 3.1. Equilibrium distribution model of compounds in tissues.
(3.3) cs = ECa
The law of mass action defines the dissociation constant (Kd) as the product of the drug
concentration in the accessible volume and the ratio of the molar densities of free (Bf) and bound
(Bb) binding sites:
caBf(3.4) Kd= Bb
The number of binding sites is assumed to be conserved so that the total binding site density (BT )
can be expressed as:
(3.5) BT = Bf + Bb
Although in the context of the law of mass action these binding site densities should be defined as
moles of binding sites per unit accessible volume, because the bound and free density are related as
in Eq. 3.4, they can be and are defined per unit total volume. By assuming a one to one ligand to
binding site ratio:
(3.6) cb = Bb
By combining Eqs. 3.1, 3.3 - 6:
(3.7) CT = E a  B7 caKd + Ca
3.2.1. Equilibrium Distribution Measurements
In these equilibrium distribution measurements, the concentration of drug in the accessible
volume (ca) is established by incubating the tissues in solutions containing radiolabeled drug until
equilibrium. The concentration of drug in the accessible volume (ca), however, is not necessarily
equal to the external or bulk phase concentration (cbulk) because of potential charged partitioning.
Thus:
(3.8) Cbulk = KCa
where ic is the partition coefficient of drug into the accessible volume. Thus:
E cbulk BT(3.9) CT = -Cbulk kBT
K KKd + Cbulk
The dissociation constant and the partition coefficient are combined into a modified dissociation
constant reflecting binding and charged association:
(3.10) K' = iKd
Similarly, a modified fractional volume of distribution reflecting sterical and charged effects can be
defined:
(3.11) e' =--
Thus:
(3.12) TcbulkBT(3.12) cT = E"cbulk +Cbulk 
T
K' + Cbulk
Thus, the total concentration is a function of the concentration outside the tissue, and the three
binding and distribution constants (e', BT, and K'), which are specific to each drug and tissue.
3.2.2. Curve Fitting and Initial Estimates
A commercially available non-linear least squares Levenberg-Marquardt algorithm including a
Pearson minimization (TableCurve 2D, Jandel Scientific) was used to fit the data and determine the
binding and distribution constants (e', BT, and K'). Because the bulk phase concentration data
must span many orders of magnitude, a fit to Eq. 3.12 would preferentially weight the data taken at
the highest bulk phase concentrations. The inherent weighting can be distributed over all of the
data points by fitting the logarithm of the measured total concentration (CT) to the following
equation:
(3.13) ln(cT) = In e'cbulk + CbulkB
Non-linear least squares algorithms are sensitive to the initial estimates of the unknown
constants. 150 The following approximate method for determining e', BT, and K' from the
equilibrium distribution curve is used to provide the initial estimates for the curve-fit. Consider an
idealized equilibrium distribution curve that is the sum of the bound and soluble drug (Fig. 3.1). A
least squares estimate of the slope (e') at high bulk phase concentrations allows the soluble
component of the data (E'cbulk) to be subtracted from the total concentration data, reducing Eq.
3.12 to:
(3.14) Cb = CbulkBT
K' + cbulk
The resulting plateau can be considered equivalent to the total number of binding sites. The
average dissociation constant can be estimated as the bulk phase concentration at which half of the
binding sites are occupied.
The reliability of the commercial software was assessed by writing an alternative curve-fitting
program utilizing a Nelder -Meade function minimization routine (Matlab, Math Works). All of the
constants computed by the former algorithm differed maximally from the later by 8%, thus
validating the former.
3.2.3. Bound and Soluble Fractions
The equilibrium distribution method also allows for the a total concentration measurement (cT)
to be resolved into bound and soluble components. By solving for Eqs. 3.1,3.3 and 3.7:
CT - BT - K'e" + \I(cT - BT - K'e')2 + 4 CTK'e'(3.15) cs =
The distinction between bound and soluble drug is important. While soluble drug binds to active
receptors and mediates extracellular signaling events, non-specific binding sites play a distinct role,
as they sequester drug in the vicinity of active receptors. 142 ,14 3 Furthermore, in terms of drug
distribution and pharmacokinetics, only the soluble fraction of drug is available to diffuse or
convect through a tissue, while potential binding sites tend to impede the movement of drug.
3.3. Experimental Methods
The equilibrium distribution method described above was used to determine the binding and
distribution constants ( BT, k' and e') for heparin in porcine carotid media with endothelium intact
and after endothelial denudation, and in the adventitia. Porcine carotid arteries were explanted and
stored on ice for no more than 2 hours. The adventitia was stripped from the media, and both were
temporarily stored in 2% Penicillin-Streptomycin (Gibco) in sterile phosphate buffered saline. The
endothelium of some of these arteries were denuded with three passes of an inflated 3 French
embolectomy catheter (Baxter).129 Arteries were cut into 10 - 40 mg pieces and incubated in
Dulbecco's Modified Eagle Media (DMEM, Gibco) with 10% Fetal Bovine Serum (Gibco) and 2%
Penicillin-Streptomycin, with 3 H-heparin (Dupont-NEN) concentrations ranging from
approximately 100 pM to 0.2 mM. All incubations were performed in 2 ml of culture media and
were carried out until equilibrium, which was achieved when the time rate of increase of drug
concentration in the tissue reached zero. Following incubation, the arterial specimens were blotted
on dry towels, weighed wet, solubilized and scintillation counted. At least four pieces of each type
of tissue were incubated at each bulk phase concentration (Cbulk). Bulk phase heparin
concentration measurements were made at the end of the incubations and were the average of three
50 itl samples from each culture well. These equilibrium distribution measurements were repeated
twice for each tissue type, using different batches of reagents. Histologic frozen sections were
taken from representative arteries for morphologic evaluation.
Prior to the above experiments, the time course of heparin equilibration was quantified in
samples of porcine carotid media with endothelium by incubating in a bulk phase concentration of
0.15 mg/ml (Fig. 3.2). Although vascular cells and interstitial molecules may continue to
exchange drug with the bulk phase, these data show that heparin reaches equilibrium with the
tissue as a whole well within 24 hours. All subsequent incubations were therefore carried out for
this duration. In separate experiments, the density of fresh porcine carotid media was measured
using a micro-graduated cylinder and an analytical balance. The resulting density of 0.983±.024
g/ml (n=5, ± standard deviation) was used to convert wet weight to volume for calculations of total
drug concentration in tissue.
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Figure 3.2. Total concentration of porcine carotid media over time when incubated in 0.15 mg/ml
of heparin (average ± SEM , n = 4).
3.4. Verification of the Equilibrium Distribution Method
Equilibrium distribution data are shown for arterial media with intact and denuded endothelium
and adventitia (Fig. 3.3, Appendix 8.5). Each point shown represents the average of at least four
total concentration measurements on samples of tissue from the same culture well and three
measurements of the bulk phase concentration in that well. Note that the error bars are present but
unappreciable on the logarithmic scale. For each tissue type, initial estimates of the fractional
volume of tissue in which drug can distribute (e') were determined through linear regression of
the high bulk phase concentration data (cbulk > 10-5 M, Table 3.1). Figure 3.4 shows all of these
data following the subtraction of the soluble fraction of drug (E'cbulk). For arterial media with
intact and denuded endothelium, initial estimates of the binding site density ( BT) were estimated as
the plateau of these curves. The dissociation constant of the average binding site (K') was
estimated as the bulk phase concentration where half of the binding sites were saturated. The
Levenberg-Marquardt curve-fit algorithm converged to the solutions shown (Table 3.2) using the
initial estimates (Table 3.1), and when these initial estimates were perturbed up or down by two
orders of magnitude for BT and K', and by 0.2 for E'. This curve-fit software also calculated
standard errors for each binding and distribution constant. These curve-fits were further assessed
by computing best-fit curves for the experimental data and the computed bound concentrations
using Eqs. 3.12 and 3.14, respectively (solid lines, Figs. 3.3 and 3.4). It was not possible to
obtain initial estimates of BT and K' for the adventitia, because the bound concentration spread
about zero following the subtraction of the linear soluble component (Fig. 3.4c). This indicated
that the binding site density in this tissue was lower than the scatter in the data at high bulk phase
concentrations. Despite this, the curve-fit algorithm converged on binding constants for the
adventitia (Table 3.2) that were consistent over a wide range of assumed initial estimates.
Table 3.1. Sample binding and distribution constants determined by 1) finding the slope (E') of
the equilibrium distribution data (Fig. 3.3) for Cbulk > 10-5 M, 2) subtracting E'Cbulk from the
data and replotting (Fig. 3.4). 3) BT is approximated as the plateau of the subsequent data, and
4) K' is approximated as Cbulk at BT/2.
e' BT (IM )  K'(JM)
Arterial Media with Intact Endothelium 0.60 4 12
Arterial Media with Denuded Endothelium 0.63 8 10
Adventitia 0.78 - -
Table 3.2. Sample binding and distribution constants determined with a non-linear least-squares
Levenberg - Marquardt algorithm (values ± SEM).
e' BT K'
Arterial Media with 0.61±0.03 4.2±1.7 (pM) 6.8±2.5 (gM)
Intact Endothelium
Arterial Media with 0.70±0.03 2.5±1.1 (9M) 5.0±2.1 (gpM)
Denuded Endothelium
Adventitia 0.87±0. 02 2.2±1.3 (nM) 8.1±5.7 (nM)
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Figure 3.3. Measured equilibrium distribution curves for heparin within a) arterial
media with endothelium, b) denuded media, and c) adventitia (average ± SEM, n >
4). Solid lines are generated from Eq. 3.12 and the curvefit binding and distribution
constants (e', BT and K) shown in Table 3.2.
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Figure 3.4. Bound concentration of drug in the tissue (cb) for a) arterial media with
endothelium, b) denuded media, and c) adventitia, determined by subtracting the
linear soluble (cs) fraction from the total concentration (c7 average ± SEM, n > 4).
The plateau corresponds to the binding site density (BT). Note that low signal:noise
ratios prevented the demonstration of the binding site density in the adventitia. Solid
lines are generated from the curvefit binding constants (BT and K) and Eq. 3.14.
The equilibrium distribution analysis for heparin within arterial tissues predicts observed
heparin-vascular tissue interactions. The fractional volume of tissue in which a drug can distribute
(E') is highest in the adventitia and increases in the arterial media following balloon denuding
injury (Table 3.2), reflecting the loose architecture and high content of connective tissues of the
former, and the role of structural damage and edematous changes in the latter.15 1,152 The analysis
also showed that the concentration of heparin binding sites (BT) in the arterial wall is larger with
intact endothelium, consistent with many reports that this monolayer binds heparin.146-148,153-155
Cultured endothelial cells posses nearly 100 fold more heparin binding sites than cultured vascular
smooth muscle cells. 145 ,147 The binding site density measured for heparin in arterial media
without the endothelium was 2.5 jgM. If the volume of a smooth muscle cell can be approximated
by a cylinder that is 10 glm long and 3 gtm in diameter, the number of binding sites per cell is
approximately 100,000, which is the density previously measured in culture. 145 The dissociation
constant of the average binding site (K') of the arterial media, assuming a partition coefficient of
one, is three orders of magnitude higher than for growth arrested cultured smooth muscle cells and
basic fibroblast growth factor and about one to two orders of magnitude higher than laminin,
fibronectin, and type I collagen, indicating that much of the binding is to arterial elements with
even lower affinity. 145,149 The dissociation constant of the arterial media is much higher than that
of the adventitia, indicating that although there are far fewer binding sites in the latter, they are of
much higher affinity. This may be explained by the large concentration of type I collagen in the
latter, whose affinity for heparin is about the same as the values reported here for the adventitia,
and the relative scarcity of cells and associated potential binding sites. 149,151,152 These trends are
consistent with known properties of the heparin-arterial tissue interaction and help validate the
equilibrium distribution technique.
3.5. Discussion
A quantitative description of how drugs distribute and bind to intact tissues was sought, with
the hope of incorporating these findings into detailed pharmacokinetic models. The equilibrium
distribution analysis described in this chapter quantifies drug binding to all the potential binding
sites and distinguishes soluble from bound components. The technique involves incubating many
samples of tissue in solutions containing a wide range of drug concentrations, measuring the
corresponding tissue concentrations, and computationally fitting these data to a model of drug
distribution and binding. Through these steps, the binding site density, dissociation constant of
the average binding site, and fractional volume of drug distribution were measured for heparin in
arterial tissues and these results were used to validate the technique.
Two methods of determining the binding and distribution constants (e', BT , and K') from an
equilibrium distribution curve have been described. The first requires a linear regression of the
data, algebraic manipulation of these data, and visual inspection of resulting curves. While this
method is relatively simple, it affords no assessment of the "goodness of fit" or statistical measure
of accuracy. In addition, errors in estimating E' are carried through to BT and K'. The second
curve-fitting technique requires the use of more sophisticated computational algorithms to arrive at
estimations of the binding and distribution constants. A commercially available software package
is used which computes the standard error for each measured constant. The former method,
however, provides the required initial estimates used in the latter method.
Although the tissue concentration data are repeatable (Fig. 3.3), some of the standard errors are
relatively high (Table 3.2). This results in part from the dependence of these particular constants
on the subtle convexity of the equilibrium distribution curve, so that small concentration
measurement errors create uncertainty. Furthermore, if the scatter in the data is greater than the
binding site density, as was encountered with the adventitia, following the subtraction of the
soluble component the bound concentration data spreads about zero (Fig. 3.4c). Thus, a low
signal to noise ratio limits the accuracy of the technique to drug-tissue interactions with relatively
large number of binding sites.
The derivation of the equilibrium distribution method assumed that there was a one-to-one
stochiometric relationship between binding sites and drug. While this may be valid for many
drugs, for some compounds a single ligand may be able to simultaneously bind several sites, thus
limiting the applicability of the law of mass action. This phenomenon may occur in some of the
heparin binding sites in arterial tissues. In addition, the partition coefficient (ic) remains
unquantified as it is difficult to measure in complicated structures such as arterial tissues, however,
it is expected to be about one for hydrophilic compounds such as heparin. Despite these possible
sources of artifact, these binding constants empirically reflect the drug-tissue interaction and allow
for the realistic distinction between bound and soluble drug.
3.6. Chapter Summary
The equilibrium distribution measurements and subsequent numerical analysis are a useful
method of describing the binding of compounds to tissues, not just individual binding sites. Each
set of measurements simultaneously determines the fractional volume of tissue available for drug
distribution, binding site density, and affinity of the average binding site. These constants allow
the determination of the bound and soluble fraction of drug from tissue concentration
measurements. This information not only describes the physical interaction between the compound
and tissue quantitatively, but also is an integral part of vascular pharmacokinetics as it characterizes
how soluble drug distributed across an artery deposits. Although demonstrated here with heparin
in vascular tissues, this technique is applicable to many compounds and tissues.
4. DRUG TRANSPORT IN THE LOCAL ARTERIAL ENVIRONMENT
4.1. Introduction
The complete vascular pharmacokinetic description includes intramural mechanisms of solute
transport, the interaction of soluble drug with potential intra-arterial binding sites, and the
movement of drug from the point of administration to the blood vessel wall. The former two have
been quantified in the preceding chapters and the latter can be thought of as providing boundary
conditions for quantitative intramural analysis of solute deposition and distribution. The pathways
by which drug released in the local arterial environment both enters the arterial wall and is siphoned
away to the rest of the organism has been characterized through the following local drug delivery
experiments using inulin and heparin:
I Routes of drug clearance from the perivascular space.
II Routes from the perivascular space to the blood vessel wall.
III Drug losses from the endovascular and perivascular spaces.
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4.1.1. Routes Of Drug Clearance From The Perivascular Space
Drug can be cleared from the perivascular space by transmural diffusion (pathway a, Fig. 4.1),
or absorption by extra-arterial micro-vessels (pathway b). The relative importance of these
pathways was determined by measuring the urinary excretion rate of perivascularly released inulin
as each route was systematically eliminated. Urinary inulin excretion can be used as a proxy for
Figure 4.1. a) Routes of clearance from the perivascular space include transarterial transport
with entry into the lumen flow (pathway a) and absorption by extra-arterial capillaries (pathway b).
drug entry into the general circulation as this polysaccharide is eliminated from plasma through the
renal glomerulus without metabolism, secretion or tubular reabsorption. 156 Initial results showed
that the overwhelming majority of adventitially released inulin is cleared from the perivascular
environment through the extra-arterial capillaries.
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4.1.2. Routes from the Perivascular Space to the Blood Vessel Wall
It is reasonable then to suspect that drug absorbed by these capillaries could join the systemic
circulation and enter the vessel wall from its endovascular aspect. This possibility, as well as the
potential for drug to diffuse in directly from the perivascular aspect, was tested by following the
deposition of heparin released from outside the blood vessel. Heparin deposition was measured in
the native unmanipulated state and after elimination of pathways that could lead to: endovascular
administration from the systemic circulation (pathway c, Fig. 4.2), extra-arterial capillary uptake
(pathway d, Fig. 4.2), or direct diffusion from the perivascular space (pathway e, Fig. 4.2).
These data showed that the majority of drug released in the perivascular space is absorbed by the
extra-arterial capillaries, yet virtually all of the drug deposited in the artery arrives directly from its
adventitial aspect.
Figure 4.2 Routes of entry to the blood vessel wall from the perivascular space include
endovascular administration from the systemic circulation (pathway c) following absorption by
extra-arterial capillaries (pathway d) and direct diffusion (pathway e).
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4.1.3. Drug Losses to the Endovascular and Perivascular Spaces
The above experiments demonstrate overwhelming loss of drug to the perivascular extra-
arterial capillaries. The extent to which drug is lost from the artery to either the rapid lumen flow
on the endovascular aspect or these extra-arterial micro-vessels on the perivascular aspect was
compared by placing equivalent polymeric controlled heparin releasing devices on either of these
surfaces and comparing arterial deposition. The results in Chapter 2 suggested that there were no
anatomic barriers to solute entry from either surface, and therefore in this preparation the
deposition with each mode of delivery was considered inversely proportional to the loss of drug to
that aspect. For example, if heparin deposition following endovascular delivery exceeds that from
perivascular administration, then the loss of drug to the perivascular microvessels exceeds the loss
to the lumen flow.
4.2. Materials And Methods
4.2.1. Drug Release from Poloxamer
Drug was released in vivo from 28% (wt./vol) gels of Poloxamer copolymer
(poly(oxyethylene)-poly(oxypropylene) [Pluronic 407, BASF Wyandotte Corp. and Anti-adhesion
28, MDV Technologies]). Poloxamer 407 solutions undergo reverse phase gelation, remaining as
a free flowing liquid until the ambient temperature is raised above the critical threshold of 15 'C,
well below room and body temperature. Above this temperature, the viscosity increases markedly
and the gel solidifies into a solid mass. Erosion of, and subsequent release from, such a gel is then
prolonged enabling use as drug depots.
4.2.2. Routes Of Clearance From The Perivascular Space
Sprague Dawley female rats (275-325 g),were anesthetized with an intraperitoneal injection of
ketamine (50 mg/kg) and xylazine (10 mg/kg). The bladder, exposed after a midline abdominal
incision, was cannulated with an 8 inch polyethylene tube (ID 0.58 mm, Clay Adams) and secured
with a purse string suture. Urinary inulin excretion was monitored continuously through this
catheter. Incisions were closed and supplementary anesthesia with ketamine (12.5 mg/kg) and
xylazine (2.5 mg/kg) was administered as necessary.
The left common carotid artery was exposed and cleaned of excess fat and fascia. In one
experimental group, a 100-tl-dose of 14 C-inulin (0.35 gtCi, 0.14 mg, NEN-Dupont) in 28%
(wt/vol) Poloxamer solution kept on ice (3-50 C) was injected into the perivascular space. The gel,
which had remained fluid while cool, gelled immediately upon contact with the artery at 370 C,
conforming to the irregular surface of the vessel. 39 Urinary flow through the bladder cannula was
collected in a clean scintillation vial which was changed every 15 minutes for the first hour, and
every half hour for the next three hours. In the second experimental group, the potential for
transarterial inulin clearance was eliminated by ligating arteries at proximal and distal sites spaced I
cm apart (blocking pathway a, Fig. 4.1). Any inulin that traversed the wall was then trapped within
the occluded segment and could not mix with systemic circulation for excretion. In the third
experimental group, the Poloxamer gel and the artery were separated from the extra-arterial
capillary beds by a Silastic sheath (ID 3.18 mm) whose ends and seam were plugged with a silicon
glue (Type A Medical Adhesive, Dow Coming). The Poloxamer solution was injected only into the
space within the sheath, retaining arterial contact with the gel but eliminating possible capillary bed
absorption of inulin (blocking pathway b, Fig. 4.1). Following all of these experiments the 14C-
inulin content within each urine sample was determined by liquid scintillation spectroscopy (1214
RackBeta, LKB-Wallac). In a fourth experimental group the integrity of the Silastic wrap was
determined. Each of the manipulations described for the previous two groups were employed and
both transmural and extra-arterial capillary clearance were eliminated (blocking pathways a and b,
Fig. 4.1). Four rats were examined in each of the four experimental groups. To visualize potential
leaks from the seam or plugs at the ends of the Silastic barrier, Evan's Blue Dye (Sigma) was
mixed into the Poloxamer solution (25 mg/ml), and then injected into a wrapped artery of an
additional animal.
4.2.3. Routes from the Perivascular Space to the Blood Vessel Wall.
In a similar fashion, drug entry and deposition into the arterial wall was characterized with
Heparin-releasing Poloxamer gels fabricated as described above. Female Sprague Dawley (275-
325 g) rats were anesthetized and their left carotid arteries isolated as above. Four animals were
examined in each experimental group. One hundred-pl of 3H-heparin (1.0 CgCi, 1.4 gLg, NEN-
Dupont) in 28% Poloxamer solution kept on ice (3-50 C) was injected into the perivascular space of
the left carotid artery. The Poloxamer 407 solution gelled immediately upon contact with the
artery. One hour after administration of the heparin-gel, the left carotid artery was excised, blotted
to remove excess fluid, and dipped into 100% ethanol to dissolve adhering Poloxamer gel. The
artery was dehydrated, weighed, solubilized with 0.5 ml of Soluene-350 (Packard) and counted by
liquid scintillation spectrometry for 3H-heparin deposition. In addition, 10 - 60 mg tissue samples
from the abdominal aorta, iliac, and femoral arteries, and liver were harvested, dehydrated,
weighed, solubilized, and counted. The liver was assayed in particular because its high density of
endothelial cells created a large potential source for heparin binding. 146 ,154 Liver samples were
bleached to reduce color quenching of tritium by adding 0.5 ml of hydrogen peroxide prior to
scintillation counting.
In a second experimental group the possibility that heparin could be deposited from blood
flowing in the lumen was eliminated by occluding the artery with proximal and distal ligatures
(blocking pathway c, Fig. 4.2). Any heparin detected in the wall could have only arrived directly
from the perivascular space . In a third group of animals the possibility that heparin might enter the
systemic circulation following extra-arterial capillary drug absorption was prevented with a Silastic
wrap. The heparin-Poloxamer solution was injected around the artery but inside a silicon glue
sealed Silastic sheath (blocking pathway d, Fig. 4.2). In the fourth experimental group heparin
deposition in the carotid artery was quantified after the Poloxamer solution was injected into the
highly vascularized peritoneal cavity (blocking pathway e, Fig. 4.2). The contribution of direct
diffusion from the perivascular space could then be determined by comparison to data obtained
after local arterial delivery. In this group, care was taken to remove liver samples that were not in
contact with any injected Poloxamer gel.
4.2.4. Drug Losses to the Endovascular and Perivascular Spaces
Heparin deposition was compared 90 minutes after endovascular and perivascular
administration to the rabbit iliac artery in vivo, through hydrogel drug delivery devices of similar
composition and geometry and therefore release rates. Perivascular hydrogel release devices were
formed in molds and wrapped around isolated arteries, and endovascular devices were formed in
situ. The hydrogel prepolymer formulation and crosslinking protocol were described in Section
2.2.3.
4.2.4.1. Perivascular Administration
The iliac arteries of New Zealand White rabbits were isolated as described in Section 2.2.3.2.
Eosin Y (20 gg/ml, Sigma) was added to heparin containing prepolymer solutions and this mixture
was injected into 70 gm thick planar glass molds where it was photopolymerized with an argon
laser (488-514 nm, 70 mW/cm 2, American Laser). The resulting films were cut into strips
approximately 7 mm wide and two were folded over adjacent segments of each iliac artery. The
abdomen was sutured closed for the 90 minute drug deposition experiment and the arteries were
harvested and assayed for heparin deposition in the same manner as described in Section Sec.
2.2.3.2.
4.2.4.2. Endovascular Administration
Rabbits were anesthetized and maintained on inhaled halothane (1 - 3% in oxygen) anesthesia
throughout the procedure. A specialized double balloon hydrogel delivery catheter (Focal, Inc.)
was inserted through a carotid arteriotomy and advanced to the iliac arteries under fluoroscopic
guidance. 157 Once in the iliac artery, the catheter was advanced so that both the proximal and
distal balloons were beyond the aortic bifurcation. The endothelium was removed by inflating the
distal balloon and withdrawing the catheter 35 mm towards the aortic bifurcation a total of 3 times.
Following denudation the catheter was repositioned and the balloons inflated, isolating a 25 mm
segment of the artery within the de-endothelialized zone. This vascular segment was subject to
sequential 3 ml flushes of saline, initiator solution (eosin Y, 20 gig/ml), saline, and the liquid
prepolymer solution. At the conclusion of the injection sequence a fiber optic element within the
catheter delivered laser light (514 nm, American Laser) to the endoluminal surface, forming a 70
pm thick layer of heparin-containing hydrogel on the vessel wall. Following the deposition
procedure the balloons were deflated, the catheter withdrawn, and the procedure repeated in the
contralateral iliac artery. Endovascular hydrogels were formed on both iliac arteries within five
minutes of each other. Shortly before excision, the abdomen was opened and the iliac arteries
were isolated, removed, and assayed for heparin deposition as described in Section 2.2.3.2.
4.3. Results
4.3.1. Routes Of Clearance From The Perivascular Space
Inulin was administered from Poloxamer 407 gels into the perivascular space of unmanipulated
native arteries, or ligature occluded arteries whose transarterial pathways to the systemic circulation
were removed (Fig. 4.1). Rates of inulin clearance from the perivascular space of these two
vessels, native and occluded, were statistically indistinguishable, implying that drug released into
the perivascular space was cleared exclusively through the extra-arterial capillaries and not through
the wall of the carotid artery into the lumen (Fig. 4.3a, Appendix 8.6). These observations are
further supported by tracking inulin excretion rates when the polysaccharide was released from the
perivascular space of wrapped arteries. The wraps served as an impermeable barrier preventing
drug from clearing through the extra-arterial capillaries. Inulin excretion rates from wrapped
arteries were far lower than for native or occluded arteries, but indistinguishable from that
observed in arteries that were both occluded and wrapped (Fig. 4.3b). Thus, the minimal amount
of inulin excretion detected with wrapped arteries reflects leakage through imperfections in the
Silastic barrier rather than transmural clearance. The presence of barrier leaks was detected visually
when Evan's Blue Dye delivered from Poloxamer 407 gel extravasated from the ends of the wrap
and migrated along the artery, ultimately spreading to the capillaries in the perivascular space.
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Figure 4.3. a) Cumulative urinary excretion of 14 C-inulin per amount administered
following pericarotid delivery to native arteries, occluded arteries, and arteries wrapped to shield the
extra-arterial capillaries from the drug. b) Cumulative urinary excretion of 14 C-inulin per amount
administered following pericarotid delivery with wrapped arteries, and both wrapped and occluded
arteries, reflects the leak from the wrap (average ± SEM, n = 4).
4.3.2. Routes from the Perivascular Space to the Blood Vessel Wall.
Deposition of heparin released into the perivascular space was followed as each potential
pathway from release device to the tissue, extra-arterial capillary absorption, delivery from the
general circulation, and direct diffusion was systematically eliminated (Fig. 4.2). Following one
hour of release, the amount of heparin in the carotid artery was much higher than in distant arteries
or the liver, and was not statistically altered by ligature occlusion of the blood vessel (Fig. 4.4,
Appendix 8.7). Following the intraperitoneal application of the heparin-Poloxamer gel, drug
deposition in the carotid artery was similar to other tissues and was 500 fold lower than with
perivascular delivery to native arteries. Drug delivery from inside a wrap surrounding the carotid
did not result in a statistically significant increase local arterial concentrations. In addition,
concentrations in distant structures were not diminished, apparently because the wrap failed to
completely eliminate extra-arterial capillary absorption.
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Figure 4.4. 3 H-Heparin deposition (pig of heparin per mg administered per mg dry tissue)
following one hour release. Poloxamer containing heparin was injected into the perivascular space
of carotid arteries that were native, occluded or wrapped, or was given through an intraperitoneal
(IP) injection (average ± SEM, n=4).
4.3.4. Drug Losses to the Endovascular and Perivascular Spaces
Deposition of 3H-heparin in rabbit iliac arteries from an interfacially formed 70-jlm thick
endovascular hydrogel was 7.7 times higher than that observed for the same release device placed
as a perivascular wrap (Fig. 4.5, Appendix 8.8).
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Figure 4.5. The in vivo heparin deposition per initial hydrogel concentration in rabbit iliac
arteries ninety minutes after either perivascular or endovascular deployment from 70-gjm-thick
hydrogels (n=12, average ± SEM).
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4.4. Discussion
Precise elucidation of the pharmacokinetics not only requires quantitative evaluation of the
forces that govern transport and binding within arterial tissues but also a description of how drug
arrives at the boundary of the blood vessel wall. In the previous chapters, transport and binding
constants were evaluated for a model vasotherapeutic compound, heparin, in vascular tissues,
however, the boundary conditions remain obscure. Controversy exists as to whether drug released
into the perivascular space diffuses directly to the artery or whether drug is absorbed by capillaries
outside the artery, mixed with the systemic circulation and only then returned to the endovascular
aspect. Furthermore, it has been assumed that locally applied drug is more likely to be lost to the
rapid lumen flow rather than to these extra-arterial structures. Countless studies have exhaustively
characterized both the mechanisms and kinetics of drug release from polymeric systems, and
devices can now be fabricated to deliver virtually any pattern of release. There is, however, a
dearth of information regarding the fate of drug once freed. In this chapter the local
pharmacokinetic administration of drug to the blood vessel wall has been characterized through
experiments that elucidated the pathways of drug clearance from the perivascular space, illustrated
the routes by which locally applied drug enters the blood vessel wall, and directly compared the
potential for drug to be lost to the lumen flow and the extra-arterial capillaries.
4.4.1. Model Pathways from the Perivascular Space to the Arterial Wall
The present studies determined the relative importance of each of the pathways by which drug
leaves the perivascular space, and by which pathways it enters the blood vessel wall. Model
drugs, inulin and heparin, were delivered perivascularly and the urinary excretion and arterial
deposition were monitored as the pathways of vessel wall clearance and entry were systematically
eliminated, respectively. The potential routes of drug clearance from the perivascular space are
absorption by extra-arterial micro-vessels or transarterial diffusion directly into the circulation (Fig.
4.1), while the pathways to the arterial wall are endovascular application from the circulation or
direct diffusion through the adventitial aspect (Fig. 4.2). Ligature occlusion of the blood vessel
lumen did not decrease inulin excretion (Fig. 4.3a) nor decrease heparin deposition (Fig. 4.4).
Extravascular wraps designed to prevent exposure of the extra-arterial capillaries to drug reduced
inulin excretion but left heparin deposition unchanged. The carotid deposition of heparin following
perivascular delivery, however, was much higher than for intraperitoneal administration. The
combination of these analyses reveals that the overwhelming amount of perivascularly released
drug is absorbed by the extra-arterial capillaries, yet virtually all the drug found in the artery
diffuses directly from the device through the perivascular space and into the arterial wall.
These seemingly contrary processes are neither paradoxical nor mutually exclusive. The
surface area for absorption of the extra-arterial capillaries is very large compared to that of the
carotid artery. Moreover, the transmural diffusive resistance of the artery is much greater than that
of an individual capillary simply because it is much thicker (Sec. 2.3.1). Both of these effects
cause the vast majority of drug to be cleared by the extra-arterial capillaries. That all of the drug
deposited in the arterial wall comes from the perivascular space, and not from the circulation,
reflects systemic dilution far below the drug concentration in the perivascular interstitial fluids.
Therefore, there is a large transmural concentration gradient forcing drug into the vessel wall from
the perivascular space. Although inulin and heparin are physically and chemically distinct
polysaccharides and may diffuse through and bind to tissues differentially, these two results have
been combined to provide a unified qualitative model of how drug is handled by vascular tissues
and their typical local environments.
4.4.2. Drug Losses to the Endovascular and Perivascular Spaces
The former analyses showed how drug arrives at the blood vessel and the following data
address how drug is likely to leave the arterial wall. Heparin deposition following endovascular
administration to the rabbit iliac artery from a 70 gtm thick sheet of hydrogel was 7.7 fold higher
than following perivascular delivery from an equivalent device (Fig. 4.5). Since, the experiments
in Chapter 2 demonstrated that there are few anatomic barriers to heparin distribution, and since the
hydrogels decrease overall arterial hydraulic conductivity to an unknown extent, the deposition in
vivo in the rabbit iliac artery mostly reflects the conditions surrounding the applied drug delivery
device. For example, the endovascular hydrogel was tightly adherent to the blood vessel wall, but
was subject to losses to rapid flow in the lumen. On the other hand, the perivascular hydrogels
were exposed to interstitial fluids which provided a low resistance pathway away from the artery.
These data suggest that the losses from perivascular dilution and clearance outweighed the losses
from the lumen flow (Fig. 4.5). Tightly adhering perivascular release devices may have negated
some of the difference in deposition. The resistance of heparin transport from the vessel wall to the
lumen flow has been shown through mass transfer boundary layer analysis to be small relative to
the resistance of traversing the arterial media.10 5 The current results imply that the perivascular
resistance to drug loss provided by extra-arterial capillaries is even smaller than the endovascular
resistance provided by the mass transfer boundary layer. These arguments will be used to justify
zero resistance boundary conditions in subsequent computational modeling of vascular drug
distribution (Chap. 5).
4.4.3. Is There a Need to Wrap both the Device and Artery?
These experiments characterize the local administration of drug to the blood vessel wall, which
is one of the determining principles of vascular pharmacokinetics. The potential loss of drug to
extra-arterial capillaries has prompted some to advocate that perivascular drug delivery might be
more efficient if the artery and release device are wrap-isolated with impermeable barriers. 138,158
These data show that inulin can still leak out of wrapped spaces, even after the ends were plugged
(Fig. 4.3b). It is possible that the continuity of the artery through the plug and beyond support a
continuous aqueous layer on the adventitial surface that provides a low resistance pathway for drug
to escape from within the wrap. This leak was noted visually by administering Evan's Blue Dye in
Poloxamer gel from within a wrap around the carotid and observing the diffusion along the arterial
surface. Although more heparin was deposited in the carotid artery when wrapped, this increase
was not statistically significant (Fig. 4.4). Likewise, the arterial wrap did not decrease deposition
in distant structures. Thus, the wrap failed to completely eliminate extra-arterial capillary
absorption. The rush to wrap arteries and release devices should be tempered, therefore, especially
in light of evidence that wrapping arteries can impose deleterious ischemic and proliferative
injury.159,160 Although the wrap did not increase deposited drug, it did slow the rate of drug
release from the Poloxamer gel and would presumably extend the duration of elevated local arterial
concentrations (Fig. 4.3).
4.5. Chapter Summary
Drug has been released into the perivascular space in vivo in an attempt to settle a long running
debate as to how drug moves from local release devices to the blood vessel wall. These studies
have shown that the overwhelming majority of drug leaves the perivascular space through the
extra-arterial microcirculation, and yet little enters the vessel wall from the endovascular aspect. All
of the small fraction of drug that enters the blood vessel wall arrives by direct diffusion from the
perivascular space. The potential for drug to be lost to the lumen flow was found to be smaller
than the loss to the extra-arterial capillaries. These experiments characterize the local administration
and the movement of drug in the arterial environment, which is a fundamental component of
vascular pharmacokinetics.
5. COMPUTATIONAL SIMULATIONS OF VASCULAR HEPARIN DEPOSITION
AND DISTRIBUTION
5.1. Introduction
The preceding chapters described how all of the relevant vascular transport and binding
parameters were measured in isolation. They also discussed mechanisms of drug administration,
distribution and clearance to, through and from the arterial wall. All of these works have been
incorporated into a series of mathematical pharmacokinetic models of heparin distribution. This
chapter illustrates the derivation of these computational models and their utility in interpreting and
designing local drug delivery systems. These simulations predict that heparin will be rapidly
cleared from the arterial wall, implying that sustained modes of delivery will be needed to treat
vascular disease with these and similar soluble compounds. The models have been validated by
comparison to local drug delivery data from a novel endovascular hydrogel delivery system. As a
consequence, the simulations added unanticipated insight into these data and the function of this
drug delivery system. In general the pharmacokinetic models derived here have spatial resolution
that far exceeds that of radiolabeled drug deposition studies, and demonstrate the kinetic movement
of drug that could only be elucidated with countless animal experiments. In addition, these
mathematical simulations distinguish soluble, reversibly bound and internalized drug, which helps
discriminate between committed biologically inactive drug from potentially useful drug. These
models are essential for the rational design of vascular pharmacotherapies.
5.2 General Model Construction
A series of generalized one-dimensional models of drug deposition and distribution across
multi-layered tissues have been written in Matlab (Mathworks) using a forward-difference
algorithm (Appendix 8.9). Each distinct tissue layer is divided into N consecutive elements each
with a computational node at its center. The drug can be in one of three phases or compartments:
soluble, bound (reversibly) and internalized (or irreversibly bound or metabolized), whose
concentrations are defined per unit tissue volume and are considered homogeneous throughout
each element. For each step in time (At) the diffusive transport of the soluble compound into and
out of each element is computed (Fig. 5. l1a). The diffusive and convective flux of soluble drug
(j") is determined through Fick's first law:
(5.1) j" = Ucs- D = Ucs
- 
D AC
dx Ax
where cs is the concentration of soluble drug in an element, Ax is the internodal distance, D is the
effective molecular diffusivity of the compound in the tissue layer, and U is the convective solute
velocity. From a mass balance on an element, the rate of change of soluble drug is equivalent to
the net vectorial flux of drug across each of its faces in a time interval (At):
c -2 c -C c -c
(5.2) Ax sn,t+At s- n, "- - =Uc + D n-1,t- sn t  Ucn, - D Csn,t •Sn+l
At n n sn-1,t Ax snt Ax
The subscript n denotes the computational element. Thus, the concentration of soluble drug in an
element depends on its prior concentration and those of its neighbors:
"-"+DAt + UAt(5.3) c = c + c + c t - 2c t) + Snl t -snt(5.3) Csn,t+At = Csn,t + Ax (Csn+l,t +sn-,t snt sn-,t snt
Eq. 5.3 allows the soluble concentration of drug to be computed at each of the interior elements, 2
through N-i, in a tissue layer. The elements at the ends, 1 and N, require special boundary
conditions that are specific for the particular application of the model.
5.2.1 Incorporation of Binding into Distribution Models
In between each step in time, after the new soluble concentrations are determined, the amount
of soluble drug that binds and the amount of reversibly bound drug that dissociates is determined
by invoking an assumption of local equilibrium within each element (Fig. 5.1 la). The total
noninternalized drug concentration (CT) is equal to the old reversibly bound and the new soluble
drug: 53
(5.4) CTn,t+A t = Csn,t + At + Cbn,t
The soluble and reversibly bound concentrations (cb) are then redistributed based solely upon the
newly computed total noninternalized concentration within each element and the density of specific
and nonspecific binding sites (BT), the fractional volume in which drug can distribute (e') and the
dissociation constant of the average binding site (K' , Eq. 3.15):
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Figure 5.1. Outline of the general scheme used in the model of vascular drug
deposition and distribution (a) and one dimensional computational grid used in the
simulations of arteries uniformly loaded with heparin (b, simulation I) and of the
endovascular hydrogel drug delivery system to the coronary artery (c, simulation
II).
.
CTnt+At - BT - K' + (CTt+At - BT - K'') 2 + 4CTnt+At K'E
(5.5) csn,t+At 2
The ^ marker on the soluble concentration denotes that drug has already been redistributed between
the soluble and the reversibly bound components according to local equilibrium. The reversibly
bound fraction in each element can now be computed as the total noninternalized concentration less
the redistributed soluble concentration defined by Eq. 5.5. Thus, static binding constants are used
to incorporate the dynamic effects of binding and dissociation on the deposition and distribution of
compounds.
5.2.2. Justification of Local Equilibrium Assumption
The complete partial differential equation of soluble drug transport that allows for drug binding
is as follows:
(5.6) Cs= -Ucs +D - koncsB f + koffc bdt dx2
where kon is the rate of heparin association to the average binding site, koff is the rate of heparin
dissociation, and Bf is the molar density of free binding sites. By assuming quasi-steady
transport and most binding sites to be free, the local equilibrium assumption can be justified by
scaling the diffusive and associative binding terms, thus defining the Damkohler number:
(5.7) Da = knl2Bf
D
Because heparin binds to many potential binding sites in the heterogeneous arterial wall,53,149 and
the rates of association potentially vary among the sites, a conservatively low estimate of kon can
be estimated from structurally homologous molecules. kon for heparan sulfate binding to basic
fibroblast growth factor (bFGF) is 0.9 x 108 min-1 M-1.143 Note that heparin and heparan sulfate
are similar in composition, and that the heparin binding domains on many proteins are
conserved. 161 Therefore, the above kon may be applicable as a lower bound since it reflects the
mechanical coupling to complicated structures and much of the binding in arterial tissues is
probably loosely charged associations that should act even faster. The Damkohler number in
arterial media will be about 10 for length scales (1) about 4 glm, indicating that the rate of binding
will exceed the rate of diffusive transport of soluble drug over this distance. Thus, equilibrium can
be assumed at each instant for elements of this length scale or longer. Note that the rate of
association, however, is also proportional to the number of free binding sites. As these sites
saturate, the Damkohler number falls, and the local equilibrium assumption may require
reevaluation. Because kon and koff are not quantified in the heterogeneous arterial tissues, Eq. 5.6
can not be solved explicitly. Rather, the forward-difference scheme outlined above, including the
local equilibrium assumption, was used to incorporate the effects of binding and dissociation (Fig.
5.1a). To describe the following simulations in the most concise notation, the governing equations
and boundary conditions of soluble drug transport were written in differential notation. Note that
although these equations do not explicitly include such terms, drug binding and internalization
were determined after each time step, the former according to local equilibrium and the latter as
described below (Fig. 5.1a).
5.2.3. Estimation of the Rate Of Heparin Internalization
Approximately 10% of the heparin bound to smooth muscle cells in culture has been shown to
be internalized with a t1 /2 of 15 to 20 minutes and an additional 10% of the bound heparin is
endocytosed at a much slower, but unquantified rate. 145 In these simulations, 5% of the bound
drug in arterial media was assumed to be on the smooth muscle cell surface, 20% of which was
assumed internalized with a t1/2 of 15 minutes. Internalization of heparin in the adventitia was
neglected since the cell density is much lower than in the media and the kinetics of heparin
internalization into fibroblasts and adipocytes are unknown. Internalized heparin has been shown
to be metabolized to smaller fragments,162 and was therefore subtracted from the reversibly bound
concentration, defined by Eq. 5.6, after each time step (Fig. 5. la).
5.3. Applications of the Model
The generalized model presented above has been applied to the transarterial distribution and
deposition of heparin.
5.3.1. Simulation I. Artery Uniformly Loaded With Heparin
The deposition and distribution of heparin throughout the media (med) and adventitia (adv)
was simulated using the following differential form of Eq. 5.3 and the above forward-difference
scheme (Fig. 5.1a):
(5.8) = -Uici,s + D i d 2 ; 0 xi 5 li where i = med and advdt dxý
The initial soluble concentration was assumed to be uniform throughout the media and adventitia:
(5.9) Ci,s(Xi) = Cinit; t=O
The intimal boundary condition was derived from a mass balance across the endothelial
monolayer:99,102
dCmed,s _ 1 ( Cmed,s(5.10) UmedCmed,s - Dined d end Cplasma - ed Xmed =0
dxmed Rend a med
The fluxes and the soluble concentrations in the available spaces was considered continuous across
the medial/adventitial interface: 95
(5.11) Umedcmed,s - Dined med, UadvCad,s - Dadv Xadv med = Imed, Xadv =0
Cmed's Cadv's "
(5.12) ed = ,d Xmed = Imed, Xadv = 0emed Eadv
A zero resistance boundary condition was assumed at the outer edge of the adventitia as suggested
by earlier data (Sec. 4.4.3):
(5.13) Cmed,s = EmedCpv; Xadv = ladv
Recall that after each time step the soluble and reversibly bound drug were redistributed according
to local equilibrium and the amount internalized by medial cells determined (Fig. 5.1a). These
simulations were carried out with an initial heparin loading (cinit) of 1 tM, and dimensions
representative of human coronary arteries, including a 160-jgm-thick media and a 40-jgm-thick
adventitia (simulation Ia, Table 5.1; Fig. 5. 1b). To investigate the effects of drug saturation of the
binding sites on the clearance, the simulation was repeated with an initial loading (cinit) of 1 mM
(simulation Ib). To investigate the effects of arterial thickness and to compare the simulations to
heparin deposition data collected in our laboratory using rabbit iliac arteries, the simulations were
repeated with half the medial (80 glm) and adventitial (20 gtm) thicknesses used above (simulation
Ic). The diffusion and binding properties of heparin in arterial media and adventitia have been
measured in Chapters 2 and 3 and are summarized in Table 5.2. The convective solute velocity
was calculated from the hydraulic velocity (Eq. 2.13) and on the convective hindrance of the
arterial media as suggested by pore theory (Section 2.3.3). As an approximation, the convective
hindrance in the adventitia is assumed to be the same as in the media and therefore the solute
velocities are the same in these layers. The transendothelial resistance to heparin (Rend) has been
measured in an in vitro perfusion preparation to be 2.5 s/jtm (Sec. 2.4.1). The boundary layer
resistance to heparin transport in the lumen flow has been shown to be negligible compared to the
diffusive resistance of the endothelium or media. 10 5 The concentration of heparin in plasma
(Cplasma) and in the perivascular space (cpv) were considered to be zero throughout this
simulation.95 ,99
Table 5.1. Summary of Simulations
Simulation I. Artery Uniformly Loaded With Heparin
Medial Thickness Adventitial
(glm) Thickness (jlm)
Simulation Ia 160 40
Simulation Ib 160 40
Simulation Ic 80 20
Simulation II. Endovascular Hydrogel Heparin Delivery to Porcine
Initial Heparin
Endovascular Concentration in
hydrogel? Endovascular
Hydrogel
Simulation IIa Y 0.33 mg/ml
Simulation IIb Y 0
Simulation IIc N -
Initial Loading (cinit)
1 AM
1 mM
1 M
Coronaries
Myocardium Loaded
Initially with
Intracoronary Bolus?
Y
Y
Y
Table 5.2. Physical constants for heparin in the hydrogel and arterial tissues.
Hydrogel Media Adventitia Myocardium
Effective Diffusivity (gm2/s) 24 7.7 12 7.7
Fractional Space 1 0.61 0.85 0.61
Binding Site Density (jgM) - 2.5 0.0022 2.5
Average Dissociation Constant (RM) - 5.0 0.0081 5.0
5.3.2. Simulation II. Endovascular Hydrogel Heparin Delivery
In a series of in vivo experiments described elsewhere, a photopolymerizable hydrogel drug
delivery system was used to deliver heparin to the endovascular aspect of the left anterior
descending (LAD) branch of porcine coronary arteries. 16 3 A bolus of heparin mixed with
hydrogel prepolymer was delivered to balloon denuded, isolated segments of artery through a
double balloon catheter that was described earlier (Sec. 4.2.4.2) The hydrogel was then
photopolymerized in situ resulting in an approximately 70-gm-thick interfacial sheet formed on the
intimal surface. Approximately 1% of the delivered volume of drug and hydrogel prepolymer were
incorporated into this endovascular sheet. The remaining drug and hydrogel prepolymer flowed
downstream, some deposited in the myocardium and the rest entered the systemic circulation. In
separate experiments, "ungelled control" animals received the same intracoronary bolus of heparin
and hydrogel prepolymer without photopolymerization and subsequent endovascular sheet
formation.
The heparin deposition in the LAD 48 hours after photopolymerization was greater than that
observed in the corresponding ungelled control. This implied that the presence of a formed 70-
gm-thick endovascular hydrogel led to increased deposition in the LAD, presumably because it
was able to provide a sustained release of drug over this duration. Subsequent to these findings,
the in vitro release kinetics (See Sec. 5.3.2.2) showed that a thicker sheet of the same hydrogel
releases its contents entirely in less than a half hour (Fig. 5.2). Thus, it seemed unlikely that the
endovascular hydrogel was releasing heparin in vivo at 48 hours and it must therefore have
increased deposition over controls by some other mechanism.
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Figure 5.2. In vitro bi-directional release of heparin from a uniformly loaded 300-Aim-thick
hydrogel sheet(average ± SEM, n=3). A numerical curvefit of this data to a theoretical release
profile for this geometry (Eq. 5.28) determined the effective diffusivity of heparin in the hydrogel to
be 24 gLm2/s (Solid line).
As a consequence of the endovascular hydrogel deployment process, following
photopolymerization the remaining 99% of the hydrogel prepolymer and heparin that was not
incorporated into the endovascular sheet was washed into the myocardium and systemic
circulation. At every time of sacrifice after endovascular hydrogel deployment, the deposition of
heparin in the myocardium and in the LAD were similar. This led to the hypothesis that the LAD
and myocardium were continuously exchanging drug and that the endovascular hydrogel, in
addition to delivering heparin to the arterial wall, also served as a barrier to limit the loss of drug
diffusing from the myocardium. This hypothesis was tested with computational simulations that
assessed the extent to which the endovascular hydrogel behaved as a drug delivery device or
alternatively as a diffusion barrier. Because the myocardium has many sources of perfusion, the
heparin clearance was assumed independent of events in the LAD. A single exponential was fit to
the myocardial deposition data obtained during these porcine coronary experiments (R = 0.62):163
(5.14) Cmyo (t) = 0.17uM- e-t/ 40.5hrs
The concentration within the peripheral myocardium was allowed to vary to a penetration depth
(lmyo*) of 200 gtm. This length scale roughly corresponds to half the distance into the
myocardium in which histologic sections showed other smaller blood vessels, which were
considered independent sources of clearance. Beyond this depth the myocardium was considered
well mixed and followed Eq. 5.14. Although the transport and binding of heparin in epicardium
and myocardium have not been characterized, as a first order approximation the peripheral
myocardium was assumed homogeneous and to resemble arterial media.
The physical constants used in this model are summarized in Table 5.2. The soluble
concentration of drug throughout the geometry was determined by applying Eq. 5.8 to each of the
following four layers: the endovascular hydrogel (gel), arterial media (med), adventitia (adv), and
peripheral myocardium (myo). Note that because the hydraulic conductivities of the endovascular
hydrogel and myocardium are unknown, the solute convective velocities (U) in Simulation II were
assumed to be zero. Initially, the hydrogel was considered uniformly loaded, and the artery and
peripheral myocardium were devoid of drug:
(5.15) cgel(xgel) =init; t=0
(5.16) ci,s(xi)= O; t = 0 where i = med, adv, and myo
The boundary layer resistance to heparin transport in the arterial lumen has been shown to be
negligible and therefore a zero resistance boundary condition is applied: 105
(5.17) Cgel = EgelCplasma; Xgel = 0
Note that as the endovascular hydrogel deployment requires endothelial denudation, the diffusive
resistance imposed by the endothelium was removed from these simulations. Although studies
have shown that the fractional space for heparin can increase slightly following balloon
denudation, 5 3 this parameter was not adjusted in these simulations. Again, the fluxes and the
soluble concentrations in the available spaces must be continuous across each interface: 95
(8cgel d c med,s .(5.18) Dgel = Dmed ' Xgel = Igel, Xmed =dxgel dxmed
(5.Cgels Cmed,s
(5.19) Xgel = lgel, Xmed = 0Egel Emed
(5.20) Dmed cXmeds g= xadv Xmed = Imed
, 
Xadv = 0
dxmed dxadv
(5.21) Cmed,s - Cadv,s(5.21) , Xmed = Imed
, 
Xadv = 0
•nmed Eadv
dcadvs eCmyo,s 
.
(5.23) , = y Xadv = lady , Xmyo = 0
e adv wmyo '
Again, the concentration within the bulk of the myocardium is assumed to follow Eq. 5.14:
(5.24) Cmyo,s = Cmyo(t) ; Xmyo = Imyo*
Recall that after each time step in the forward-difference scheme, the soluble and reversibly bound
drug were redistributed according to local equilibrium and the amount internalized by medial cells
determined (Fig. 5.1a). The plasma concentration was assumed to be zero and the initial heparin
concentration in the endovascular hydrogel (cinit) was 0.33 mg/ml, as was used in the
corresponding in vivo studies. 16 3 The thickness of each arterial layer and the number of
computational elements to which each was divided into are shown (Fig. 5.1c).
5.3.2.1. Permutations on the Porcine Coronary Simulations
The simulations were also carried out with the following permutations (Table 5.1). Simulation
Ha models the heparin delivery experiments performed on porcine LADs, where heparin was
mixed in with hydrogel prepolymer, a 70-gm-thick endovascular hydrogel was formed, and the
myocardium was loaded from the intracoronary bolus. In simulation IIb the myocardium was
assumed to be loaded by the same initial intracoronary bolus of drug and hydrogel prepolymer,
however, the endovascular hydrogel formed initially contained no drug. In this simulation the
following initial condition replaced Eq. 5.15:
(5.25) Cgel(xgel)=; t= 0
This represents a case where an unloaded endovascular hydrogel was formed and then heparin was
administered to the myocardium by an initial intracoronary bolus. In simulation IIc the
myocardium was assumed loaded with the same initial intracoronary bolus of drug and hydrogel
prepolymer, but there was no endovascular hydrogel formation at all. In this simulation the
following boundary condition replace Eqs. 5.17-19:
(5.26) Cmed,s = EmedCplasma; Xmed = 0
This simulated the ungelled control experiments performed in vivo, where the heparin and
hydrogel prepolymer were introduced to the LAD but were not photopolymerized.
5.3.2.2 In Vitro Release Kinetics
Flat 300-gm-thick sheets were formed between two glass slides from the same hydrogel
prepolymer containing an identical concentration of 3H-heparin (NEN Dupont) as in the porcine
coronary experiments. These sheets were placed in 2 ml of phosphate buffered saline at 370 C,
which was replaced periodically. The in vitro release data (Fig. 5.2) were used to estimate the
effective diffusivity of 3H-heparin within the hydrogel. The concentration of drug at each face
was considered zero, so that the following equation describes the dynamic concentration
profiles: 164
(5.27) c(x, t)= init Delin] 2
j=1,3,5... J
where x is the spatial coordinate across the thickness (1). Integration across the thickness resulted
in a relation that was used to numerically curve-fit (TableCurve 2D, Jandel Scientific) the in vitro
release data:
j-(t) 8 e-Dgelt[1ja/l]2(5.28) %cumulative release = 1- _ 8 e- elt  ll.2j=1,3,5... J
The effective diffusivity of heparin in the hydrogel was thus determined to be 24 glm 2/s. Note that
this method of measuring the effective diffusivity of heparin incorporates potential binding and
therefore only the total concentration in the hydrogel was computed in the simulations.
Findings from the Simulations
5.4.1. Simulation I. Artery Uniformly Loaded With Heparin
The predicted heparin concentration profiles for the case of a uniformly loaded arterial cross
section are shown (Fig. 5.3). At 4 minutes there was significant loss of drug at the periphery of
the artery. At 15 minutes the average medial concentration was about 25% and by one hour the
concentration was about 2% of the original concentration. At four hours the heparin in the blood
vessel wall was 4 orders of magnitude lower than what it had been initially, and was entirely in the
internalized fraction. The clearance of heparin from the blood vessel wall was even more rapid for
higher initial loadings (Fig. 5.3b) and for thinner vessels (Fig. 5.3c). These results strongly
suggest that soluble drugs such as heparin must be continuously supplied to the vessel wall in
order to maintain therapeutic levels.
5.4.2. Simulation II. Endovascular Hydrogel Heparin Delivery
Simulated soluble and total transmural concentration profiles following endovascular hydrogel
heparin delivery are shown at 3 minutes, 10 minutes, and 3 hours (Fig. 5.4). Within 3 minutes,
much of the heparin initially in the endovascular hydrogel was lost to the lumen flow, and the peak
concentration was 14% of the initial hydrogel concentration located at the interface with the media.
At 10 minutes the peak concentration was in the media and was about 4% of the initial hydrogel
concentration. There were gradients from the media both toward the myocardium as well as the
lumen, implying that at this early time, drug released from the media was loading the adventitia and
myocardium. A concentration gradient was also evident from the myocardium towards the
adventitia, indicating that drug entered the artery from the external aspect. At 3 hours the only
existing concentration gradients came from the myocardium, and the peak medial concentration
was about 0.6% of the initial hydrogel concentration. Note that all of the drug in the adventitia was
in the soluble phase indicating that these binding sites were saturated. Conversely, the binding
sites in the media and myocardium did not appear to be filled.
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Figure 5.3. Predicted heparin concentration profiles for a uniformly loaded artery at 0, 4, 15, 60,
and 240 minutes showing the effects of arterial thickness and initial drug loading. The ordinate
is the total concentration of drug and the abscissa is the distance from the lumen. Dashed lines
denote the boundaries of each tissue layer. a) Simulation Ia: medial thickness of 160 pm, adventitial
thickness of 40 pm, and initial concentration of 1 gM. b) Simulation Ib: medial thickness of 160
pm, adventitial thickness of 40 pm, and initial concentration of 1 mM. c) Simulation Ic: medial
thickness of 80 pm, adventitial thickness of 20 pm, and initial concentration of 1 gM.
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Figure 5.4. Predicted total and soluble transmural concentration profiles from
endovascular hydrogel heparin delivery to porcine coronary arteries (simulation IIa).
Heparin profiles across the endovascular hydrogel, media, adventitia, and peripheral
myocardium are shown at a) 3 minutes, b) 10 minutes and c) 3 hours. Concentrations
are expressed as a percentage of the initial concentration of the endovascular hydrogel.
In addition to the above simulation where the endovascular hydrogel initially was loaded with
heparin (simulation IIa), simulations were also carried out in which the endovascular hydrogel
initially contained no heparin (simulation IIb), and alternatively when there was no endovascular
hydrogel formed (simulation IIc). The average concentration of heparin in the arterial media from
all three of these simulations are shown normalized by the initial heparin concentration in the
hydrogel (Fig. 5.5). In all of these permutations the myocardium was considered to be initially
loaded to the same level and cleared at the same rate, according to Eq. 5.14. Note that the average
heparin concentrations include soluble, reversibly bound and internalized drug. Including drug
initially in the endovascular hydrogel resulted in the highest average medial concentration at all
times, and having no endovascular hydrogel resulted in the lowest average medial concentration.
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Figure 5.5. Simulated average medial total (soluble, reversibly bound and internalized)
heparin concentration following endovascular hydrogel delivery to porcine coronaries
as a function of time, expressed as a percentage of the initial concentration in the
hydrogel (if formed and initially loaded with heparin). Simulations are performed
with a) heparin delivered in the endovascular hydrogel, b) no heparin initially in the
endovascular hydrogel, and c) no endovascular hydrogel formed. The drug delivery
potential (cross-hatched) of the endovascular hydrogel is defined as the difference
between tracings (a) and (b). The barrier potential (stippled) is defined as the
difference between tracings (b) and (c).
_ __
5.5. Discussion
More often than not, proposed pharmacologic therapies that show promise in vitro do not
succeed in animals or humans. It is just as often not clear whether this arises from biologic or
pharmacologic etiologies. In other words, whether the drug is impotent in the disease is a question
of whether drug deposition and distribution within tissues is ultimately inadequate. Detailed
quantitative pharmacokinetic analyses are required to differentiate between these failure modes, and
future study designs must include such analyses to ensure that costly animal experiments and
clinical trials are not doomed by limited deposition and distribution of drug. These issues are
especially acute with local modes of vascular therapy, which by its nature imparts large
concentration gradients across tissues with potentially chaotic kinetics. Local delivery has been
studied to date phenomenologically, mostly through radiolabeled drug deposition studies. In this
chapter, generalized models of drug deposition and distribution were applied to local heparin
delivery data using quantitative analyses of the transport and binding within arterial tissues
(Chapters 2 - 4). These models have spatial resolution that far exceed that of radiolabeled drug
deposition studies, and they demonstrate the kinetic movement of drug that could only be
elucidated with tremendous numbers of animal experiments. In addition, these mathematical
simulations distinguish soluble, reversibly bound and internalized drug, which helps discriminate
between committed biologically inactive drug from potentially useful drug. Such distinctions could
never be determined in drug deposition experiments in vivo. This modeling approach describes the
net effects of diffusive and convective transport, binding, dissociation and cellular internalization.
Many physiologic, pathologic, and therapeutic processes that involve intracellular signaling
through soluble mediators are dependent upon and are potentially dampened by these physical
interactions. Similar models to the one described here, with the incorporation of appropriate
transport and binding properties, can be used to augment biological studies of these processes.
5.5.1. Simulation I. Artery Uniformly Loaded With Heparin
The predicted heparin transmural concentration profiles for the case of a uniformly loaded
artery (simulation Ia) show extremely rapid clearance (Fig. 5.3), as a result of the relatively high
diffusivity and the weakness of the overall binding. Increasing the initial loading (Fig. 5.3b,
simulation Ib) has the effect of filling more binding sites, forcing a greater fraction of drug into the
soluble phase, which results in even faster clearance. Simulations were performed on arterial
thicknesses representative of human coronary (200 gm) and rabbit iliac arteries (100 Cgm). The
clearance was much more rapid for thinner vessels (Fig. 5.3c, simulation Ic) because the diffusive
resistance of the artery is proportional to its thickness (Sec. 2.3.1). This rapid clearance has been
noted with other compounds delivered from porous balloon catheters.2 3,165 The rapid loss of
drug from the blood vessel wall bodes poorly for the clinical application of soluble compounds
such as heparin from catheter-based bolus delivery systems. No matter how well an endovascular
catheter loads the arterial wall, drug will rapidly diffuse back into the lumen and to the
extravascular microcirculation. This implies that soluble compounds such as heparin must be
deployed from locally implanted continuous-release systems in order to sustain adequate levels of
drug to treat vascular diseases.
These simulations predict that a small percentage ( < 0.01%) of drug initially in the artery is
internalized before it clears, implying that this fraction may be detectable following bolus delivery
if the infusion concentrations are very high. This early internalization helps explain how some
have observed drug within the arterial wall days after bolus endovascular delivery. 4 6
Unfortunately, experimental studies using fluorescent tracers are inherently unquantitative due to
arterial autofluorescence and limitations in cryo-sectioning.
5.5.2. Simulation II. Endovascular Hydrogel Heparin Delivery
In the porcine coronary experiments, the deposition was greater when the hydrogel prepolymer
was photopolymerized than when it was not, indicating that the endovascular sheet delivered drug.
Simulations of both of these scenarios and an intermediate condition where an endovascular
hydrogel was formed but initially devoid of drug showed that this system influences arterial drug
concentration through more subtle mechanisms.
The difference in average medial concentration when heparin was initially incorporated into the
endovascular hydrogel (simulation IIa) from when the hydrogel initially contained no drug
(simulation IIb) was considered to be the drug delivery potential (Fig. 5.5, cross-hatched). The
presence of the initially unloaded endovascular hydrogel (simulation IIb) caused a higher average
medial concentration than when the endovascular hydrogel was not formed (simulation IIc). This
difference was considered to be the barrier potential of the endovascular hydrogel (Fig. 5.5,
stippled), as it apparently slowed the loss of drug from the myocardium to the lumen flow. The
average medial noninternalized (soluble and reversibly bound) concentrations are shown for these
three simulations (Fig. 5.6). After the first few hours the initial inclusion of heparin into the
endovascular hydrogel did not lead to any more medial noninternalized drug than when the
endovascular hydrogel initially contained no drug. Thus, with respect to noninternalized heparin,
the drug delivery potential rapidly falls to zero. The presence of the endovascular hydrogel,
however, still leads to more medial noninternalized drug then when it was not formed, and thus it
still behaves as a barrier for noninternalized drug that diffuses from the myocardium. Appreciation
of these important functions in vivo would require countless animal experiments with many
endpoints and controls.
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Figure 5.6. Simulated average medial noninternalized (soluble and reversibly
bound) heparin concentration (soluble and bound) following endovascular hydrogel
delivery to porcine coronaries as a function of time, expressed as a percentage of
the initial concentration in the hydrogel (if formed and initially loaded with heparin).
Simulations are performed with a) heparin delivered in the endovascular hydrogel,
b) no heparin initially in the endovascular hydrogel, and c) no endovascular hydrogel
formed. The drug delivery and barrier potentials are defined as in the caption of
Figure 5.5.
5.5.3. Empirical Verification
The simulations of the endovascular hydrogel delivery system to porcine LADs, and the model
in general, were verified by comparing the predicted average medial concentrations to the
deposition measured experimentally. 163 The experimental deposition at 4 hours, 48 hours and 6
days is compared to both the predicted (simulation Ha) average medial noninternalized and total
concentrations (Fig. 5.7). For all times, the experimental deposition was below the predicted total
and above the noninternalized concentration. As time progresses these discrepancies grow. A
possible explanation for this trend is that either the rate of cellular internalization or the fraction of
total binding sites residing on cell surfaces were over estimated in the model. Another is that some
of the internalized drug may be eliminated from the cells and artery, possibly as metabolites. 162
5.5.4. Advantages of Augmenting Experiments with Simulations
These simulations discriminate soluble, bound, and internalized drug; an impossible feat to
perform experimentally in vivo. These distinctions can lead to markedly different interpretations of
deposition data. For example, examination of the total amount of drug indicates that the
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Figure 5.7. Comparison of model predictions (simulation IIa) of average medial concentrations
following endovascular hydrogel heparin delivery to experimental deposition in porcine coronaries
at 4 hours, 48 hours, and 6 days. Internalized concentrations (open) are superimposed on
noninternalized concentrations (cross-hatched). Computational predictions were converted to
deposition per dry tissue mass by assuminqbwet:dry mass ratio of 5. Experimental heparin
de osition (closed from is the avera e ± SD.
endovascular hydrogel drug delivery system indeed had drug delivery potential for all times (Fig.
5.5), while examination of the noninternalized fraction showed that there is no drug delivery
potential past the first few hours (Fig. 5.6). The goal of a controlled-release drug delivery system
is to continually provide new drug, and these simulations suggest that the endovascular hydrogel
delivery system used in the porcine LAD experiments did not do so after a few hours. Thus, some
of the drug found in the LAD in vivo after a few days must have been internalized earlier within
cells. This fraction of drug is committed to the cell it is internalized within and may not be
available to exert a biologic effect. In fact, one potential mechanism for heparin's antiproliferative
effects is that it binds and inactivates extracellular mitogenic stimuli. 166 ,167 In vivo drug
deposition experiments almost universally utilize radiolabeled drug, and unfortunately this assay
determines the fate of the label and not that of the drug. Of a radiolabel signal observed in a tissue,
it is unknown how much is extracellular viable drug and how much represents internalized,
committed drug or metabolites. The estimates of heparin internalization in these models provides a
valuable feel for the elimination of biologically potent drug and the persistence of misleading
radiolabel signal.
The aforementioned traditional radiolabeled drug deposition experiments lack spatial resolution.
The assays employed in vascular pharmacokinetic studies almost universally consist of removing
the entire artery at sequential sacrifice times and quantifying deposition in the entire organ. In such
experiments, there is no means to discriminate deposition in the media or adventitia. Since
vascular pharmacotherapies target medial smooth muscle cells, it is of critical importance to resolve
the concentration gradients across the artery imposed by local delivery strategies. These
computational simulations can quantify transmural concentration gradients and can assess whether
drug reaches target tissues (Fig. 5.4).
5.6. Chapter Summary
These simulations have provided valuable insights into local vascular drug delivery systems.
They have shown that regardless of the method of applying soluble drugs to arteries, their rapid
clearance mandates sustained modes of delivery. In addition, many of the deficits of the standard
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labeled-drug assays can be overcome by augmenting experimental work with numerical models.
These simulations provide spatial resolution, elucidate the kinetic nature of local vascular
distribution without numerous costly animal experiments, and help discriminate biologically active
drug from label signal. An example has been illustrated where the implications of experimental
local heparin delivery data were reinterpreted following computational simulation. This modeling
approach also serves as a paradigm for studying the physical interactions between tissues and
chemical signals that modulate many physiologic and pathologic phenomenon.
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6. NEXT STEPS
The work presented in this thesis has attempted to describe the physical interaction between
vasoactive drugs and arterial tissues. The deposition and distribution of heparin following any
mode of vascular administration can now be predicted. However, there are several avenues that
remain unexplored. The following analyses will broaden the applicability of the models to other
compounds and states of arterial injury, will improve the accuracy by refining some of the
measurements and assumptions, and will further demonstrate the utility of pharmacokinetic
modeling by allowing dose response experiments in vivo that were formerly only achievable in cell
culture:
I. Extension of pharmacokinetic modeling to other compounds.
II. Extension to more complete models of vascular pathology.
III. Measurement of the average rate of drug internalization.
IV. Measurement of transendothelial resistance in vivo.
V. Dose response of intimal hyperplasia in injured arteries to heparin.
6.1. Extension of Pharmacokinetic Modeling to Other Compounds
Several of the analyses in this work show that heparin differs from standard tracer molecules in
terms of fundamental transport and binding properties in vascular tissues, such as effective
molecular diffusivity in arterial media, convective hindrance coefficients, transendothelial diffusive
resistance, fractional tissue volume, nonspecific binding site density and average binding affinity.
These transport and binding properties are in part a function of solute molecular characteristics.
For example albumin is a 65 kD globular protein and heparin is a linear, flexible
glycosaminoglycan of dispersed molecular weights between 6 and 20 kD. These two compounds
should move through and interact with arterial tissues differently. Unfortunately, endogenous
growth regulators and potential pharmacologic agents exhibit broad ranges of chemical properties,
including molecular weight, charge density, and three-dimensional conformation. Rather than
measure the arterial transport and binding properties of every potential therapeutic compound,
principles by which each of them vary with solute chemical properties will be established. For
example, the impact of solute molecular weight on effective molecular diffusivity in arterial media
will be determined by measuring this transport property for families of dextrans that vary only in
molecular weight. Similarly, these compounds will be used to correlate solute weight with all other
transport and binding properties. The effects of solute charge and solubility will be determined
with dextrans, dextran sulfates of varying charge density, and hydrophobic carbohydrate
polymers. The effects of geometrical conformation will be examined by comparing albumin to
dextran sulfates of comparable molecular weight or effective molecular radius. These series of
measurements will allow the estimation of the transport and binding properties and therefore
prediction of vascular deposition and distribution of any vasoactive drug or compound by simply
knowing standard solute chemical properties.
6.2. Extension to More Complete Models of Vascular Pathology
All of the analyses in this work have used normal healthy or balloon deendothelialized arteries.
The transport and binding properties will be assessed in more complicated and complete forms of
acute and chronic vascular injury. Acute injuries can be caused by mechanical revascularizations
including balloon angioplasty, and synthetic and venous interposition grafts. Endovascular stents
are wire mesh devices that can be expanded within arteries to remain in place for the lifetime of the
recipient and impose both acute and chronic forms of injury. Other chronic conditions arise more
slowly from years of subacute arterial insult, such as atherosclerotic arteries with calcified plaques.
Drug deposition and distribution through these chronically diseased vessels will be studied in vivo
with Watanabe heritable hyperlipidemic rabbits, and in vitro with adult porcine carotid and
coronary arteries which are known to have pathologies similar to human vascular lesions. 168,169
All of these forms of arterial injury carry a unique set of hemodynamic and cell/tissue reactions and
are expected to impact drug transport and binding properties in distinct manners. These studies
will help elucidate how the arterial wall may potentially modulate transport and binding, either to
help assist in repair or alternatively to further exacerbate vascular pathology.
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6.3. Measurement of the Average Rate of Drug Internalization
The internalization of heparin by smooth muscle cells was shown to be crucial in terms of drug
deposition and the interpretation of experimental data (Chap. 5). The rate of heparin internalization
used in the current pharmacokinetic analyses has been measured in cell culture but not the intact
three-dimensional arterial architecture. 145,170 It is possible that isolated cells may not exhibit the
same internalization characteristics as organized tissues. For example, the free and matrix exposed
surface binding site densities of sparse cells in culture may be dramatically different and also
distinct from cells in a three dimensional hierarchy. The rate of vesicular formation and
endocytosis may also be regulated in a manner that is effected by three-dimensional cell-to-cell
contact. Therefore, in order to better predict vascular drug distribution and to add insight into
fundamental biological phenomenon, the rate of cellular internalization of radiolabeled compounds
will be studied in organ-culture-uptake studies and interpreted through mathematical analysis of the
data.
Drug will be administered to arterial segments in their native tube configuration so that the in
vivo cell architecture is preserved and that transport is essentially one-dimensional. The segments
will be exposed to drug at a fixed concentration (cbulk) and the tissue average concentration will be
measured as a function of time. The following set of differential equations and boundary
conditions describes the transmural diffusion and first order internalization of soluble drug.
(6.1) ec 2 ec(6.1) = Dart 
- ricec
(6.2) Cec(O) = Cec(l) = E'cbulk
(6.3) = ricec
where Cec is the extracellular drug concentration, cic is the intracellular concentration, ri is the first
order internalization rate constant. Initially cec and cic are zero. The analytic solutions to these
equations can be integrated across the wall of the artery to describe the space-average
concentrations as a function of time. The total concentration of drug (CT) is the sum of the
internalized and extracellular concentrations, and is represented by the following analytic solution:
107
C0T(t) 8 Da.t[J/l] 2 e-tart[jl]2-r + ri
(6.4) - (t)+c(t) = rit + - • 2 2 (Dart[ 2 ri)
'cbulk Elcbulk j=1,3,5... 
-
The arterial drug uptake profiles will be measured at 4°C, where the internalization rate constant
will be assumed zero. The resulting time-varying deposition data will be fit to the analytic solution
to establish the diffusivity of drug in the interstitium of the artery (Dart). The measurements will be
repeated at 370C and will be fit to the full solution to determine the internalization rate constant.
The measured rate of drug internalization will be incorporated into computational simulations of
drug transport and will also be contrasted to rates obtained in cell culture models, thus potentially
illustrating the advantage of preserving arterial architecture when quantitatively studying this
process.
6.4. Measurement of Transendothelial Resistance In Vivo
The endothelial resistance to heparin measured in vitro was several orders of magnitude lower
than values predicted from in vivo studies of other macromolecules (Chap. 2). The resistance to
transport imposed by the endothelium may for many compounds depend upon tight intracellular
junctions, and slight changes in these gaps caused by moving this organ to culture may have lead
to significant artifact. The endothelial barrier to transport will be examined in vivo by measuring
the difference in deposition between both wire deendothelialized and unmanipulated native arteries.
The former procedure has been shown to remove the endothelial monolayer with minimal
subsequent damage to the underlying arterial media.17 1 Drug will be given in an intravenous bolus
and the resulting increase in deposition in deendothelialized over native arteries will correlate with
the transendothelial resistance to solute transport. More precise definition of this property will be
provided by augmenting this data with computational simulations of transmural drug deposition
and distribution. These simulations will be repeated by adjusting the endothelial resistance to
transport until the hypothetical removal of this resistance in the model yields the same increment in
deposition observed in the rat carotid artery experiments. The endothelial resistance measurements
will be repeated for molecules that vary in chemical characteristics such as molecular weight,
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charge density, and three dimensional conformation (Sec. 6.1). The quantitative determination of
the barrier function of the endothelium to these molecules may help rigorously explain the
observation that this organ acts as a barrier to plasma proteins such as albumin but not to
endogenous vascular regulators that are secreted by endothelial cells to act on vascular smooth
muscle, such as heparin.
6.5. Dose Response of Intimal Hyperplasia in Injured Arteries to Heparin
Although in vivo experiments have shown that heparin prevents intimal hyperplasia during
experimental models of arterial injury, 10 ,13,26,127 the concentration of heparin in the pericellular
environment needed to achieve these effects are unknown. Dose response analyses are readily
performed in cell culture as there are no limitations of drug distribution. These goals, however, are
difficult to achieve in isolated organs in vivo because the correlation between the administered dose
and the organ concentration varies from one mode of drug delivery to another. For example, drug
delivered systemically will produce much lower arterial levels than drug released perivascularly.
Thus, a method of determining local arterial drug requirements that is independent of the mode of
administration is desired. This goal will be achieved through a combination of perivascular heparin
delivery and computational modeling of vascular drug distribution. Heparin eluting ethylvinyl
acetate copolymer matrices that circumferentially wrap around arteries will be coated with an
impermeable material so that release is constrained towards the artery. Rat common carotid arteries
will be balloon denuded and the matrices will be placed around the injured segment. Two weeks
after injury the tissue will be harvested, sectioned, stained for proliferative indices and the
intima:media ratios measured. The delivered dose will be varied by substituting a fraction of the
heparin loaded into the matrices with bovine serum albumin. The computational models will predict
the heparin concentration in the pericellular milieu, and thus the relationship between local
concentration and neointimal thickening will be determined independent of the drug delivery
vehicle.
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7. CONCLUDING REMARKS
This work has attempted to illustrate how vascular pharmacokinetics should be assessed for
any mode of delivery of any solute. The administration, distribution, and elimination of
compounds have been evaluated by quantifying the mechanisms of intramural soluble drug
transport, the sequestration and potential binding to biologically active and nonspecific sites, and
the movement of drug in the perivascular and endovascular extramural spaces. Almost all of these
phenomena have been elucidated with novel in vitro and in vivo and techniques. It has been
shown that many of these properties are markedly different for vasoactive drugs than standard
tracer compounds. Therefore, these measurements have been illustrated with a potentially
vasotherapeutic agent, heparin. The results have been assembled into computational models of
drug deposition and distribution that provide insights that could not be appreciated from in vivo
studies. They provide spatial resolution, elucidate the kinetic nature of local vascular distribution
without numerous costly animal experiments, and help discriminate biologically active drug from
label signal. In addition, these models have already been used extensively to assist experimental
drug delivery protocol design. It is hoped that such analyses will be routine in formulating actual
pharmacologic therapies to be used in the clinic, and that trials of novel compounds and drug
delivery devices will not be attempted until they are shown in simulations to provide adequate drug
concentrations for sufficient periods of time.
Although the preceding analyses have been motivated by arterial diseases and a desire to treat
them, the techniques used could easily be adapted to study the physical interaction between any
compound in and around any tissue. Transport and binding characteristics are important in many
physiological, pathophysiological, and therapeutic scenarios where cells communicate through
soluble mediators. Similar models to the ones described here, with the incorporation of
appropriate transport and binding properties, can be used to augment biological studies of these
processes.
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8. APPENDICES
8.1. Rat Perfusion Morphometry
Native, AH=0 Lumen Medial Adventitial Medial Adventitial
section IEL EEL Area Area Area Thickness Thickness
(cm) (cm) (cm2) (cm2) (cm2) (cm) (cm)
p31-1 0.350 0.375 0.00451 0.00170 0.00221 0.00468 0.00588
p31-3 0.365 0.397 0.00682 0.00174 0.00205 0.00457 0.00515
p3 1 -5  0.377 0.407 0.00856 0.00204 0.00258 0.00521 0.00633
p31-7 0.365 0.392 0.00518 0.00190 0.00170 0.00502 0.00435
p3 1-9  0.317 0.351 0.00334 0.00163 0.00134 0.00488 0.00380
p31-11 0.359 0.396 0.00663 0.00210 0.00185 0.00555 0.00468
p3 1-12  0.367 0.404 0.00844 0.00231 0.00200 0.00599 0.00496
average 0.357 0.389 0.00621 0.00513 0.00502
p32-1 0.341 0.384 0.00222 0.00243 0.00200 0.00670 0.00520
p3 2 -3  0.344 0.387 0.00225 0.00250 0.00226 0.00684 0.00584
p32-5 0.341 0.379 0.00185 0.00228 0.00169 0.00635 0.00445
p32 -7  0.313 0.351 0.00148 0.00196 0.00190 0.00591 0.00543
p32-9  0.317 0.351 0.00202 0.00210 0.00220 0.00629 0.00627
p32-11 0.315 0.354 0.00394 0.00186 0.00278 0.00629 0.00627
average 0.329 0.368 0.00229 0.00642 0.00544
p33-1 0.333 0.374 0.00736 0.00250 0.00162 0.00706 0.00433
p33-3  0.346 0.385 0.00602 0.00235 0.00223 0.00644 0.00580
p3 3-5  0.323 0.382 0.00330 0.00242 0.00278 0.00687 0.00728
p33-7  0.307 0.351 0.00263 0.00223 0.00180 0.00678 0.00513
p33-9  0.344 0.382 0.00210 0.00228 0.00163 0.00629 0.00426
p33-11 0.338 0.375 0.00393 0.00215 0.00113 0.00602 0.00300
average 0.332 0.375 0.00422 0.00657 0.00497
p34-1 0.319 0.348 0.00551 0.00163 0.00209 0.00487 0.00599
p34-2  0.307 0.341 0.00379 0.00170 0.00133 0.00525 0.00390
p34-7  0.327 0.359 0.00060 0.00187 0.00115 0.00546 0.00321
p3 4 -10  0.315 0.362 0.00045 0.00184 0.00162 0.00543 0.00447
p34-13 0.334 0.370 0.00292 0.00197 0.00187 0.00559 0.00505
p34-15 0.328 0.369 0.00616 0.00211 0.00241 0.00604 0.00652
average 0.322 0.358 0.00324 0.00544 0.00486
p35-1 0.300 0.333 0.00558 0.00175 0.00144 0.00551 0.00431
p35-4  0.300 0.329 0.00145 0.00163 0.00220 0.00517 0.00667
p35-7 0.319 0.351 0.00093 0.00153 0.00168 0.00456 0.00480
p35-10 0.342 0.381 0.00256 0.00227 0.00166 0.00629 0.00437
p35-12  0.373 0.411 0.00740 0.00225 0.00310 0.00574 0.00755
average 0.327 0.361 0.00359 0.00546 0.00554
Rat Perfusion Morphometry (con't)
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Denuded, AH=O Lumen Medial Adventitial Medial Adventitial
section IEL EEL Area Area Area Thickness Thickness
(cm) (cm) (cm2) (cm2) (cm2 ) (cm) (cm)
p3 6-3  0.287 0.317 0.00262 0.00145 0.00035 0.00481 0.00109
p36-5 0.275 0.309 0.00125 0.00147 0.00051 0.00502 0.00165
p36-7 0.311 0.334 0.00114 0.00158 0.00083 0.00491 0.00248
p36-9  0.297 0.338 0.00075 0.00160 0.00084 0.00505 0.00248
p36-11  0.277 0.309 0.00051 0.00131 0.00075 0.00446 0.00243
p36-13  0.274 0.307 0.00042 0.00139 0.00054 0.00477 0.00178
p36-15 0.300 0.323 0.00219 0.00159 0.00057 0.00512 0.00175
average 0.289 0.320 0.00127 0.00488 0.00195
p37-1  0.294 0.341 0.00570 0.00220 0.00480 0.00692 0.01408
p37-4  0.305 0.338 0.00112 0.00176 0.00195 0.00547 0.00577
p37-7  0.309 0.343 0.00066 0.00163 0.00234 0.00500 0.00682
p37-10  0.317 0.349 0.00176 0.00157 0.00190 0.00471 0.00543
p3 7 -12  0.313 0.339 0.00483 0.00183 0.00160 0.00560 0.00471
p37-13  0.341 0.380 0.00769 0.00200 0.00179 0.00556 0.00471
average 0.313 0.348 0.00363 0.00554 0.00692
p3 8 -10  0.290 0.325 0.00090 0.00157 0.00178 0.00509 0.00548
p3 8 -13  0.303 0.342 0.00115 0.00165 0.00139 0.00512 0.00407
p3 8 -4  0.304 0.341 0.00059 0.00175 0.00209 0.00541 0.00614
p3 8 -7  0.287 0.319 0.00066 0.00158 0.00295 0.00521 0.00924
p3 8 -15  0.335 0.374 0.00140 0.00237 0.00278 0.00669 0.00743
p3 8 -2  0.319 0.353 0.00201 0.00189 0.00189 0.00563 0.00535
average 0.306 0.342 0.00112 0.00552 0.00628
p40-1 0.303 0.347 0.00409 0.00226 0.00193 0.00695 0.00558
p40-3 0.284 0.327 0.00106 0.00175 0.00125 0.00574 0.00383
p40-11 0.279 0.302 0.00051 0.00138 0.00159 0.00477 0.00527
p40-13 0.264 0.311 0.00124 0.00174 0.00213 0.00607 0.00684
p40-5 0.280 0.309 0.00047 0.00140 0.00148 0.00477 0.00478
p40-7 0.270 0.305 0.00046 0.00145 0.00120 0.00503 0.00392
p40-9 0.274 0.304 0.00052 0.00138 0.00162 0.00478 0.00531
average 0.279 0.315 0.00119 0.00544 0.00508
Rat Perfusion Morphometry (con't)
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Native, AH=100 cm Lumen Medial Adventitial Medial Adventitial
section IEL EEL Area Area Area Thickness Thickness
(cm) (cm) (cm2) (cm2) (cm2) (cm) (cm)
p50-1 0.433 0.433 0.01433 0.00235 0.00235 0.00778 0.01023
p5 0 -7  0.461 0.461 0.01507 0.00298 0.00298 0.00638 0.00188
p5 0 -3  0.432 0.432 0.01213 0.00196 0.00027 0.00454 0.00062
p5 0 -5  0.420 0.481 0.01080 0.00199 0.00048 0.00475 0.00100
average 0.437 0.457 0.01308 0.00464 0.00081
p5 1 -1  0.381 0.433 0.00991 0.00096 0.00038 0.00252 0.00101
p51-10  0.396 0.430 0.00973 0.00180 0.00180 0.00454 0.00420
p51-3  0.393 0.393 0.00948 0.00155 0.00154 0.00395 0.00392
p51-5 0.402 0.422 0.00871 0.00156 0.00074 0.00386 0.00176
average 0.393 0.415 0.00946 0.00372 0.00272
p52-13 0.455 0.499 0.01379 0.00209 0.00082 0.00460 0.00164
p52-10  0.469 0.487 0.01523 0.00190 0.00105 0.00404 0.00214
p52-7 0.410 0.00000 0.00133 0.00102 0.00324 0.00249
p52-1 0.405 0.485 0.00000 0.00196 0.00119 0.00484 0.00244
average 0.435 0.490 0.00726 0.00418 0.00218
0.00035 0.00020
p53-0 0.439 0.471 0.01389 0.00207 0.00212 0.00470 0.00450
p53-2.5 0.452 0.482 0.01209 0.00151 0.00152 0.00334 0.00316
p53-4 0.397 0.428 0.00872 0.00132 0.00132 0.00333 0.00308
p53-6 0.476 0.513 0.01588 0.00233 0.00099 0.00489 0.00193
p53-8 0.485 0.510 0.01416 0.00184 0.00147 0.00378 0.00289
p53-10 0.465 0.493 0.01474 0.00178 0.00112 0.00383 0.00227
average 0.452 0.483 0.01325 0.00396 0.00254
p54-1 0.421 0.434 0.00757 0.00234 0.00164 0.00556 0.00379
p54-3 0.413 0.433 0.00877 0.00157 0.00087 0.00379 0.00201
p54-5 0.402 0.431 0.00962 0.00170 0.00066 0.00422 0.00153
p54-9 0.380 0.406 0.00804 0.00143 0.00071 0.00376 0.00176
p54-12 0.358 0.393 0.00725 0.00167 0.00081 0.00466 0.00205
average 0.395 0.419 0.00825 0.00411 0.00184
Rat Perfusion Morphometry (con't)
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Denuded, AH=100 cm Lumen Medial Adventitial Medial Adventitial
section IEL EEL Area Area Area Thickness Thickness
(cm) (cm) (cm2) (cm2) (cm2) (cm) (cm)
p55-1 0.427 0.444 0.00949 0.00163 0.00186 0.00381 0.00418
p55-4 0.456 0.490 0.01490 0.00188 0.00156 0.00412 0.00318
p55-7 0.459 0.484 0.01323 0.00174 0.00179 0.00379 0.00370
p55-11 0.431 0.457 0.01225 0.00176 0.00279 0.00408 0.00610
p55-14 0.441 0.469 0.01065 0.00168 0.00106 0.00382 0.00225
p55-16 0.424 0.444 0.01163 0.00151 0.00143 0.00355 0.00323
average 0.440 0.464 0.01203 0.00386 0.00377
p56-1 0.457 0.476 0.01517 0.00161 0.00156 0.00352 0.00327
p56-3 0.422 0.440 0.01235 0.00113 0.00113 0.00268 0.00256
p56-5 0.464 0.492 0.01367 0.00153 0.00165 0.00330 0.00337
p56-7 0.424 0.455 0.01268 0.00138 0.00139 0.00326 0.00306
p56-11 0.433 0.466 0.01336 0.00163 0.00165 0.00377 0.00354
average 0.440 0.466 0.01345 0.00331 0.00316
p57-4 0.373 0.398 0.01033 0.00127 0.00136 0.00341 0.00341
p57-7 0.393 0.416 0.01172 0.00135 0.00164 0.00344 0.00394
p57-10 0.408 0.435 0.01175 0.00158 0.00181 0.00389 0.00416
p57-13.5 0.397 0.416 0.00945 0.00126 0.00198 0.00318 0.00476
p57-14.5 0.423 0.449 0.01384 0.00170 0.00211 0.00401 0.00470
average 0.399 0.423 0.01142 0.00358 0.00419
p58-1 0.418 0.445 0.01137 0.00149 0.00254 0.00356 0.00571
p58-4 0.377 0.399 0.01016 0.00160 0.00244 0.00423 0.00613
p58-7 0.415 0.444 0.01136 0.00178 0.00215 0.00430 0.00484
p58-10 0.435 0.467 0.01447 0.00216 0.00286 0.00496 0.00611
p58-13 0.447 0.485 0.01500 0.00238 0.00320 0.00533 0.00660
average 0.418 0.448 0.01247 0.00448 0.00588
8.2. Rat Abdominal Aorta Perfusion Summary
Native, AH=O
Rat # p31 p32  p33 p34 p3 5
Heparin Transport (j) (mg/s) 1.02E-05 9.77E-06 1.13E-05 1.21E-05 7.94E-06
Length cm 0.89 0.99 1.18 1.09 1.05
Perimeter (IEL) cm 0.357 0.329 0.332 0.322 0.327
Concentration Difference mg/ml 3.69 4.05 3.68 4.53 2.61
Volume Flow Rate ml/s 0.0064 0.0060 0.0078 0.0101 0.0061
Hydraulic Diameter cm 0.0688 0.0280 0.0507 0.0402 0.0430
Lumen Area sq. cm 0.0062 0.0023 0.0042 0.0032 0.0036
Average Lumen Velocity cm/s 1.14 2.86 2.22 6.1342 2.9957
Re (d) 8.26 8.39 10.79 14.35 8.59
Sh(d) developing 26.76 18.93 23.94 25.06 21.73
Boundary Layer Resistance s/cm 1,776 1,022 1,460 1,108 1,365
W 1.00 0.99 1.05 0.90 1.07
Denuded, AH=O
Rat # p36 p37 p38 p39 p40
Heparin Transport (j) (mg/s) 1.3IE-05 1.22E-05 1.09E-05 1.71E-05 1.25E-05
Length cm 1.14 0.95 1.21 0.98 1.00
Perimeter (IEL) cm 0.289 0.313 0.306 0.302 0.279
Concentration Difference mg/ml 3.12 3.19 3.06 4.69 4.75
Volume Flow Rate ml/s 0.0049 0.0130 0.0068 0.0103 0.0029
Hydraulic Diameter cm 0.0175 0.0458 0.0144 0.0402 0.0166
Lumen Area sq. cm 0.0013 0.0036 0.0011 0.0030 0.0012
Average Lumen Velocity cm/s 5.68 7.53 7.23 3.59 4.19
Re (d) 7.79 19.10 10.20 15.72 4.75
Sh(d) developing 14.73 30.24 14.86 26.84 12.62
Boundary Layer Resistance s/cm 819 1,045 670 1,033 908
S1.02 1.22 0.91 1.09 0.84
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Rat Abdominal Aorta Perfusion Summary (con't)
Native, AH=100 cm
Rat #
Heparin Transport (j)
Length
Perimeter (IEL)
Concentration Difference
Volume Flow Rate
Hydraulic Diameter
Lumen Area
Average Lumen Velocity
Re (d)
Sh(d) developing
Boundary Layer
Resistance
p50
(mg/s) 1.20E-05
cm 0.66
cm 0.457
mg/ml 3.87
ml/s 0.0033
cm 0.1075
sq. cm 0.0131
cm/s 0.2927
3.61
25.99
s/cm 2,855
0.98
p51
1.43E-05
0.95
0.415
2.82
0.0027
0.0964
0.0095
0.2858
3.16
21.04
3,162
1.16
p52
1.81E-05
0.88
0.490
3.58
0.0063
0.1256
0.0073
0.4384
6.32
30.10
2,880
1.11
p5 3
1.56E-05
0.95
0.483
3.64
0.0047
0.1162
0.0132
0.3729
4.79
25.94
3,092
0.86
p5 4
1.04E-05
0.88
0.419
2.81
0.0063
0.0866
0.0083
0.7618
7.54
28.18
2,121
0.93
p60
1.23E-05
0.90
0.431
3.06
0.0033
0.1080
0.0112
0.3015
3.70
23.58
3,162
0.86
Denuded, AH=100 cm
Rat # p55 p56 p5 7  p5 9  p5 8
Heparin Transport (j) (mg/s) 2.38E-05 1.36E-05 1.42E-05 1.85E-05 1.27E-05
Length cm 1.1557 0.8128 0.9906 1.2446 0.9398
Perimeter (IEL) cm 0.464 0.466 0.423 0.425 0.448
Concentration Difference mg/ml 3.43 2.89 2.48 3.09 2.87
Volume Flow Rate ml/s 0.0058 0.0054 0.0020 0.0057 0.0118
Hydraulic Diameter cm 0.1092 0.1221 0.1143 0.1016 0.1187
Lumen Area sq. cm 0.0120 0.0134 0.0114 0.0102 0.0125
Average Lumen Velocity cm/s 0.4910 0.4054 0.1777 0.5896 0.1636
Re (d) 6.05 5.67 2.30 6.59 2.20
Sh(d) developing 25.75 29.49 19.71 25.21 20.02
Boundary Layer Resistance s/cm 2,926 2,857 4,001 2,781 4,091
V 0.85 0.71 0.89 0.68 0.87
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8.3. Heparin Deposition in Calf Carotid Arteries In Vitro
Artery Start
# EV
DPM
Native, Perivascular
pc37 11786.4
11622.5
11999.5
pc39 7990.1
8975.5
8755.3
pc41 12065.5
11954.0
12045.9
pc43 10425.4
10845.2
11149.2
Denuded,
pc38
Administration, AH = 100
52.7
46.5
54.3
46.3
36.2
54.9
60.3
46.8
56.9
96.1
61.9
78.9
10575.9
11041.1
10769.5
7111.6
6425.9
7088.1
10999.4
11594.9
11555.2
10179.2
10448.0
10489.3
Perivascular Administration, AH =
10575.9
11041.1
10769.5
pc40 11744.3
10326.3
14499.4
pc42 10999.4
11594.9
11555.2
pc44 10179.2
10448.0
10489.3
38.4
26.3
50.0
54.5
38.5
30.1
48.3
74.3
52.5
53.8
85.2
60.1
7990.1
8975.5
8755.3
12065.5
11954.0
12045.9
10425.4
10845.2
11149.2
9473.1
9292.2
10343.5
cm
38.4
26.3
50.0
50.5
44.5
74.7
48.3
74.3
52.5
53.8
85.2
60.1
100 cm
46.3
36.2
54.9
60.3
46.8
56.9
96.1
61.9
78.9
88.6
88.4
57.8
7.3
2.9
3.9
1119.9
402.9
682.6
8.4 1071.7
10.7 1114.0
7.3 915.8
10.0
126.6
11.3
8.0
6.4
8.2
6.8
4.0
4.9
3748.4
6699.7
3437.5
2399.3
1612.7
2252.8
823.1
595.3
1117.9
9.8 2632.5
5.2 1283.6
11.8 3575.5
9.3 2163.7
14.0 3675.0
9.4 4056.1
9.6
8.2
6.5
2427.9
1747.2
1478.8
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Start
PV
DPM
End
EV
DPM
End
PV
DPM
Artery
Dry (mg)
Artery
DPM
Deposition
gIg/g/(pg/ml)
0.656
0.553
0.730
0.798
0.653
0.780
1.590
0.226
1.289
1.398
1.164
1.279
0.596
0.718
1.139
1.096
0.990
1.242
1.033
1.175
1.933
1.244
1.041
1.106
Heparin Deposition in Calf Carotid Arteries In Vitro (con't)
Artery Start
# EV
DPM
Start
PV
DPM
End
EV
DPM
End
PV
DPM
Artery Artery
Dry (mg) DPM
Native Endovascular
pc45 11233.1
11518.3
11837.4
pc47 11031.5
11450.5
11389.7
pc49 226.0
223.0
11538.3
pc51 385.6
441.1
11796.8
Administration, AH = 100
63.8
56.0
30.3
63.8
56.0
30.3
63.8
56.0
30.3
63.8
56.0
30.3
11336.9
11945.2
11665.3
11036.2
11909.9
11649.4
11683.3
11789.7
11746.6
11247.2
11233.7
11841.0
cm
71.7
58.4
64.5
207.0
226.0
223.0
342.1
385.6
441.1
243.3
208.6
251.7
9.6 2655.9
10.8 2604.0
10.9 3187.9
11.3 7287.2
12.2 7823.7
8.5 6048.3
11.5 5314.8
12.8 4492.6
12.4 4370.5
9.8 3765.1
12.3 4473.0
7.6 3190.4
Denuded, Endovascular Administration, AH =
pc46 11336.9 63.8 11031.5
11945.2 56.0 11450.5
11665.3 30.3 11389.7
pc48 11036.2
11909.9
11649.4
pc50 289.8
261.5
11746.6
pc52 361.5
367.6
11841.0
63.8
56.0
30.3
63.8
56.0
30.3
63.8
56.0
30.3
11229.0
10555.1
11538.3
11012.7
11781.2
11796.8
11796.8
11374.3
11699.3
12419.4
100 cm
209.6
224.1
225.2
198.9
289.8
261.5
405.5
361.5
367.6
242.0
222.0
206.8
14.2 9738.4
17.7 12897.7
17.6 7840.5
12.3 7695.3
13.5 7312.1
12.2 5292.2
17.6
12.6
15.9
10.9
13.8
9.8
7.7
17401.7
8053.5
9780.7
7119.4
6367.1
5673.2
5015.2
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Deposition
gg/g/(Rg/ml)
1.181
1.029
1.252
2.824
2.809
3.112
2.936
2.226
2.235
2.447
2.320
2.668
2.992
3.182
1.941
2.763
2.391
1.911
6.356
4.098
3.948
4.185
2.882
3.613
4.061
Heparin Deposition in Calf Carotid Arteries In Vitro (con't)
Artery Start
# EV
DPM
Start
PV
DPM
End
EV
DPM
End
PV
DPM
Artery Artery Deposition
Dry (mg) DPM glg/g/(gig/ml)
Native, Perivascular
pc53 54.9
56.2
42.6
pc55 59.5
86.3
68.8
pc57 66.1
66.2
78.4
pc59 58.7
66.4
107.2
Administration, AH = 0
11717.7
12403.4
12250.1
11361.1
12171.2
12102.6
12016.5
12310.0
12548.9
11893.4
12188.5
12474.6
36.3
44.3
48.0
66.1
54.1
103.1
111.5
78.4
66.4
79.7
78.1
87.1
11682.6
11757.2
11639.5
12313.6
12465.0
12444.4
11628.7
12511.9
12821.1
10982.0
12182.6
12342.3
12.6 4823.0
13.0 4346.2
12.4 3945.8
2498.2
2702.5
2540.2
8.4 2278.6
12.4 3868.2
9.2 2694.0
10.6 3224.9
9.4 2640.6
10.4 3722.8
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1.578
1.376
1.308
1.394
1.362
1.479
1.103
1.282
1.195
1.246
1.146
1.470
Denuded, Perivascular Administration, AH = 0
pc54 36.3 11682.6 59.5 11361.1 8.2 3498.8 1.751
44.3 11757.2 86.3 12171.2 6.6 2564.4 1.584
48.0 11639.5 68.8 12102.6 7.0 2892.0 1.689
pc56 66.1 12313.6 66.1 11185.1 7.5 4086.1 2.241
54.1 12465.0 66.2 12341.6 7.5 4386.2 2.408
103.1 12444.4 78.4 12057.6 9.7 5050.5 2.148
pc58 111.5 11628.7 58.7 11893.4 11.0 3959.5 1.480
78.4 12511.9 66.4 12188.5 16.1 5376.5 1.381
66.4 12821.1 107.2 12474.6 12.5 4896.3 1.615
pc60 79.7 10982.0 70.3 10633.5 14.6 5025.3 1.420
78.1 12182.6 92.6 11913.3 14.0 5341.5 1.575
87.1 12342.3 76.4 12440.9 17.4 6413.6 1.524
Heparin Deposition in Calf Carotid Arteries In Vitro (con't)
Artery Start
# EV
DPM
Native, Endovascular
pc61 15404.4
16242.2
15978.5
pc63 15513.9
15538.3
16309.9
pc65 15513.9
15538.3
16309.9
pc67 15513.9
15538.3
16309.9
Administration, AH = 0
58.1
36.1
52.1
58.1
36.1
52.1
58.1
36.1
52.1
58.1
36.1
52.1
15404.5
16357.9
16384.7
15404.5
16357.9
16384.7
15404.5
16357.9
16384.7
15335.4
15788.9
15907.3
57.6
49.8
44.5
57.6
49.8
44.5
57.6
49.8
44.5
66.5
76.5
48.3
11.9 3592.0
16.5 5510.9
17.3 6807.6
1967.7
2624.2
1573.4
2293.5
1976.7
4304.4
10.4 3987.6
17.3 6002.9
17.5 6492.3
120
Start
PV
DPM
End
EV
DPM
End
PV
DPM
Artery
Dry (mg)
Artery
DPM
Deposition
lg/g/(lg/ml)
0.948
1.053
1.243
0.711
0.901
0.535
1.037
1.160
2.335
1.205
1.095
1.171
8.4. Deposition in Rabbit Iliac Arteries from Perivascular Collars
<------Artery------ >
Rabbit # Artery #
dry mass
(mg)
mass
DPM (mg)
Initial Gel -------- >
activity
DPM (DPM/mg)
Deposition / [Gel]o
DPM/mg / (DPM / mg)
Native
fr12 6 1.5 7,607 100 7,163,792 71638 0.08274
fr21 8 1.5 1,132 130.9 7,649,169 60941 0.01393
fr21 9 0.8 2,906 118.4 7,519,592 60941 0.06892
fr22 7 2.0 4,027 100 6,087,959 60941 0.03839
fr23 7 1.8 10,984 100 5,843,483 60941 0.11726
fr30 8 1.3 16,204 100 6,350,965 70570 0.20715
fr30 9 0.9 8,343 100 7,362,166 70570 0.15361
fr30 10 1.6 8,581 100 7,067,632 70570 0.08888
fr30 11 0.9 6,389 70570 0.11741
enuded
fr12 7 2.4 9,358 100 7,163,792 71638 0.06369
fr21 7 1.8 10,003 75 4,566,019 60941 0.10675
fr22 8 2.1 8,349 100 6,087,959 60941 0.07630
fr22 9 1.2 10,551 100 5,843,483 60941 0.16894
fr23 8 1.1 7,673 100 6,350,965 60941 0.13378
fr23 9 0.8 5,403 60941 0.12918
fr29 8 1.8 12,501 100 6,741,333 70570 0.11531
fr29 9 1.2 6,906 100 7,362,166 70570 0.09525
fr29 10 1.3 10,076 100 7,067,632 70570 0.12857
fr29 11 1.3 6,427 70570 0.09930
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8.5. Equilibrium Distribution Data
122
Equilibrium Distribution Data (con't)
Media with Intact Endothelium II
Cbulk Tissue
(M) wet wt
(mg)
Arterial
Cbulk
(M)
6.29E-10
6.29E-10
6.29E-10
6.29E-10
1.78E-09
1.78E-09
1.78E-09
1.78E-09
5.25E-09
5.25E-09
5.25E-09
5.25E-09
1.57E-08
1.57E-08
1.57E-08
1.57E-08
4.64E-08
4.64E-08
4.64E-08
4.64E-08
1.36E-07
1.36E-07
1.36E-07
1.36E-07
4.17E-07
4.17E-07
4.17E-07
4.17E-07
1.27E-06
1.27E-06
1.27E-06
Tissue
wet wt
(mg)
13.3
11.3
10.4
8.1
17.2
9.3
8
6.5
14.2
10.9
15.7
9.3
9.1
10.3
8.3
3.6
13.8
8.7
11.9
12.3
7.4
12.5
10.5
6.2
10.4
7.5
8.5
10.3
16.2
10.5
4.4
Tissue CT
DPM (M)
Tissue
DPM
199.9
196
186.9
155.4
828.8
559.3
295.7
298
1292.3
1206.3
1468.1
969.5
3267.5
2695.8
2352
1304.4
11582.9
6217.6
9571.3
9834.6
25371.3
52947.9
34200.7
16864.8
105678
86829.5
64035
114354
485040
218033
86561.4
CT
(M)
5.51E-10
6.32E-10
6.43E-10
6.33E-10
2.27E-09
2.62E-09
1.51E-09
1.88E-09
4.34E-09
5.26E-09
4.48E-09
4.79E-09
1.77E-08
1.27E-08
1.38E-08
1.78E-08
4.18E-08
3.52E-08
3.97E-08
3.95E-08
1.72E-07
2.10E-07
1.61E-07
1.28E-07
5.04E-07
5.74E-07
3.74E-07
5.51E-07
1.49E-06
1.03E-06
9.76E-07
Cb
(M)
1.86E-10
2.66E-10
2.77E-10
2.67E-10
1.23E-09
1.59E-09
4.77E-10
8.44E-10
1.28E-09
2.20E-09
1.42E-09
1.74E-09
8.60E-09
3.60E-09
4.62E-09
8.62E-09
1.48E-08
8.17E-09
1.27E-08
1.25E-08
9.31E-08
1.31E-07
8.23E-08
4.93E-08
2.62E-07
3.32E-07
1.31E-07
3.09E-07
7.48E-07
2.93E-07
2.38E-07
6.8
8.5
15.9
9
10.2
17.1
11.9
7
12.6
19.6
10
15.3
6.9
5.3
10.7
11.7
25.1
18.1
16.5
18.5
8.7
11.2
14.8
7.7
11.1
14.9
7.4
15.7
11.2
19.6
144525
995.5
1649.7
1067.4
989.1
4900
3124.2
1960.1
4168
12282.8
6360.1
9223
4480
4962.2
11260.6
10614.2
28026.4
23217
22478.6
25993.1
11532.7
19941.1
24089.2
13708.5
22270.7
29816.9
15791
34980.5
25490.4
44782.3
1.05E-06
4.28E-06
3.83E-06
4.30E-06
3.50E-06
1.09E-05
9.83E-06
1.04E-05
1.24E-05
2.39E-05
2.40E-05
2.28E-05
2.44E-05
3.53E-05
3.99E-05
3.47E-05
4.25E-05
4.88E-05
5.09E-05
5.34E-05
5.03E-05
6.76E-05
6.19E-05
6.76E-05
7.63E-05
7.61E-05
8.10E-05
8.47E-05
8.81E-05
8.69E-05
1.27E-06
5.11E-06
5.11E-06
5.11E-06
5.11E-06
1.48E-05
1.48E-05
1.48E-05
1.48E-05
3.65E-05
3.65E-05
3.65E-05
3.65E-05
5.73E-05
5.73E-05
5.73E-05
5.73E-05
8.03E-05
8.03E-05
8.03E-05
8.03E-05
1.01E-04
1.01E-04
1.01E-04
1.25E-04
1.25E-04
1.25E-04
1.43E-04
1.43E-04
1.43E-04
Cb
(M)
3.17E-07
1.30E-06
8.53E-07
1.32E-06
5.24E-07
2.32E-06
1.23E-06
1.78E-06
3.84E-06
2.64E-06
2.78E-06
1.58E-06
3.19E-06
1.95E-06
6.56E-06
1.34E-06
9.12E-06
2.07E-06
4.16E-06
6.73E-06
3.58E-06
8.98E-06
3.20E-06
8.89E-06
3.81E-06
3.66E-06
8.58E-06
1.38E-06
4.73E-06
3.57E-06
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Equilibrium Distribution Data (con't)
Arterial Media with Denuded Endothelium I
Cbulk Tissue
(M) wet wt
(mg)
1.82E-11
1.82E- 11
1.82E-11
1.82E-11
4.31E-10
4.31E-10
4.31E-10
4.31E-10
1.26E-09
1.26E-09
1.26E-09
1.26E-09
3.16E-09
3.16E-09
3.16E-09
1.05E-08
1.05E-08
1.05E-08
2.85E-08
2.85E-08
2.85E-08
2.85E-08
8.88E-08
8.88E-08
8.88E-08
8.88E-08
2.41E-07
2.41E-07
2.41E-07
7.83E-07
12.6
16.1
18.4
14.6
19.9
17.8
18.7
8
20.9
20.8
22.5
11.2
18.1
19.2
29.7
15.8
22.8
15.1
16.9
15.3
14
14.5
22.9
13.7
12.5
14.7
37
18.6
21.8
27.2
Tissue
DPM
56.8
58
67.4
60.2
317.7
294.1
328.1
178.6
818.9
790.2
940.5
463.6
1832.7
1806.1
3025.5
4839.3
6710.7
5709.9
12101.7
10524.7
11832.6
11975.1
48031.6
36325
25271.8
27384.4
258546
100530
129321
515601
CT
(M)
1.49E-11
1.55E-11
3.88E-11
2.41E-11
6.51E-10
6.70E-10
7.16E-10
8.17E-10
1.81E-09
1.75E-09
1.95E-09
1.80E-09
4.89E-09
4.52E-09
4.95E-09
1.42E-08
1.46E-08
1.85E-08
3.53E-08
3.41E-08
4.16E-08
4.07E-08
1.04E-07
1.31E-07
9.98E-08
9.20E-08
3.47E-07
2.70E-07
2.92E-07
9.45E-07
Cb
(M)
1.76E-12
2.30E-12
2.57E- 11
1.10E-11
3.41E-10
3.59E-10
4.06E-10
5.07E-10
9.02E-10
8.42E-10
1.04E-09
8.86E-10
2.61E-09
2.24E-09
2.67E-09
6.62E-09
7.08E-09
1.10E-08
1.48E-08
1.36E-08
2.11E-08
2.02E-08
3.96E-08
6.69E-08
3.58E-08
2.79E-08
1.73E-07
9.66E-08
1.18E-07
3.80E-07
Cbulk Tissue
(M) wet wt
(mg)
7.83E-07
7.83E-07
7.83E-07
5.03E-06
5.03E-06
5.03E-06
5.03E-06
1.73E-05
1.73E-05
1.73E-05
1.73E-05
4.15E-05
4.15E-05
4.15E-05
6.34E-05
6.34E-05
6.34E-05
8.07E-05
8.07E-05
8.07E-05
8.07E-05
1.08E-04
1.08E-04
1.29E-04
1.29E-04
1.43E-04
1.43E-04
1.43E-04
1.43E-04
19
23.7
59.3
14.5
13.2
11.8
12.3
26
27.3
13.6
23
25.4
19.6
33.8
13.4
26.6
18.6
22.5
25.2
12.6
16.9
17.5
26.7
11.1
15.1
11.7
21.3
11.6
13.2
Tissue CT
DPM (M)
417441
469765
948879
1172.2
1511.5
1502.8
1403.9
8293.6
8755.9
4037
7088.5
15472.4
12026.2
21100.3
12879.1
25560.3
18191.6
25593.6
30870.9
14488.3
22652
27278.8
40272.2
20708.7
28329.5
26343.7
42378.7
24529.9
25890.2
1.04E-06
9.93E-07
8.08E-07
4.17E-06
5.97E-06
6.75E-06
5.98E-06
1.72E-05
1.72E-05
1.58E-05
1.66E-05
3.31E-05
3.30E-05
3.39E-05
5.13E-05
5.22E-05
5.27E-05
6.16E-05
6.66E-05
6.19E-05
7.58E-05
7.83E-05
8.14E-05
1.01E-04
1.01E-04
1.21E-04
1.07E-04
1.14E-04
1.06E-04
Cb
(M)
4.78E-07
4.28E-07
2.43E-07
5.44E-07
2.34E-06
3.13E-06
2.36E-06
4.74E-06
4.78E-06
3.38E-06
4.15E-06
3.18E-06
3.12E-06
4.06E-06
5.66E-06
6.53E-06
7.02E-06
3.42E-06
8.42E-06
3.72E-06
1.77E-05
3.85E-07
3.53E-06
7.84E-06
8.47E-06
1.84E-05
4.39E-06
1.10E-05
2.78E-06
Equilibrium Distribution Data (con't)
Arterial Media with Denuded Endothelium II
Cbulk Tissue Tissue CT
(M) wet wt DPM (M)
(mg)
6.11E-11
6.11E-11
6.11E-11
6.11E-11
5.94E- 10
5.94E-10
5.94E-10
5.94E-10
1.78E-09
1.78E-09
1.78E-09
1.78E-09
4.95E-09
4.95E-09
4.95E-09
4.95E-09
1.45E-08
1.45E-08
1.45E-08
1.45E-08
4.44E-08
4.44E-08
4.44E-08
4.44E-08
1.29E-07
1.29E-07
1.29E-07
1.29E-07
3.98E-07
3.98E-07
3.98E-07
3.98E-07
1.19E-06
6.7
10
5.9
5.4
15.4
21.5
14.6
8.9
10.8
11.1
11.2
11.9
14.4
13.4
10.6
8.5
11.7
9.7
5.6
5.7
13.2
12.5
10.1
16.6
11
20.1
12.1
11.6
15.5
20.5
6.6
13.8
6.3
66.8
70.7
65.6
58.6
291.6
328.7
230.3
166.6
399
473.4
503.5
539.6
1647
1692.5
1209.1
1010.5
3669.6
3538.7
1757.7
1969.7
12574.2
13981.8
9659.3
16322.5
24678.2
61890.5
38375
29572.4
109663
200150
72600.6
94187.1
176993
1.08E-10
9.28E-11
1.13E-10
5.78E-11
7.72E-10
6.38E-10
6.06E-10
6.38E-10
1.59E-09
1.88E-09
2.02E-09
2.03E-09
5.58E-09
6.08E-09
5.42E-09
5.60E-09
1.56E-08
1.78E-08
1.54E-08
1.67E-08
4.71E-08
5.53E-08
4.77E-08
4.87E-08
1.11E-07
1.54E-07
1.57E-07
1.26E-07
3.51E-07
4.82E-07
5.46E-07
3.39E-07
1.44E-06
Cb
(M)
7.70E- 11
6.16E-11
8.16E-11 I
2.66E-11
4.69E-10
3.35E-10
3.03E-10
3.35E-10
6.88E-10
9.78E-10
1.11E-09
1.13E-09
3.05E-09
3.55E-09
2.90E-09
3.07E-09
8.20E-09
1.04E-08
7.98E-09
9.29E-09
2.45E-08
3.27E-08
2.51E-08
2.60E-08
4.51E-08
8.75E-08
9.12E-08
6.03E-08
1.48E-07
2.80E-07
3.43E-07
1.36E-07
8.32E-07
Cbulk Tissue Tissue CT
(M) wet wt DPM (M)
(mg)
1.19E-06
1.19E-06
1.19E-06
4.74E-06
4.74E-06
4.74E-06
4.74E-06
1.40E-05
1.40E-05
1.40E-05
1.40E-05
3.58E-05
3.58E-05
3.58E-05
3.58E-05
5.78E-05
5.78E-05
5.78E-05
5.78E-05
7.76E-05
7.76E-05
7.76E-05
7.76E-05
1.01E-04
1.01E-04
1.01E-04
1.01E-04
1.22E-04
1.22E-04
1.44E-04
1.44E-04
1.44E-04
1.44E-04
10
19.2
13.4
10.7
18.5
16
7
9.5
13.8
10
16.2
12.2
12.1
7.8
8.7
11.2
8.4
7
11.4
11.5
17.6
6.8
6.7
10.7
11.8
6
10.7
13.9
9.6
11.8
15.5
12.4
15
231028
441990
354672
1065.2
1920.6
1610.9
816.3
3178.5
4486.7
4947.4
5326.5
8520.6
8489.6
5183.2
5319.4
11040.9
8297.5
7606.7
12146.5
16605.1
24359.5
9137.9
9099.8
21491.5
25886.8
12327.1
24964.6
23932.5
18189.8
26957.9
32884.7
27749.6
31781.3
1.16E-06
1.14E-06
1.33E-06
3.71E-06
3.85E-06
3.71E-06
4.16E-06
1.25E-05
1.21E-05
1.85E-05
1.25E-05
2.64E-05
2.68E-05
2.51E-05
2.31E-05
3.74E-05
3.74E-05
4.64E-05
4.19E-05
5.53E-05
5.29E-05
5.09E-05
5.14E-05
7.70E-05
8.34E-05
7.79E-05
9.04E-05
6.54E-05
7.27E-05
8.69E-05
8.07E-05
8.51E-05
8.06E-05
Cb
(M)
5.50E-07
5.28E-07
7.25E-07
1.29E-06
1.43E-06
1.29E-06
1.74E-06
5.41E-06
4.94E-06
1.13E-05
5.35E-06
8.19E-06
8.53E-06
6.81E-06
4.81E-06
7.90E-06
7.92E-06
1.69E-05
1.24E-05
1.57E-05
1.33E-05
1.13E-05
1.19E-05
2.58E-05
3.21E-05
2.67E-05
3.91E-05
3.24E-06
1.05E-05
1.35E-05
7.29E-06
1.17E-05
7.18E-06
Equilibrium Distribution Data (con't)
Adventitia I
Cbulk Tissue
(M) wet wt
(mg)
1.42E- 11
1.42E-11
1.42E-11
1.42E-11
2.97E-10
2.97E-10
2.97E-10
2.97E-10
9.86E-10
9.86E-10
9.86E-10
9.86E-10
3.03E-09
3.03E-09
3.03E-09
3.03E-09
9.42E-09
9.42E-09
9.42E-09
9.42E-09
2.53E-08
2.53E-08
2.53E-08
2.53E-08
8.24E-08
8.24E-08
8.24E-08
8.24E-08
2.38E-07
2.38E-07
2.38E-07
2.38E-07
7.08E-07
7.08E-07
24.1
32.1
7.1
23.2
15.6
20.1
26
19.8
23.3
24.7
12
13.3
11.9
28
31.6
28.4
38.2
26.1
18
21.2
25.6
32.1
27.2
9.3
26.9
18
34.4
12.2
21.2
29.3
14.1
22
27.2
18.3
Tissue
DPM
69.1
84.3
88.6
71.5
200.6
99.6
171.7
186.8
430
518.8
253.8
256.3
849.1
1442.6
1956.5
1449.5
6029
4155.2
2818.5
3175.3
9823.4
12822.4
10280.7
4117.5
41803.2
24026.5
44785.6
16339
70837.8
104593
54355.4
82981.8
262038
217921
CT
(M)
5.77E- 11
7.38E-11
3.88E-10
6.95E-11
5.99E-10
1.63E-10
2.88E-10
4.30E-10
9.79E-10
1.12E-09
1.02E-09
9.56E-10
4. 10E-09
2.91E-09
3.61E-09
3.02E-09
9.55E-09
9.32E-09
9.48E-09
9.14E-09
2.28E-08
2.31E-08
2.30E-08
2.60E-08
9.08E-08
7.74E-08
7.55E-08
7.75E-08
1.95E-07
2.09E-07
2.25E-07
2.22E-07
5.59E-07
6.99E-07
Cb
(M)
4.65E-11
6.26E- 11
3.76E-10
5.83E-11
3.65E-10
-7.09E-11
5.41E-11
1.96E-10
2.03E-10
3.40E-10
2.48E-10
1.80E-10
1.72E-09
5.29E-10
1.22E-09
6.41E-10
2.13E-09
1.91E-09
2.06E-09
1.72E-09
2.89E-09
3.20E-09
3.12E-09
6.08E-09
2.60E-08
1.25E-08
1.07E-08
1.27E-08
7.81E-09
2.16E-08
3.82E-08
3.49E-08
1.90E-09
1.42E-07
Cbulk Tissue
(M) wet wt
(mg)
7.08E-07
7.08E-07
5.27E-06
5.27E-06
5.27E-06
5.27E-06
1.14E-05
1.14E-05
1.14E-05
1.14E-05
3.74E-05
3.74E-05
3.74E-05
3.74E-05
6.00E-05
6.00E-05
6.00E-05
6.00E-05
8.30E-05
8.30E-05
8.30E-05
8.30E-05
1.00E-04
1.00E-04
1.00E-04
1.00E-04
1.29E-04
1.29E-04
1.29E-04
1.29E-04
1.43E-04
1.43E-04
1.43E-04
1.43E-04
34.9
20.7
13.7
39
24.6
14.6
49.4
42.8
15.9
31.6
27.7
31.4
49.6
40.3
38.5
29.6
25.2
49.4
18.9
15.4
29.4
37.4
16.1
61.6
28.9
27.3
41.3
29.9
37.1
21.8
24.6
30.7
38.4
36.5
Tissue CT
DPM (M)
349777
233052
854.1
1727.1
1340.3
914.7
6538.3
5886.6
2475.7
4375.2
10579
12846.5
18671.1
15381.3
18209.7
17435.4
14893.9
24201.9
12822.6
43847.1
23982.6
33219.7
14366.6
63984.6
30734.8
29440.4
40691.2
38166.8
51334
23977.2
36593.3
38944
53796.4
54804.6
5.87E-07
6.54E-07
4.98E-06
3.58E-06
4.41E-06
4.41E-06
1.10E-05
1.14E-05
1.28E-05
1.15E-05
3.18E-05
3.45E-05
3.14E-05
3.21E-05
3.99E-05
4.91E-05
4.93E-05
4.11E-05
5.74E-05
2.41E-04
6.81E-05
7.46E-05
7.44E-05
8.73E-05
8.88E-05
9.00E-05
8.25E-05
1.07E-04
1.16E-04
9.18E-05
1.26E-04
1.06E-04
1.17E-04
1.25E-04
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Cb
(M)
2.95E-08
9.62E-08
8.31E-07
-5.69E-07
2.56E-07
2.63E-07
2.03E-06
2.45E-06
3.83E-06
2.57E-06
2.40E-06
5.13E-06
2.00E-06
2.66E-06
-7.38E-06
1.88E-06
2.03E-06
-6.10E-06
-7.90E-06
1.76E-04
2.74E-06
9.22E-06
-4.46E-06
8.51E-06
9.95E-06
1.12E-05
-1.87E-05
5.45E-06
1.44E-05
-9.36E-06
1.29E-05
-6.61E-06
4.14E-06
1.25E-05
Equilibrium Distribution Data (con't)
Adventitia II
Cbulk Tissue
(M) wet wt
(mg)
Cbulk
(M)
1.42E-11
1.42E-11
1.42E- 11
1.42E- 11
2.97E-10
2.97E-10
2.97E-10
2.97E-10
9.86E-10
9.86E-10
9.86E-10
9.86E-10
3.03E-09
3.03E-09
3.03E-09
9.42E-09
9.42E-09
9.42E-09
9.42E-09
2.53E-08
2.53E-08
2.53E-08
8.24E-08
8.24E-08
8.24E-08
2.38E-07
2.38E-07
2.38E-07
7.08E-07
7.08E-07
7.08E-07
5.27E-06
5.27E-06
5.27E-06
1.14E-05
1.14E-05
1.14E-05
1.14E-05
3.74E-05
3.74E-05
3.74E-05
3.74E-05
6.00E-05
Tissue
wet wt
(mg)
16.8
25.1
13.3
11.8
33.6
8.5
6
17.9
20
11
16.7
16
35.8
10.8
10.1
41.2
15
4
23.2
39.2
15.7
32.5
39.3
30.6
17.7
38.1
12.3
16
20
17.6
19.6
20.2
16.6
10.5
17
39.5
40.5
7.4
13.6
46.1
46.9
33.7
30
Tissue CT
DPM (M)
Tissue
DPM
60
57.7
54.5
52
271.6
121.1
116.3
120.4
350.7
273.6
315.4
306
1905.9
762.6
654.1
5874.5
2350.2
930.5
3478.8
17524.1
6226.4
12295.6
53564.3
40290.1
23308.1
137942
48732.9
60016.8
216700
207348
225170
1345.2
938.5
548.5
2419.6
5836.3
4879.7
1217.4
5425.4
15767.8
16985.9
13270
18543.4
CT
(M)
5.61E-l1
3.23E-11
4.75E- 11
4.07E-11
4.01E-10
5.47E-10
6.57E-10
2.52E-10
9.04E-10
1.29E-09
9.67E-10
9.34E-10
3.08E-09
3.86E-09
3.51E-09
8.10E-09
8.81E-09
1.20E-08
8.52E-09
2.60E-08
2.29E-08
2.18E-08
7.93E-08
7.64E-08
7.59E-08
2.11E-07
2.30E-07
2.32E-07
6.29E-07
6.84E-07
6.67E-07
5.47E-06
4.48E-06
3.94E-06
1.18E-05
1.23E-05
9.98E-06
1.40E-05
3.36E-05
2.86E-05
3.03E-05
3.30E-05
5.16E-05
Cb
(M)
4.53E-11
2.15E-11
3.67E-11
2.99E- 11
1.76E-10
3.22E-10
4.32E-10
2.76E-11
1.57E-10
5.48E-10
2.20E-10
1.86E-10
7.87E-10
1.57E-09
1.21E-09
9.56E-10
1.67E-09
4.83E-09
1.38E-09
6.78E-09
3.68E-09
2.64E-09
1.69E-08
1.39E-08
1.35E-08
3.12E-08
4.97E-08
5.21E-08
9.22E-08
1.47E-07
1.30E-07
1.47E-06
4.82E-07
-5.34E-08
3.12E-06
3.66E-06
1.35E-06
5.39E-06
5.26E-06
3.26E-07
2.02E-06
4.69E-06
6.06E-06
6.00E-05
6.00E-05
6.00E-05
8.30E-05
8.30E-05
8.30E-05
8.30E-05
1.00E-04
1.00E-04
1.00E-04
1.00E-04
1.29E-04
1.29E-04
1.29E-04
1.43E-04
1.43E-04
1.43E-04
1.43E-04
5.27E-06
1.14E-05
1.14E-05
1.14E-05
3.74E-05
3.74E-05
3.74E-05
3.74E-05
6.00E-05
6.00E-05
6.00E-05
8.30E-05
8.30E-05
8.30E-05
1.00E-04
1.00E-04
1.00E-04
1.29E-04
1.29E-04
1.29E-04
1.29E-04
1.43E-04
1.43E-04
1.43E-04
1.43E-04
28.6
39.3
45.2
24.2
34.6
37
26.1
40
32.2
34.2
20
12
31.2
25.9
27.4
34.8
40.4
7.8
10.5
39.5
40.5
7.4
13.6
46.1
46.9
33.7
30
39.3
45.2
34.6
37
26.1
40
34.2
20
12
31.2
25.9
11.6
27.4
34.8
40.4
7.8
16834.6
25143.3
29594.5
20405.2
25767
33511.8
22013.2
41776.3
33452.4
32223.5
16144.9
12549.2
35817.6
36331.3
34779.5
44556.9
43174.7
11513.3
548.5
5836.3
4879.7
1217.4
5425.4
15767.8
16985.9
13270
18543.4
25143.3
29594.5
25767
33511.8
22013.2
41776.3
32223.5
16144.9
12549.2
35817.6
36331.3
13768.7
34779.5
44556.9
43174.7
11513.3
4.91E-05
5.35E-05
5.49E-05
7.15E-05
6.22E-05
7.46E-05
7.04E-05
8.72E-05
8.73E-05
7.89E-05
6.73E-05
8.71E-05
9.59E-05
1.18E-04
1.06E-04
1.07E-04
8.95E-05
1.25E-04
3.94E-06
1.23E-05
9.98E-06
1.40E-05
3.36E-05
2.86E-05
3.03E-05
3.30E-05
5.16E-05
5.35E-05
5.49E-05
6.22E-05
7.46E-05
7.04E-05
8.72E-05
7.89E-05
6.73E-05
8.71E-05
9.59E-05
1.18E-04
9.98E-05
1.06E-04
1.07E-04
8.95E-05
1.25E-04
Cb
(M)
3.59E-06
8.04E-06
9.41E-06
8.60E-06
-7.66E-07
1.17E-05
7.45E-06
1.13E-05
1.14E-05
2.97E-06
-8.62E-06
-1.03E-05
-1.54E-06
2.06E-05
-2.73E-06
-1.47E-06
-1.92E-05
1.58E-05
-5.34E-08
3.66E-06
1.35E-06
5.39E-06
5.26E-06
3.26E-07
2.02E-06
4.69E-06
6.06E-06
8.04E-06
9.41E-06
-7.66E-07
1.17E-05
7.45E-06
1.13E-05
2.97E-06
-8.62E-06
-1.03E-05
-1.54E-06
2.06E-05
2.37E-06
-2.73E-06
-1.47E-06
-1.92E-05
1.58E-05
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8.6. Urinary Inulin Clearance Following Perivascular Administration
Native
Rat #
DPM Injected
time (min)
15
30
45
60
75
90
105
120
135
150
165
180
195
210
225
240
Ligature Occluded
Rat #
DPM Injected
time (min)
15
30
45
60
75
90
105
120
135
150
165
180
195
210
225
240
L9
53,788
DPM
84.9
429.7
107.9
1189.7
1287.6
1044.7
1208.0
1221.2
1194.9
1210.6
1026.5
761.1
1309.8
1100.3
981.3
968.6
L7
53,788
DPM
286.5
828.3
1047.2
1344.1
1274.7
1368.5
1245.5
1274.9
1212.4
928.7
691.1
819.6
1235.1
983.0
1159.6
984.6
Lll
53,788
Urine Samples
DPM
213.2
712.3
864.6
818.8
898.8
1490.7
1233.8
1190.7
1084.1
1140.4
790.8
1259.5
1104.2
849.2
898.2
1244.4
L15
12,616
Urine Samples
DPM
485.4
202.7
251.3
294.0
305.3
293.5
602.5
578.6
511.9
467.7
471.1
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L12
53,788
DPM
210.2
100.6
1078.8
1191.5
1247.4
1438.7
1450.3
1308.7
1298.7
1513.2
1535.9
1215.5
1276.5
1216.3
1257.9
1353.3
L13
53,788
DPM
113.0
593.8
1044.2
1478.7
1532.1
1615.4
3310.6
2599.5
3151.9
2659.5
1822.0
L16
12,616
DPM
39.5
138.5
179.5
166.6
209.7
213.3
347.0
384.6
314.1
454.4
347.1
L17
12,616
DPM
36.4
180.8
219.8
495.5
631.6
633.3
603.4
611.2
518.2
464.8
Urinary inulin clearance following perivascular administration (con't)
Wrapped
Rat #
DPM Injected
time (min)
15
30
45
60
90
120
150
180
210
240
Wrapped & Occluded
Rat #
DPM Injected
time (min)
15
30
45
60
90
120
150
180
210
240
L39
77,992
DPM
24.8
25.8
19.3
33.2
60.5
50.5
100.6
80.1
108.3
85.6
L35
78,423
DPM
40.1
79.1
152.1
222.1
591.5
639.3
792.6
751.2
737.6
676.4
Background
L41
77,992
Urine Samples
DPM
37.4
40.7
29.9
35.4
37.4
28.7
41.4
198.6
47.9
46.8
L36
78,423
Urine Samples
DPM
44.4
59.5
56.8
72.1
126.8
227.3
82.3
85.4
94.2
107.1
28.7
129
L43
77,736
DPM
123.0
430.7
422.0
689.3
1559.1
1580.0
792.9
773.9
180.2
1354.2
L42
77,992
DPM
51.1
35.3
22.4
52.4
56.9
60.0
59.7
40.7
53.6
66.5
L38
78,423
DPM
53.2
58.7
59.0
50.4
80.9
73.3
64.6
53.7
77.5
57.0
L40
78,423
DPM
26.7
176.0
174.9
189.5
609.0
602.3
990.9
686.9
736.7
503.8
DPM
8.7. Heparin Deposition Following Administration from Poloxamer
Native
Rat # r16 r17 r18 r19
Deposited DPM L carotid 34555.1 16237.4 14517.2 36537.4
A Aorta 256.1 169.6 345.3 224
Iliac 119.5 151.6 341.7
Femoral 115.1 73.8 176.9 122.1
Liver 833.6 339.8 408.2 400.1
Dry Mass (mg) L carotid 1.2 1.2 1.1 1.8
A Aorta 4.9 2.8 4.3 2.4
Iliac 1.8 4.3 2.1
Femoral 1.0 0.7 1.3 0.4
Liver 26.2 10.5 28.8 13.8
Deposition L carotid 13.2281 6.2032 6.0475 9.3255
(gLg/mg/mg) A Aorta 0.0182 0.0177 0.0303 0.0310
Iliac 0.0147 0.0096 0.0613
Femoral 0.0244 0.0077 0.0406 0.0690
Liver 0.0136 0.0122 0.0055 0.0113
Ligature Occluded
Rat # r21 r22 r23 r32
Deposited DPM L carotid 21813.9 14357.9 17429.1 45058.8
A Aorta 149.0 226.0 264.2 185.9
Iliac 173.7 227.4 143.2 192.2
Femoral 809.2 104.4 91.3 144.4
Liver 820.7 427.7 414.3 350.6
Dry Mass (mg) L carotid 1.3 0.7 1.7 1.0
A Aorta 2.0 4.1 4.4 3.2
Iliac 3.6 7.9 3.2 2.4
Femoral 0.7 1.3 0.9 1.0
Liver 25.9 18.1 21.3 22.9
Deposition L carotid 7.700 9.398 4.701 20.707
(gLg/mg/mg) A Aorta 0.020 0.018 0.021 0.018
Iliac 0.014 0.010 0.012 0.025
Femoral 0.491 0.015 0.015 0.038
Liver 0.013 0.009 0.008 0.006
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Heparin Deposition Following Administration from Poloxamer (con't)
Wrapped
Rat # r23 r26 r28 r30
Deposited DPM L carotid 56322.3 16367.6 61945.2 53077.9
A Aorta 448 535.7 125.1 182.8
Iliac 148.7 105.8 80.4 190.7
Femoral 82.1 72.4 65.2 107.2
Liver 258.5 282 201 300.6
Dry Mass (mg) L carotid 2.2 1.3 1.2 1.7
A Aorta 4.6 3.5 8.4 3.9
Iliac 2 1.5 4 4.5
Femoral 1.1 0.5 0.6 0.8
Liver 17.8 19.3 20.6 21.1
Deposition L carotid 11.603 5.772 23.732 14.352
(jtg/mg/mg) A Aorta 0.039 0.062 0.003 0.014
Iliac 0.020 0.013 0.002 0.013
Femoral 0.008 0.009 0.002 0.026
Liver 0.005 0.005 0.003 0.005
Intraperitoneal
Rat # r25 r27 r29 r31
Deposited DPM L carotid 126.9 73.3 95.7 228
A Aorta 108.3 135.5 662.8 850.1
Iliac 131.8 100.9 171.1 243.7
Femoral 85 91.2 64.2 210.2
Liver 325 331.9 238.5 659.2
Dry Mass (mg) L carotid 1.2 1.1 1.3 0.9
A Aorta 4 8.4 4 5.5
Iliac 4.6 7.2 5.4 4.8
Femoral 0.7 0.8 0.6 0.7
Liver 20.4 28.4 13.9 33.8
Deposition L carotid 0.025 0.005 0.012 0.085
(pg/mg/mg) A Aorta 0.005 0.004 0.069 0.066
Iliac 0.007 0.002 0.009 0.017
Femoral 0.015 0.017 0.002 0.097
Liver 0.006 0.004 0.006 0.008
INJECTED DOSE 2,172,969 DPM
BACKGROUND 62.1 DPM
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Perivascular Vs Endovascular Heparin Delivery to Rabbit iliac
Arteries
Rabbit # Artery #
<------Artery------ >
dry mass
(mg) DPM
<--------
mass
(mg)
Initial Gel -------- >
activity
DPM (DPM/mg)
Deposition / [Gel]o
DPM/mg / (DPM / mg)
Perivascular
FR13 7 1.3 1789.8 100 7123630.7 71162.2 0.02213
8 0.9 1354.3 100 7048050.8 71162.2 0.02396
9 1.1 2837.2 100 7176988.1 71162.2 0.04189
10 1 2476.7 71162.2 0.04012
Frl4 8 1.3 1148 100 7123630.7 71162.2 0.01396
9 1.1 656.8 100 7048050.8 71162.2 0.00912
10 1.1 1829.2 100 7176988.1 71162.2 0.02674
11 1.1 992.5 71162.2 0.01417
FR24 8 1.8 2981 100 6541863.9 62829.7 0.03049
9 1.8 1943.2 100 6407135.8 62829.7 0.01969
10 1.6 2961.8 145 8554870.0 62829.7 0.03408
11 1.4 2327.1 62829.7 0.03046
Endovascular
FR15 4 1.9 3018.9 50 949761.1 18995.2 0.09678
5 2.2 7972.2 50 949761.1 18995.2 0.22303
6 1.2 3140.9 50 949761.1 18995.2 0.15953
7 2.1 7721.1 18995.2 0.22624
9 1.1 695.1 18995.2 0.03632
10 1.1 5505.8 18995.2 0.30719
FR25 4 1.5 457 100 2055120.7 20551.2 0.01553
5 1.7 3714.1 50 1027560.3 20551.2 0.12338
6 1.9 9963.9 50 1027560.3 20551.2 0.29870
7 1.5 3536.8 20551.2 0.13307
8 1.5 14286.7 20551.2 0.54333
FR28 4 1.5 4478 100 2319000.0 23190.0 0.14976
5 1.7 6978 100 2319000.0 23190.0 0.20675
6 2 7686.4 100 2319000.0 23190.0 0.19370
7 1.5 12079.1 23190.0 0.40684
Bkrnd 50 DPM
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8.8
8.9. Code for Simulations of Arterial Deposition and Distribution
% Matlab Code of Simulations of Heparin Delivery to LAD from Endovascular Hydrogel
clear
hold off
tic
%gtm, mg, s units
dgel = 2.37e-7*1e4*1e4;
dmed = 7.73e-8*1e4*1e4;
dadv = 1.21e-7*1e4*1e4;
dmyo = dadv;
% Diffusivities%
cgi= 1/3 % mg/ml = g/1l
mw = 14000
cgi = cgi / mw;
epm =.612
epa = 0.846
epy =.612
epg = 1
btm = 2.67e-6
bta = 2.21e-9
bty = bta ;
kdm = 5.30e-6
kda = 8.09e-9
kdy = kda;
initial gel concentration
%fractional volume of distribution:
%Binding site density
%average binding affinity
% Length of each layer
outt = [];
time = [];
Igel = 70
Imed = 160;
ladv = 40 ;
Imyo = 200;
ngel = 5;
nmed = 20;
nadv = 5;
nmyo= 10;
tci = log(2) * 20*60;
tau = 4.18E+01
cyinf0 = 1.58E-07 ; %
dxa = ladv/nadv ;
dxg = Igel/ngel;
dxm = Imed/nmed;
dxy = Imyo/nmyo ;
dtg = dxgA2/dgel/2.01 ;
dtm = dxmA2/dmed/2.01;
dta = dxaA2/dadv/2.01 ;
dty = dxyA2/dmyo/2.01;
(M)
% time constant for heparin internalization
% time constant for myocardial clearance
% initial myocardial loading
% Width of computational element
% time step appropriate for each layer
dt = min([dta dtm dtg dty])
%dt = round(dt*10)/10 ;
%dt = 6
% initial concentration of drug in gel
gel
media
adventitia
myocardium
media
adventitia
myocardium
gel
cas= zeros(1,nadv);
cab= zeros(1,nadv);
cat= zeros(1,nadv);
cmb= zeros(1,nmed);
cmt= zeros(1,nmed);
cms=zeros(1,nmed);
cint = cms;
cyns= zeros(1,nmyo);
cyb= zeros(1,nmyo);
cyt= zeros(1,nmyo);
cys= zeros(1,nmyo);
cg = zeros(1,ngel);
time = [];
avgtot= [];
avgsol = [];
avgint=[];
for i= 1:ngel , cg(i)=cgi ;, end
% for i= 1:ngel, cg(i)=0 ;, end
% concentrations
% for cg in gel is zero
% set up dimensional coordinates of each element
for i = 1: ngel, x(i)=dxg*(i-1/2) ; , end
for i = 1 : nmed, x(i+ngel) =dxg*ngel+dxm*(i-1/2) ; xb(i) =x(i+ngel);, end
for i = 1 :nadv, x(i+ngel+nmed) = dxg*ngel+dxm*nmed+dxa*i-dxa/2;
xb(i+nmed)= x(i+ngel+nmed); , end
for i = 1 :nmyo, x(i+ngel+nmed+nadv) = dxg*ngel+dxm*nmed+dxa*nadv+dxy*(i-1/2);
xb(i+nmed+nadv)= x(i+ngel+nmed+nadv); , end
outt = [xb'] ;
outb = [xb'];
coefg = dt*dgel/dxg/dxg ;
coefm = dt*dmed/dxm/dxm;
coefa = dt*dadv/dxa/dxa ;
coefy = dt*dmyo/dxy/dxy ;
ntime = 3600* 1/dt * 180/60
ct = 0;
termm = 2*dmed/dxm;
terma = 2*dadv/dxa;
termy = 2*dmyo/dxy;
termg = 2*dgel/dxg;
cgli = 0;
for j = 1:ntime
cyinf = cyinf0*exp(-j*dt/3600/tau)
% Interfaces: lower edge
cyli = (terma*cas(nadv)+termy*cys(1))/(terma*epa/epy+termy);
cali = (termm*cms(nmed)+terma*cas(1))/(termm*epm/epa+terma);
cmli = (termg* cg(ngel)+termm*cms(1))/(termg*epg/epm+termm);
% Interfaces: upper edge
cani = cyli *epa/epy;
cmni = cali *epm/epa;
cgni = cmli *epg/epm;
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:soluble
:bound
: total
cgn(1) = cg(1) + coefg*(2*cgli-3*cg(1)+cg(2)) ;
cmns(1) = cms(1) + coefm*(2*cmli-3*cms(1)+cms(2));
cans(l) = cas(1) + coefa*(2*cali-3*cas(1)+cas(2)) ;
cyns(1) = cys(1) + coefy*(2*cyli-3*cys(1)+cys(2));
cyns(nmyo) = cys(nmyo) + coefy*(cys(nmyo-1) - 3* cys(nmyo) +2* cyinf);
cans(nadv) = cas(nadv) + coefa*(cas(nadv-1) - 3* cas(nadv) +2* cani);
cmns(nmed) = cms(nmed) + coefm*(cms(nmed-1) - 3* cms(nmed) +2* cmni);
cgn(ngel) = cg(ngel) + coefg*(cg(ngel-1) - 3* cg(ngel) +2* cgni);
dfg = coefg * diff(cg) ;
dfm = coefm * diff(cms);
dfa = coefa * diff(cas);
dfy = coefy * diff(cys);
cgn(2:ngel-1) = cg(2:ngel-1) + diff(dfg(1:ngel- 1));
cmns(2:nmed-1) = cms(2:nmed-1) + diff(dfm(1:nmed-1));
cans(2:nadv-1) = cas(2:nadv-1) + diff(dfa(1 :nadv-1));
cyns(2:nmyo-1) = cys(2:nmyo-1) + diff(dfy(1:nmyo- 1));
cg = cgn;
% Redistribution between soluble and bound phases
cmt = cmns + cmb ;
b = btm - cmt+epm*kdm ;
c = - cmt *epm*kdm
cms = (-b +sqrt(b.^2 - 4 * c))/ 2;
cmb = cmt - cms
cat = cans + cab;
b = bta - cat+epa*kda ;
c = - cat *epa*kda
cas = (-b +sqrt(b.^2 - 4 * c))/ 2;
cab = cat - cas
cyt = cyns + cyb;
b = bty - cyt+epy*kdy ;
c = - cyt *epy*kdy
cys = (-b +sqrt(b.^2 - 4 * c))/ 2;
cyb = cyt - cys
% internalization, assume 0.5% of bound is internalized with tl/2 = 15 minutes
% this is applicable if all binding sites are on SMC surface and therefore
% is an over estimation
interf = cmb * 0.005 * (1- exp(-dt/tci));
cint = cint + interf
cmb = cmb - interf
if -rem(j, 100)
time = [time j*dt/3600 ];
avgint = [ avgint sum(cmt+cint)/length(cmt)/cgi ];
avgtot = [ avgtot sum(cmt)/length(cmt)/cgi ];
avgsol = [avgsol sum(cms)/length(cms)/cgi ];
end
end
outt = [time' avgint' avgtot' avgsol' ];
plot (x, [cg (cmt+cint) cat cyt]/cgi,'r',x, [cg (cms) cas cys]/cgi,'b')
toc
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9. NOMENCLATURE
Al Cross sectional area of arterial lumen
bend Coefficient of endothelial resistance, (0- absent, 1- present)
B Binding site density (specific and nonspecific) of compound in a tissue
c Concentration of compound in a volume of tissue or fluid
d Hydraulic diameter of arterial cross section
D Effective diffusivity of compound in a tissue or solution
fC Convective hindrance coefficient
fD Diffusive hindrance coefficient
j Mass transfer rate of solute
j" Mass flux of solute
kon Rate of association of a compound to the average binding site
koff Rate of dissociation of a compound from the average binding site
Kd Dissociation constant of ligand from receptor
K' Dissociation constant of compound from average binding site in a tissue
1 Average thickness of a tissue layer, length scale
L Length of an artery
N Total number of computational elements in a tissue layer
P Perimeter of arterial cross section, length of Internal Elastic Lamina (IEL)
Pe Peclet number, nondimensional ratio of convective to diffusive forces
R Resistance to (diffusive) transport
t Time
U Convective velocity of solute in hydraulic flow
u Convective hydraulic velocity in transmural direction
Vl Average fluid velocity flowing in arterial lumen
Va Tissue Volume
x Transmural coordinate
AH Hydrostatic head of the perfusate in the artery
AP Hydrostatic pressure difference
E' Fractional space in which drug can distribute through a tissue
i/ Measured mass transfer dondimensionalized by the diffusive driving potential and
diffusive resistance
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Subscripts
a
adv
aq
b
bl
bulk
ec
end
f
gel
h
h*
ic
init
med
mem
myo
n
P
plasma
s
T
pv
Ic
Accessible space in tissue for solute
Adventitial
Aqueous solutions
Reversibly bound drug phase or occupied binding sites
Boundary layer
Bulk phase or external solution
Extracellular
Endothelial
Free or unoccupied binding sites
Photopolymerized hydrogel
Heparin
3H-heparin
Intracellular, internalized
Initial, in uniformly loaded artery and photopolymerized hydrogel
Medial
Membrane
Myocardial
Index for computational elements in a tissue layer
Perfusate, endovascular compartment
Plasma
Soluble
Total noninternalized ( soluble and reversibly bound) drug phase
Perivascular
Partition coefficient of drug into the accessible volume
137
10. REFERENCES
1. Wolinsky H, Glagov S. Nature of species differences in the medial distribution of aortic vasa
vasorum in mammals. Circ Res. 1967;20:409-421.
2. Rubanyi GM. Endothelium-derived relaxing and contracting factors. J Cell Biochem.
1991;46:27-36.
3. Ohno M, Gibbons GH, Dzau VJ, Cooke JP. Shear stress elevates endothelial cGMP. Role of
a potassium channel and G protein coupling. Circulation. 1993;88:193-197.
4. Furchgott RF, Vanhoutte PM. Endothelium-derived relaxing and contracting factors. FASEB
J. 1989;3:2007-2018.
5. Schweigerer L, Nuefeld G, Friedman J, Abraham JA, Fiddes JC, Gospodarowicz D.
Capillary endothelial cells express basic fibroblast growth factor, a mitogen that stimulates their
own growth. Nature (lond). 1987;325:257-259.
6. Conolly DT, Stoddard BL, Harakas NK, Feder J. Human fibroblast-derived growth factor is a
mitogen and chemoattractant for endothelial cells. Biochem Biophys Res Comm. 1987; 144:705-
712.
7. Lidner V, Majack RA, Reidy MA. Basic fibroblast growth factor stimulates endothelial
regrowth and proliferation in denuded arteries. J Clin Invest. 1990;85:2004-2008.
8. Lidner V, Reidy MA. Proliferation of smooth muscle cells after vascular injury is inhibited by
an antibody against basic fibroblast growth factor. Proc Natl Acad Sci USA. 199 1;88:3739-3743.
9. Lidner V, Lappi DA, Baird A, Majack RA, Reidy MA. Role of basic fibroblast growth factor
in vascular lesion formation. Circ Res. 199 1;68:106-113.
10. Clowes AW, Clowes MM. Kinetics of cellular proliferation after arterial injury. II: Inhibition
of smooth muscle cell growth by heparin. Lab Invest. 1985;52:611-616.
11. Castellot JJJ, Addonizio ML, Rosenberg RD, Karnovsky MJ. Cultured endothelial cells
produce a heparin-like inhibition of smooth muscle growth. J Cell Biol. 1981 ;90:372-379.
12. Castellot JJJ, Cochran DL, Karnovsky MJ. Effect of Heparin on Vascular Smooth Muscle
Cells. I. Cell Metabolism. J Cell Physiol. 1985;124:21-28.
13. Clowes AW, Karnovsky MJ. Suppression by heparin of smooth muscle cell proliferation in
injured arteries. Nature. 1977;265:625 - 626.
14. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature.
1993;362:801-809.
15. Ross R. The pathogenesis of atherosclerosis. New Eng J Med. 1986;314:488-500.
16. Ip JH, Fuster V, Badimon L, Badimon J, Taubman MB, Chesebro JH. Syndromes of
accelerated atherosclerosis: Role of vascular injury and smooth muscle proliferation. J Am Coll
Cardiol. 1990;15:1667-1687.
138
17. Reidy MA, Ringerle J, Lindner V. Factors controlling the development of arterial lesions after
injury. Circulation. 1992;86:III43-III46.
18. Clowes AW, Reidy MA. Prevention of restenosis after vascular reconstruction:
Pharmacologic control of intimal hyperplasia. J Vasc Surg. 1991;13:885-891.
19. Landau C, Lange RA, Hillis D. Percutaneous transluminal coronary angioplasty. New Eng J
Med. 1994;330:981-993.
20. Faxon DP, Currier JW. Prevention of post-PTCA restenosis. Ann NY Acad Sci.
1995;748:419-427.
21. Castellot JJJ, Wright TC, Karnovsky MJ. Regulation of vascular smooth muscle cell growth
by heparin and heparan sulphate. Semin Thromb Hemost. 1987; 13:489-503.
22. Hoover RL, Rosenberg R, Haering w, Karnovsky MJ. Inhibition of rat arterial smooth
muscle cell proliferation by heparin. II. in vitro studies. Circ Res. 1980;47:578-583.
23. March KL, Mohanraj S, Ho PPK, Wilensky RL, Hathaway DR. Biodegradable
microspheres containing a colchicine analogue inhibit DNA synthesis in vascular smooth muscle
cells. Circulation. 1994;89:1929-1933.
24. Weissberg PL, Grainger DJ, Shanahan CM, Metcalfe JC. Approaches to the development of
selective inhibitors of vascular smooth muscle cell proliferation. Cardiovasc Res. 1993;27:1191-
1198.
25. Naftilan AJ. The role of angiotensin II in vascular smooth muscle cell growth. Journal of
Cardiovascular Pharmacology. 1992;20 (Suppl I):S37-S40.
26. Edelman ER, Adams DA, Karnovsky MJ. Effect of controlled adventitial heparin delivery on
smooth muscle cell proliferation following endothelial injury. Proc Natl Acad Sci USA.
1990;87:3773-3777.
27. Guyton J, Rosenberg R, Clowes A, Karnovsky M. Inhibition of rat arterial smooth muscle
cell proliferation by heparin I. In vivo studies with anticoagulant and non-anticoagulant heparin.
Circ Res. 1980;46:625-634.
28. Muller DWM, Gordon D, Topol EJ, Levy RJ, Golomb G. Sustained-release local hirulog
therapy decreases early thrombosis but not neointimal thickening after arterial stenting. Am Heart
J. 1996;131:211-218.
29. Villa A, Guzman L, Chen W, Golomb G, Levy R, Topol E. Local delivery of dexamethasone
for prevention of neointimal proliferation in a rat model of balloon angioplasty. J Clin Invest.
1994;93:1243-1249.
30. Muller DWM, Golomb G, Gordon D, Levy RJ. Site-specific dexamethasone delivery for the
prevention of neointimal thickening after vascular stent implantation. Coron Art Dis. 1994;5:435-
442.
31. Powell JS, Clozel JP, Muller RKM, Kuhn H, Hefti F, Hosang M, Baumgartner HR.
Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after injury. Science.
1989;245:186-188.
139
32. Muller DWM, Ellis SG, Topol EJ. Colchicine and antineoplastic therapy for the prevention of
restenosis after percutaneous coronary interventions. JAm Coll Cardiol. 1991; 17:126B- 131B.
33. Gradus-Pizlo I, Wilensky RL, March KL, Fineberg N, Michaels M, Sandusky GE,
Hathaway DR. Local delivery of biodegradable microparticles containing colchicine or a colchicine
analogue: effects on restenosis and implications for catheter-based drug delivery. J Am Coll
Cardiol. 1995;26:1549-1557.
34. Lambert T, Dev V, Rechavia E, Forrester JS, Litvack F, Eigler NL. Localized arterial wall
drug delivery from a polymer-coated removable metallic stent. Kinetics, distribution, and
bioactivity of forskolin. Circulation. 1994;90:1003-1011.
35. Strauss BH, Wilson RA, Houten Rv, Suylen Rv, Murphy ES, Escaned J, Verdouw PD,
Serruys PW, Giessen WJvd. Late effects of locally delivered mitomycin c on formation of
neointima and on vasomotor response to acetylcholine. Coron Art Dis. 1994;5:633-641.
36. Hansson GK, Holm J. Interferon-gamma inhibits arterial stenosis after injury. Circulation.
1991;84:1266-1272.
37. Edelman ER, Simons M, Sirois MG, Rosenberg RD. C-myc in vasculoproliferative disease.
Circ Res. 1995;359:69-73.
38. Shi Y, Fard A, Galeo A, Hutchinson HG, Vermani P, Dodge GR, Hall DJ, Shaheen F,
Zalewski A. Transcatheter delivery of c-myc antisense oligomers reduces neointimal formation in
a porcine model of coronary artery balloon injury. Circulation. 1994;90:9440951.
39. Simons M, Edelman ER, Langer R, DeKeyser JL, Rosenberg RD. Antisense c-myb
oligonucleotides inhibit intimal arterial smooth muscle accumulation in vivo. Nature. 1992;359:69-
73.
40. Pastore CJ, Isner JM, Bacha PA, Kearney M, Pickering JG. Epidermal growth factor
receptor-targeted cytotoxin inhibits neointimal hyperplasia in vivo. Circ Res. 1995;77:519-529.
41. Katzung BG. Basic and clinical pharmacology. Ed. 6 ed. Norwalk, CT: Appleton and
Lange, 1995.
42. Gervin AS. Complications of heparin therapy. In: Kg S, al. e, eds. Venous surgery in the
lower extremities. St. Louis: Green; 1975:307-25.
43. Porter J, Fick H. Drug-related deaths among medical in patients. JAMA. 1977;237:879.
44. Mitchel JF, Fram DB, Palme DF, Foster R, Hirst JA, Azrin MA, Bow LA, Eldin AM, Waters
DD, Mckay RG. Enhanced Intracoronary thrombolysis with urokinase using a novel, local drug
delivery system. Circulation. 1995;91:785-793.
45. Hong MK, Wong SC, Farb A, Mehlman MD, Virmani R, Barry JJ, Leon MB. Feasibility
and drug delivery efficiency of a new balloon angioplasty catheter capable of performing
simultaneous local delivery. Coron Art Dis. 1993;4:1023-1027.
46. Wolinsky H, Thung SN. Use of perforated balloon catheter to deliver concentrated heparin
into the wall of the normal canine artery. JAm Coll Cardiol. 1990;15:475-81.
140
47. Wilensky RL, March KL, Hathaway DR. Direct intraarterial wall injection of microparticles
via a catheter: a potential drug delivery strategy following angioplasty. Am Heart J.
1991;122:1136-1140.
48. Sawhney AS, Pathak CP, Hubbell JA. Bioerodible hydrogels based on photopolymerized
poly(ethylene glycol)-co-poly(alpha-hydroxy acid) diacrylate macromers. Macromolecules.
1993;26:581-587.
49. Hill-West JL, Chowdhury SM, Slepian MJ, Hubbell JA. Inhibition of thrombosis and intimal
thickening by in situ photopolymerization of thin hydrogel barriers. Proc Natl Acad Sci USA.
1994;91:5967-5971.
50. Slepian MJ. Polymeric endoluminal paving: Evolving therapeutic methods extending the
spectrum of local endovascular interventions. In: Liermann D, eds. Stents: State of the art and
future developments. Morin Heights, Canada: Polyscience Publications, Inc.; 1995:339-355.
51. Rogers C, Karnovsky MJ, Edelman ER. Inhibition of experimental neointimal hyperplasia
and thrombosis depends on the type of vascular injury and the site of drug administration.
Circulation. 1993;88:1215-1221.
52. Rogers C, Edelman ER. Controlled release of heparin reduces neointimal hyperplasia in
stented rabbit arteries: Ramifications for local therapy. JInterv Cardiol. 1992;5:195-202.
53. Lovich MA, Edelman ER. Tissue average binding and equilibrium distribution: an example
with heparin in arterial tissues. Biophys J. 1996;70:1553-1559.
54. Dayton S, Hashimoto S. Recent advances in molecular pathology: a review. Exp Mol Path.
1970;13:253-268.
55. Zilversmit DB. Cholesterol flux in the atherosclerotic plaque. Ann NY Acad Sci.
1968; 149:710-724.
56. Rutledge JC, Curry F-RE, Lenz JF, Davis PA. Low density lipoprotein transport across a
microvascular endothelial barrier after permeability is increased. Circ Res. 1990;66:486-495.
57. Lin S-J, Jan K-M, Schuessler G, Weinbaum S, Chien S. Enhanced macromolecular
permeability of aortic endothelial cells in association with mitosis. Atherosclerosis. 1988;73:223-
232.
58. Chien S, Lin S-J, Weinbaum S, Lee MML, Jan K-M. The role of arterial endothelial cell
mitosis in macromolecular permeability. Adv Exp Med Bio. 1988;242:59-73.
59. Truskey GA, Roberts WL, Hermann RA, Malinauskas RA. Measurment of endothelial
permeability to 125I-low density lipoproteins in rabbit arteries by use of en face preparations. Circ
Res. 1992;71:883-897.
60. Morrel EM, Holland JA, Pritchard KA, Colton CK, Stemerman MB. Endothelial cell
perturbation and low-density lipoprotein: Quantitative autoradiography. Ann NY Acad Sci.
1987;516:412-417.
61. Chuang PT, Cheng HJ, Lin SJ, Jan KM, Lee MML, Chien S. Macromolecular transport
across arterial and venous endothelium in rats: Studies with Evans Blue-albumin and horseradish
peroxidase. Arteriosclerosis. 1990;10:188-197.
62. Bell FP, Adamson IL, Schwartz CJ. Aortic endothelial permeability to albumin: Focal and
regional patterns of uptake and transmural distribution of 131I-albumin in the young pig. Exp Mol
Path. 1974;20:57-68.
63. Bratzler RL, Chisolm GM, Colton CK, Smith KA, Zilversmit DB, Lees RS. The distribution
of labeled low-density lipoproteins across the rabbit thoracic aorta in vivo. Atherosclerosis.
1977;28:289-307.
64. Tompkins RG, Yarmush ML, Schnitzer JJ, Colton CK, Smith KA, Stemerman MB. Low-
density lipoprotein transport in blood vessel walls of squirrel monkeys. Am J Physiol.
1989;257:H452-H464.
65. Curmi PA, Juan L, Tedgui A. Effect of transmural pressure on low density lipoprotein and
albumin transport and distribution across the intact arterial wall. Circ Res. 1990;66:1692-1702.
66. Scott PJ, Hurley PJ. The distribution of radio-iodinated serum albumin and low-density
lipoprotein in tissues and the arterial wall. Atherosclerosis. 1971;11:77-103.
67. Ghosh S, Finkelstein JN, Moss DB, Schweppe JS. Evaluation of the permeability parameters
(influx, efflux, and volume of distribution) of arterial wall for LDL and other proteins. In: Day
CE, eds. Atherosclerosis:Drug Discovery. New York: Plenum Press; 1976:191-204.
68. Bretherton KN, Day AJ, Skinner SL. Effect of hypertension on the entry of 125I-labeled low
denisty lipoprotein into the aortic intima in normal-fed rabbits. Atherosclerosis. 1976;24:99-106.
69. Calvert GD, Scott PJ, Sharpe DN. The plasma and tissue turnover and distribution of two
radio-iodine labelled pig plasma low dendity lipoproteins. Atherosclerosis. 1975;22:601-628.
70. Duncan LE, Buck K, Lynch A. Lipoprotein movement through canine aortic wall. Science.
1963;142:972-973.
71. Fry DL, Cornhill JF, Sharma H, Pap JM, Mitschelen J. Uptake of low density lipoprotein,
albumin, and water by deendothelialized in vitro minipig aorta. Arteriosclerosis. 1986;6:475-490.
72. Okishio T. Studies on the transfer of 131I-labelled serum lipoproteins into the aorta of rabbits
with experimental atherosclerosis. Med J Osaka Univ. 1961;11:367-381.
73. Stemerman MB, Morrel EM, Burke KR, Colton CK, Smith KA, Lees RS. Local variation in
arterial wall permeability to low density lipoprotein in normal rabbit aorta. Arteriosclerosis.
1986;6:64-69.
74. Virag S, Pozsonyi T, Denes R, Gero S. Uptake of 125I-labeled 3-lipoprotein by the aortas of
animals differently susceptible to cholesterol induced atherosclerosis. Atherosclerosis Res.
1968;8:859-860.
75. Adams CWM, Morgan RS, Bayliss OB. The differntial entry of [125I]albumin into mildly
and severely atheromatous rabbit aortas. Atherosclerosis. 1970; 11:119-124.
76. Bratzler RL, Chisolm GM, Colton CK, Smith KA, Zilversmit DB, Lees RS. The distribution
of labeled albumin across the rabbit thoracic aorta in vivo. Circ Res. 1977;40:182-190.
77. Caro CG, Ebel W, Laver-Rudich Z, Liron N, Meyer F. Steady albumin transport in the rabbit
common caraotid artery. JPhys. 1979;289:497-511.
142
78. Caro CG, Lever MJ, Laver-Rudich Z, Meyer F, Liron N, Ebel W, Parker KH, Winlove CP.
Net albumin transport across the wall of the rabbit common caraotid artery perfused in situ.
Atherosclerosis. 1980;37:497-511.
79. Colton CK, Schneiderman G, Ramirez CA, Smith KA, Lees RS, Stemerman MB. Labeled
albumin transport into normal and de-endothelialized rabbit thoracic aorta in vivo. In: Nerem RM,
Guyton JR, eds. Hemodynamics and the arterial wall, proceedings from a specialists meeting.
Houston: University of Houston; 1980:42-46.
80. Duncan LE, Cornfield J, Buck K. Circulation of iodonated albumin through the aortic and
other connective tissues of the rabbit. Circ Res. 1958;6:244-245.
81. Duncan LE, Cornfield J, Buck K. Circulation of labeled albumin through the aortic wall of
the dog. Circ Res. 1959;7:390-397.
82. Duncan LE, Buck K. Passage of labeled albumin into canine aortic wall in vivo and in vitro.
Am J Physiol. 1960;200:622-624.
83. Duncan LE, Cornfield J, Buck K. The effect of blood pressure on the passage of labelled
plasma albumin into canine aortic wall. J Clin Invest. 1962;41:1537-1545.
84. Fry DL, Mahley RW, Wersgraber KH, Oh SY. Simultaneous accumulation of Evans blue
dye and albumin in canine aortic wall. Am J Physiol. 1977;233:H66-H79.
85. Fry DL, Melchior GW, Mitschelen J. Effect of serum and stirring on diffusive 125I-albumin
and Evans Blue Dye uptake. Am J Physiol. 1982;243:H708-H712.
86. Fry DL. Effect of pressure and stirring on in vitro aortic transmural 125I-albumin transport.
Am J Physiol. 1983;245:H977-H991.
87. Ramirez CA, Colton CK, Smith KA, Stemmerman MB, Lees RS. Transport of 125I-albumin
across normal and deendothelialized rabbit thoracic aorta in vivo. Arteriosclerosis. 1984;4:283-
291.
88. Tedgui A, Lever J. The interaction of convection and diffusion in the transport of 131,1
Albumin within the media of the rabbit thoracic aorta. Circ Res. 1985;57:856-863.
89. Tedgui A, Merval R, Esposito B. Albumin transport characteristics of rat aorta in early phase
of hypertension. Circ Res. 1992;71:932-942.
90. Weinberg PD. Application of fluorescence densitometry to the study of net albumin uptake by
the rabbitaortic wall up- and downstream of intercostal ostia. Atherosclerosis. 1988;74:139-148.
91. Goldman B, Blamke H, Wolinsky H. Influence of pressure on permeability of normal and
diseased muscular arteries to horseradish peroxidase. Atherosclerosis. 1987;65:215-225.
92. Penn MS, Koelle MR, Schwartz SM, Chisolm GM. Visualization and quantification of
transmural concentration profiles of macromolecules across the arterial wall. Circ Res. 1990;67:11-
22.
93. Penn MS, Chisolm GM. Relation between lipopolysaccharide-induced endothelial cell injury
and entry of macromolecules into the rat in vivo. Circ Res. 1991;68:1259-1269.
143
94. Penn MS, Saidel GM, Chisolm GM. Vascular injury by endotoxin: changes in
macromolecular transport parameters in rat aortas in vivo. Am JPhysiol. 1992;262:H1563-H1571.
95. Penn MS, Saidel GM, Chisolm GM. Relative significance of endothelium and internal elastic
lamina in regulating the entry of macromolecules into arteries in vivo. Circ Res. 1994;74:74-82.
96. Karnovsky MJ, Shea SM. Transcapillary transport by pinocytosis. Microvasc Res.
1970;2:353-360.
97. Bratzler RL, Colton CK, Smith KA. Endothelium and permeability: theoretical models for
transport of low-density lipoproteins in the arterial wall. In: Manning GW, Daria-Haust M, eds.
Atherosclerosis: metabolic, morphologic, and clinical aspects. New York: Plenum; 1975:943-951.
98. Fry DL. Mathematical models of arterial transmural transport. Am J Physiol.
1985;248:H240-H263.
99. Saidel GM, Morris ED, Chisolm GM. Transport of macromolecules in arterial wall in vivo:
A mathematical model and analytical solutions. Adv Exp Med and Bio. 1987;49:153-169.
100. Truskey GA, Colton CK, Smith KA. Quantitative analysis of protein transport in the arterial
wall. In: Schwartz CJ, Werthessen NT, Wolf S, eds. Structure and Function of the Circulation.
New York: Plenum Press; 1981:287-355.
101. Weinbaum S, Caro CG. A macromolecule transport model for the arterial wall and
endothelium based on the ultrastructural specialization observed in electron microscopic studies. J
Fluid Mech. 1976;74:611-640.
102. Fry DL, Vaishnav RN. Mass transport in the arterial wall. In: Patel DJ, Vaishnav RN, eds.
Basic Hemodynamics and its Role in Disease Processes. Baltimore: University Park Press;
1980:425-485.
103. Krishnan L, Krishnan EC, Jewell WR. Theoretical treatment of the distribution and
degradation of vascular interstitial, and intracellular albumin. J Theor Biol. 1977;67:609-623.
104. Fry DL. Response of the arterial wall to certain physical fators. In: Scheinberg P, eds.
Atherogenesis: Initiating factors, Ciba. symposium. Amsterdam: Associated Scientific Publishers;
1973:93-124.
105. Lovich MA, Edelman ER. Mechanisms of transmural heparin transport in the rat abdominal
aorta after local vascular delivery. Circ Res. 1995;77:1143-1150.
106. Caro CG. Transport of 14C-cholesterol between intraluminal serum and artery wall in
isolated dog common carotid artery. J Phys. 1973;233:37P-38P.
107. Nerem RM, Polsey JS, Robinson DL, Carey WE. Shear dependent transport of albumin
between blood and the arterial wall. 26th annual conference on engineering in medicine and
biology. Ed. Maryland: 1973. 15: 413.
108. Weinbaum S. Mathematical models for transport across the endothelial cell layer. Ann NY
Acad Sci. 1983;416:92-114.
109. Yuan F, Chien S, Weinbaum S. A new view of convective-diffusive transport processes in
the arterial intima. J Biomech Eng. 1991;113:314-329.
110. Tzeghai G, Ganatos P, Pfeffer R, Weinbaum S, Nir A. A theoretical model to study the
effect of convection and leaky junctions on macromolecule transport in artery walls. J Theor Biol.
1986;121:141-162.
111. Weinbaum S, Tzeghai G, Ganatos P, Pfeffer R, Chien S. Effect of cell turnover and leaky
junctions on arterial macromolecular transport. Am J Physiol. 1985;248:H945-H960.
112. Nir A, Pfeffer R. Transport of macromolecules across arterial wall in the presence of local
endothelial injury. J Theor Biol. 1979;81:685-711.
113. Weinbaum S, Ganatos P, Pfeffer R, Wen GB, Lee M, Chien S. On the time-dependent
diffusion of macromolecules through transient open junctions and their subendothelial spread I.
Short-time model for cleft exit region. J Theor Biol. 1988;135:1-30.
114. Wen GB, Weinbaum S, Ganatos P, Pfeffer R, Chien S. On the time-dependent diffusion of
macromolecules through transient open junctions and their subendothelial spread 2. Long time
model for interaction between leakage sites. J Theor Biol. 1988;135:219-253.
115. Lin S-J, Jan K-M, Weinbaum S, Chien S. Transendothelial transport of low density
lipoprotein in association with cell mitosis in rat aorta. Arteriosclerosis. 1989;9:230-238.
116. Caplan BA, Schwartz CJ. Increased endothelial cell turnover in areas of in vivo evans blue
uptake in the pig aorta. Atherosclerosis. 1973;17:401-417.
117. Smith EB, Staples EM. Distribution of plasma proteins across the human aortic wall.
Atherosclerosis. 1980;37:579-590.
118. Fung YC. Biomechanics: Mechanical properties of living tissues. second edition ed. New
York: Springer-Verlag, 1993.
119. Tedgui A, Lever MJ. Effect of pressure and intimal damage on 131I-albumin and
[14C]sucrose spaces in aorta. Am J Physiol. 1987;253:H1530-H1539.
120. Tedgui A, Lever MJ. Filtration through damaged and undamaged rabbit thoracic aorta. Am J
Physiol. 1984;247:H784-H791.
121. Whale MD, Grodzinsky AJ, Johnson M. The effect of aging and pressure on the specific
hydraulic conductivity of the aortic wall. Biorheology. 1995;33:17-44.
122. Caro CG, Lever MJ. Effect of vasoactive agents and applied stress on the albumin space of
excised rabbit caraotid arteries. Atherosclerosis. 1983;46:137-146.
123. Curry FE, Michel CC. A fiber matrix model of capillary permeability. Microvasc Res.
1980;20:96-99.
124. Curry FE. Mechanics and thermodynamis of transcapillary exchange. In: Renkin EM,
Michel CC, Geiger SR, eds. THe handbook of physiology, Section 2, The Cardiovascular
System. Bethesda, MD: American Physiological Society; 1984:351-363.
125. Curry FE. Determinants of capillary permeability: a review of mechanisms based on single
capilary studies in the frog. Circ Res. 1986;59:367-380.
126. Kim W-S, Tarbell JM. Macromolecular transport through the deformable porous media of
an artery wall. Transactions of the ASME. 1994;116:156-163.
145
127. Clowes AW, Clowes MM. Kinetics of cellular proliferation after arterial injury. IV. Heparin
inhibits rat smooth muscle mitogenesis and migration. Circ Res. 1986; 58:839-845.
128. Nugent MA, Karnovsky MJ, Edelman ER. Vascular cell-derived heparan sulfate shows
coupled inhibition of basic fibroblast growth factor binding and mitogenesis in vascular smooth
muscle ell. Circ Res. 1993;73:1051-1060.
129. Clowes AW, Reidy MA, Clowes MM. Kinetics of cellular proliferation after arterial injury.
I: Smooth muscle cell proliferation following endothelial injury. Lab Invest. 1983;49:327-333.
130. Rohsenow WM, Choi HY. Mass transfer in turbulent flow and experimental results. In:
Rohsenow WM, Choi HY, eds. Heat, Mass, and Momentum Transfer. Englewood Cliffs, NJ:
Prentice-Hall, Inc.; 1961:410-424.
131. Mills AF. Forced convection. In: Mills AF, eds. Heat Transfer. Homewood, IL: Richard
D. Irwin, Inc.; 1992:269-293.
132. Vargas CB, Vargas FF, Pribyl JG, Blackshear PL. Hydraulic conductivity of endothelial
and outer layers of the rabbit aorta. Am J Physiol. 1979;236:H53-H60.
133. Bungay PM, Brenner H. The motion of a closely-fitting sphere in a fluid-filled tube. Int J
Multiphase Flow. 1973;1:25-56.
134. Deen WM. Hindered transport of large molecules in liquid-filled pores. AICHE J.
1987;33:1409-1425.
135. Granath KA, Kvist BE. Molecular weight distribution analysis by gel chromotography on
sephadex. J Chromot. 1967;28:69-81.
136. Siflinger A, Parker K, Caro CG. Uptake of 1251 albumin by the endothelial surface of the
isolated dog common carotid artery: effect of certain physical factors and metabolic inhibitors.
Cardiovasc Res. 1975;9:478-489.
137. Meyer G, Merval R, Tedgui A. Effects of pressure-induced strectch and convection on low-
density lipoprotein and albumin uptake in the rabbit aortic wall. Circ Res. 1996;79:532-540.
138. Okada T, Bark DH, Mayberg MR. Localized release of perivascular heparin inhibits intimal
proliferation after endothelial injury without systemic anticoagulation. Neurosurg. 1989;25:892-
898.
139. Fry DL. Mass transport, atherogenesis, and risk. Arteriosclerosis. 1987;7:88-100.
140. Casu B. Heparin structure. Haemostasis. 1990;20 Suppl 1:62-73.
141. Ferro D, Provasoli A, Ragazzi M, Casu B, Torri G, Bossennec V, Perly B, Sinay P, Petitou
M, Choay J. Conformer populations of L-iduronic acid residues in glycosaminoglycan sequences.
Carbohyd Res. 1990;195:157-167.
142. Edelman ER, Nugent MA, Karnovsky MJ. Perivascular and intravenous bFGF
administration: Vascular and solid organ deposition. Proc Natl Acad Sci USA. 1993;30:1513-
1517.
146
143. Nugent MA, Edelman ER. Kinetics of basic fibroblast growth factor binding to its receptor
and heparan sulfate proteoglycan: A mechanism for cooperativity. Biochemistry. 1992;31:8876-
8883.
144. Pukac L, Ottlinger ME, Karnovsky M. Heparin suppresses specific second messenger
pathways for protooncogene expression in rat vascular smooth muscle cells. J Biol Chem.
1992;267:3707-3711.
145. Castellot JJJ, K.Wong, Herman B, Hoover RL, Albertini DF, Wright TC, Caleb BL,
Karnovsky MJ. Binding and internalization of heparin by vascular smooth muscle cells. J Cell
Physiol. 1985;124:13-20.
146. Barzu T, Molho P, Tobelem G, Petitou M, Caen J. Binding and endocytosis of heparin by
endothelial cells in culture. Biochimica et Biophysica Acta. 1985;845:196-203.
147. Psuja P. Affinity of radiolabeled (1251) Heparin and low molecular weight heparin fraction
CY 222 to endothelium in culture. Folia Haematol. 1987;114:429-436.
148. Vannucchi S, Pasquali F, Chiarugi V, Ruggiero M. Internalization and metabolism of
endogenous heparin by cultured endothelial cells. Biochem Biophys Res Commun.
1986;1140:294-301.
149. San Antonio JD, Slover J, Lawler J, Karnovsky MJ, Lander AD. Specificity in the
interactions of extracellular matrix proteins with subpopulations of the glycosaminoglycan heparin.
Biochemistry. 1993;32:4746-4755.
150. Press W, Flannery B, Teukolsky S, Vetterling W. Modeling of data: Nonlinear models. In:
eds. Numerical Recipes. Cambridge, England: Cambridge University Press; 1986:521-528.
151. Haas K, Phillips S, Comerota A, White J. The architecture of adventitial elastin in the canine
infrarenal aorta. Anat Rec. 1991 ;230:86-96.
152. Murata K, Motayama T, Kotake C. Collagen types in various layers of the human aorta and
their changes with the atherosclerotic process. Atherosclerosis. 1986;60:251-262.
153. Barzu T, Rijn JLMLV, Petitou M, Molho P, Tobelem G. Endothelial binding sites for
heparin: specificity and role in heparin neutralization. Biochem J. 1986;238:847-854.
154. Glimelius B, Busch C, Hook M. Binding of heparin on the surface of cultured human
endothelial cells. Thromb Res. 1978; 12:773-782.
155. Hiebert LM, McDuffie NM. The intracellular uptake and protracted release of exogenous
heparins by cultured endothelial cells. Artery. 1989; 16:208-222.
156. Brown LR, Wei CL, Langer R. In vivo and In vitro release of macromolecules from
polymeric drug delivery systems. J Pharm Sci. 1983;72:1181-1185.
157. Slepian MJ. Polymeric endoluminal gel paving: Therapeutic hydrogel barriers and sustained
drug delivery depots for local arterial wall biomanipulation. Semin Intervent Cardiol. 1996; 1:103-
116.
158. Mayberg MR. Localized release of perivascular heparin. Persp Neuro Surg. 1990;1:77-95.
147
159. Booth RFG, Martin JF, Honey AC, Hassall DG, Beesley JE, Moncada S. Rapid
development of atherosclerotic lesions in the rabbit artery induced by perivascular manipulation.
Atherosclerosis. 1989;76:257-268.
160. Huth F, Kojimahara M, Franken T, Rhedin P, Rosenbauer KA. Aortic alterations in rabbits
following sheathing with silastic and polyethylene tubes. Curr Top Pathol. 1975;60:1-32.
161. Cardin AD, Weintraub HJR. Molecular modelling of protein-glycosaminoglycan
interactions. Arteriosclerosis. 1989;9:21-32.
162. Letourneur D, Caleb BL, Castellot JJJ. Heparin binding, internalization, and metabolism in
vascular smooth muscle cells: II. Degradation and secretion in sensitive and resistant cells. J Cell
Physiol. 1995;165:687-695.
163. Slepian MJ, Weselcouch E, Cambell P, Roth L, Massia SP, Kieras M, Philbrook M.
Endoluminal hydrogel polymer layers provide prolonged heparin delivery to porcine coronary
artery wall in vivo. JAm Coil Cardiol. 1996;27 (Supplement A):85A.
164. Holman JP. Heat Transfer. Ed. 6th ed. New York: McGraw-Hill Book Co., 1963. 131-
133.
165. Lincoff AM, Topol EJ, Ellis SG. Local Drug Delivery for the prevention of restenosis: Fact,
fancy and future. Circulation. 1994;90:2070-2084.
166. Ruoslahti E, Yamaguchi Y. Proteoglycans as modulators of growth factor activity. Cell.
1991 ;64:867-869.
167. Burgess WH, Maciag T. The heparin binding (fibroblast) growth factor family of proteins.
Am Rev Biochem. 1989;58:575-606.
168. Imai H, Connell CE, Lee KT, Kim DN, Thomas WA. Differential counts by electron
microscopy of cell types in normal intimal cell masses in swine abdominal aortas. Exp Mol Path.
1985;42:377-388.
169. Scott RF, Thomas WA, Lee WM, Reiner JM, Florentin RA. Distribution of intimal smooth
muscle cell masses and their relationship to early atherosclerosis in the abdominal aortas of young
swine. Atherosclerosis. 1979;34:291-301.
170. Letourneur D, Caleb BL, Castellot JJJ. Heparin binding, internalization, and metabolism in
vascular smooth muscle cells: I. Upregulation of heparin binding correlates with antiproliferative
activity. J Cell Physiol. 1995;165:676-686.
171. Fingerle J, Au YPT, Clowes AW, Reidy MA. Intimal lesion formation in rat carotid arteries
after endothelial denudation in absence of medial injury. Arteriosclerosis. 1990;10: 1082-1087.
148
